Histone Deacetylase 3 Coordinates Heart Development Through Stage-Specific Roles in Cardiac Progenitor Cells by Lewandowski, Sara L.
University of Massachusetts Medical School 
eScholarship@UMMS 
GSBS Dissertations and Theses Graduate School of Biomedical Sciences 
2016-12-21 
Histone Deacetylase 3 Coordinates Heart Development Through 
Stage-Specific Roles in Cardiac Progenitor Cells 
Sara L. Lewandowski 
University of Massachusetts Medical School 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss 
 Part of the Cell Biology Commons, Congenital, Hereditary, and Neonatal Diseases and Abnormalities 
Commons, Developmental Biology Commons, and the Molecular Genetics Commons 
Repository Citation 
Lewandowski SL. (2016). Histone Deacetylase 3 Coordinates Heart Development Through Stage-Specific 
Roles in Cardiac Progenitor Cells. GSBS Dissertations and Theses. https://doi.org/10.13028/M26P4D. 
Retrieved from https://escholarship.umassmed.edu/gsbs_diss/883 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and 
Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
	 
 
 
 
HISTONE DEACETYLASE 3 COORDINATES HEART DEVELOPMENT 
THROUGH STAGE-SPECIFIC ROLES IN CARDIAC PROGENITOR CELLS 
A Dissertation Presented  
By  
SARA LYNN LEWANDOWSKI 
Submitted to the Faculty of the  
University of Massachusetts Graduate School of Biomedical Sciences, Worcester 
in partial fulfillment of the requirements for the degree of 
DOCTOR OF PHILOSOPHY  
DECEMBER 21, 2016 
TRANSLATIONAL SCIENCE PROGRAM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 
HISTONE DEACETYLASE 3 COORDINATES HEART DEVELOPMENT 
THROUGH STAGE-SPECIFIC ROLES IN CARDIAC PROGENITOR CELLS 
A Dissertation Presented  
 
By 
SARA LYNN LEWANDOWSKI 
 
Dissertation Defense Committee GSBS Members 
 
 Thomas Fazzio 
 
Interdisciplinary Graduate Program 
 
Nathan Lawson 
 
Interdisciplinary Graduate Program 
 
Jaime Rivera 
 
Cell Biology Program 
 
Chair of the Dissertation Committee 
 
Roger Davis 
 
Translational Science Program 
 
External Dissertation Committee Member 
 
Glenn Gaudette 
 
Professor, WPI 
 
Student Program  
Translational Science Program 
 
December 21, 2016
	iii 
Acknowledgements 
I would like to thank the many people who have provided support and guidance 
throughout this work. First, the past and present members of the Trivedi lab, 
including summer students, who have contributed to this work through 
experiments, discussions, and advice, and who have made the journey through 
graduate school an interesting one. I am grateful for everyone in cardiovascular 
medicine for being friendly and supportive and sharing their diverse expertise 
both to assist in my work and to broaden my understanding of topics in 
cardiovascular heath and disease. Members of my qualifying exam committee, 
TRAC committee, and dissertation exam committee, including Roger Davis, Tom 
Fazzio, Nathan Lawson, Jaime Rivera, Glenn Gaudette, Jane Freedman, Tony 
Imbalzano, have all generously shared their expertise to critically evaluate my 
work, offer input, and promote my development as a scientist. I am thankful for 
the support of the GSBS and their efforts to provide both a robust and successful 
graduate school experience. I appreciate everyone at UMass who has 
contributed to the success of my projects through their technical advice, insightful 
questions, sharing of ideas, equipment, and reagents, and general 
encouragement. Finally, I would like to thank my friends and family, as this work 
would not have been possible without their continuous encouragement and 
support. 
 
 
	iv 
Abstract 
 
 
Disruptions in cardiac development cause congenital heart disease, the most 
prevalent and deadly congenital malformation. Genetic and environmental factors 
are thought to contribute to these defects, however molecular mechanisms 
remain largely undefined. Recent work highlighted potential roles of chromatin-
modifying enzymes in congenital heart disease pathogenesis. Histone 
deacetylases, a class of chromatin-modifying enzymes, have developmental 
importance and recognized roles in the mature heart. This thesis aimed to 
characterize functions of Hdac3 in cardiac development. We found loss of Hdac3 
in the primary heart field causes precocious progenitor cell differentiation, 
resulting in hypoplastic ventricular walls, ventricular septal defect, and mid-
gestational lethality. In primary heart field progenitors, Hdac3 interacts with, 
deacetylates, and functionally suppresses transcription factor Tbx5. Furthermore, 
a disease-associated Tbx5 mutation disrupts this interaction, rendering Tbx5 
hyperacetylated and hyperactive. By contrast, deletion of Hdac3 in second heart 
field progenitors bypasses these defects, instead causing malformations in the 
outflow tract and semilunar valves, with lethality prior to birth. Affected semilunar 
valves and outflow tract vessels exhibit extracellular matrix and EndMT defects 
and activation of the Tgfβ1 signaling pathway. In normal second heart field 
development, Hdac3 represses Tgfβ1 transcription, independent of its 
deacetylase activity, by recruiting the PRC2 methyltransferase complex to 
methylate the Tgfβ1 promoter. Importantly, knockouts of Hdac3 in differentiated 
	v 
cardiac cells do not fully recapitulate the progenitor-specific knockout 
phenotypes. These results illustrate spatiotemporal roles of Hdac3, both 
deacetylase-dependent and deacetylase-independent, in cardiac development, 
suggesting that dysregulation of Hdac3 in cardiac progenitor cells could be a 
contributing factor in congenital heart disease pathogenesis. 
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Chapter I: Introduction: The complex developmental basis of congenital 
heart disease – evidence for the role of chromatin-modifying enzymes as 
modifier genes 
 
Congenital heart disease – importance and statistics 
 
Congenital heart disease, the most prevalent and deadly class of 
congenital malformations, affects an estimated 1% of all live births, 10% of 
stillbirths, and 20% of spontaneous abortions 1-7. Of the approximately 1.35 
million infants born with heart defects each year, roughly a quarter of these cases 
will require medical intervention within the first year of life. Improvements in 
surgical interventions have prolonged survival such that millions of adults are 
now living with congenital heart disease 8,9. However, despite our enhanced 
ability to manage this disease, the cause and molecular mechanisms which lead 
to cardiac malformations remain poorly understood 10. As such, there are no 
preventative treatments or cures for heart defects and growing interest in the 
heritability and long-term consequences of congenital heart disease in adults. 
Advances in our understanding of normal and abnormal cardiogenesis help to 
shed light on potential pathogenic factors and mechanisms underlying the 
development of congenital cardiac malformations. 
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Cardiac development – morphogenesis and evolution of the mammalian 
heart 
 
Much of our understanding of cardiac development comes from studies of 
model organisms. Although cardiac complexity varies, heart development, both 
morphologically and molecularly, is a highly conserved process across species 
11-13.  Many land-dwelling organisms, such as mammals and birds, have four-
chambered hearts featuring separate pulmonary and systemic circulations. 
Amphibians, which spend portions of their lifespans in water and on land, feature 
a three-chambered heart with two atria and a partially-septated ventricle, which 
pumps blood to both pulmonary and systemic circulations. This is similar to the 
arrangement observed in lungfish. Zebrafish, which do not have lungs, have a 
looped, two-chambered heart, which pumps blood to the gills for oxygenation and 
then on to nourish the rest of the body. Other small organisms, such as insects, 
have simple, vessel-like hearts with more open circulatory systems 12. 
The basic heart tube in fish and higher organisms forms from two pools of 
pre-cardiac progenitor cells in the splanchnic mesoderm, which migrate to the 
embryonic midline, creating the cardiac crescent 14. In mice, these progenitor 
pools arise around embryonic day (E) 6.5 and form the cardiac crescent a day 
later. In a process conserved across species, the two sides of the crescent 
converge and fuse in a caudal to cranial direction, generating a closed tube with 
an outer myocardial layer lined with endothelial cells 14. Once closed, the linear 
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tube commences beating. The heart is the first functional organ in a mammalian 
embryo, first beating around E8.0 in mice and three weeks gestation in humans. 
A functional heart tube is required to supply sufficient circulation to support 
further development. 
Once the primary heart tube has formed, it elongates and loops rightward, 
breaking the bilateral symmetry of the embryo. This rightward looping is 
observed in the two-chambered zebrafish heart, as well as the more complex 
amphibian, avian, and mammalian hearts 12,13. Mammalian and avian hearts then 
proceed to undergo convergence of the inflow tract and outflow tract along the 
anterior-posterior axis of the embryo facilitating further looping of the tube. This 
convergence allows the outflow tract to nestle into the atrioventricular canal, 
aligning the septating vessels above the appropriate ventricles. With this 
arrangement, the pulmonary artery and aorta fuse with the right and left 
ventricles, respectively, establishing the distinct pulmonary and systemic 
circulations 15. This elegant looping process transforms the linear heart tube into 
a mature, organized heart. 
 
Progenitor cells in cardiac development – the primary heart field 
 
Making a functional heart requires the development of cardiac lineages, 
including cardiomyocytes, smooth muscle cells, and endothelial cells to be 
coordinated in both time and space with the morphologic changes such as tube 
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formation, looping, and septation. This is achieved through dynamic regulation of 
multiple progenitor sources. The majority of the heart derives from the 
mesoderm, with the major exception of ectodermal-derived neural crest, which 
contributes to smooth muscle of the outflow tract 16-18.  
The first of the two major mesodermal-derived heart fields, the primary 
heart field progenitor cells are initially specified in the cardiac crescent, identified 
by expression of the transcription factor Nkx2-5 12,13. These progenitors 
differentiate into cardiomyocytes, smooth muscle cells, and endothelial cells as 
they form the primary heart tube, which will later give rise to the left ventricle and 
contribute to both atria (Figure 1.1). Signals, including BMP and FGF, from the 
surrounding tissues promote this differentiation 16,19. 
The key molecular regulators of heart development are highly conserved 
throughout evolution. In species down to insects, the progenitor cells that give 
rise to the primitive heart tube, or insect-equivalent dorsal vessel, express 
orthologs of Nkx2-5, which marks cardiac commitment 12. The primitive heart 
tube, which initially expresses Nkx2-5, is later marked by expression of the 
transcription factor Tbx5 20-22. Tbx5-derived cells go on to contribute 
cardiomyocytes, smooth muscle, and endothelial cells of the left ventricle, 
atrioventricular canal, and parts of the atria 20-22. Differences in expression 
patterns of Tbx5 in reptiles and mammals suggest that it may be evolutionarily 
important in the patterning of the four-chambered heart 11. Loss of Tbx5 in mice 
causes failed septation while misexpression in a reptile-like pattern results in a  
	5 
 
 
Figure 1.1: Diagram of mesodermal cardiac progenitor contribution to heart 
development. (A) Branching diagram illustrating progressive differentiation of 
mesoderm into primary heart field progenitors, second heart field progenitors, 
and subsequent end lineages. (B) Cartoon model of cardiac morphology from 
specification through birth. Yellow marks first heart field-derived regions while 
orange indicates regions of second heart field origin. FHF = first heart field, SHF 
= second heart field, OFT = outflow tract, IFT = inflow tract, LV = left ventricle, 
RV = right ventricle, LA = left atrium, RA = right atrium. 
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single ventricle similar to the reptilian heart 11. Thus, Tbx5 is a critical factor in 
specifying the primary heart field structures. 
Proper formation of the primary heart field and linear heart tube are 
essential to support further embryonic development. Failure of the primary heart 
field to form a closed tube results in cardia bifida, a severe and embryonic lethal 
malformation 23-25. Due to the severity and early timing of this defect, it has not 
been documented in humans, though it has been described in model organisms 
23-25. This and other catastrophic failures in early primary heart field development 
may contribute to early miscarriage 5. Less severe defects affecting the primary 
heart field include septal defects and malformations of the left ventricle, such as 
hypoplastic left heart syndrome and left ventricular noncompaction 26-29. 
Mutations in key primary heart field transcription factors, including Nkx2-5 and 
Tbx5, have been causally implicated in congenital heart disease, as will be 
described below 26,29,30. 
 
Progenitor cells in cardiac development – the second heart field 
 
Lineage tracing experiments in chick embryos revealed that the outflow 
tract of the heart is not derived from the linear heart tube 31. Instead, a population 
of splanchnic mesoderm in the pharyngeal region adjacent to the linear heart 
tube was found to express classic cardiac markers, including Nkx2-5 and Gata4, 
along with the differentiation marker Hnk1, suggesting an undifferentiated cardiac 
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progenitor population 32. Explants of this pharyngeal mesoderm, termed the 
second heart field, were able to proliferate and differentiate in vitro into cardiac 
cells 31,32. Similarly, in vivo, differentiation of this progenitor pool is suppressed by 
Wnt and β-catenin signaling from the neural tube, but upon migration into the 
ends of the linear heart tube, these progenitor cells lose Hnk1 expression and 
gain expression of the myocardial marker MF20 32. The second heart field cells 
differentiate to form the cardiomyocytes, smooth muscle cells, and endocardial 
cells of the outflow tract, inflow tact, and right ventricle (Figure 1.1) 31-33. 
Consistent with that, ablation of the pharyngeal splanchnic mesoderm in chick 
embryos results in absence of outflow tract development 31,34. 
While there is debate over whether the second heart field progenitor cells 
represent a completely separate progenitor population or merely a subpopulation 
of a singular progenitor source, the concept of a second heart field, in which cells 
from a specified region outside of the primitive heart tube differentiate to 
gradually add to and extend the heart tube, is observed in species from humans 
down to zebrafish 12,13,35. Molecularly, the second heart field progenitors share 
many similar cardiac markers and modes of induction with the primary heart field, 
however they also express additional factors somewhat restricted to the second 
heart field, including the transcription factor Isl1 32,33. Cre-based lineage tracing 
studies in mice suggest that derivatives of Isl1-expressing cells comprise over 
90% of cells in the right ventricle and outflow tract, 65-70% of cells in the atria, 
and less than 20% of cells in the left ventricle, the major derivative of the primary 
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heart field (Figure 1.1) 33. Isl1 is conserved in humans, mice, Xenopus, zebrafish, 
lamprey, Amphioxus, Ciona, and Drosophila, though the invertebrate Isl1 is 
somewhat divergent from the vertebrate Isl1 12. In chick, the pattern of second 
heart field Isl1 expression is observed at later stages, though at early stages, Isl1 
expression is observed throughout the heart. As development progresses, Isl1 
expression becomes restricted to the second heart field region as it invades the 
ends of the heart tube 12. This is similar in lower organisms.  
Isl1 is important for second heart field development, as evidenced by 
deletion studies in mice. Isl1-null mice exhibit misshapen, un-looped hearts 33. 
Staining analysis suggests a lack of outflow tract and right ventricle, with the 
entire heart expressing the left ventricular markers Tbx5 and EHand. These 
embryos show increased apoptosis and reduced proliferation and migration of 
second heart field cells into the heart tube, suggesting that Isl1 is necessary for 
survival and development of the second heart field 33. Certain Isl1 haplotypes are 
associated with a 2-3 fold increased odds ratio of congenital heart disease in 
humans, further supporting its important role in heart development 36. 
Nearly two-thirds of all congenital heart disease affects structures derived 
from the second heart field, outweighing the prevalence of defects in primary 
heart field or neural crest-derived structures 7. These second heart field-
associated defects include: double outlet right ventricle, Tetralogy of Fallot, right 
ventricular hypoplasia, pulmonary stenosis, and defects in the semilunar valves, 
including the most common congenital heart defect, bicuspid aortic valve 7,37. 
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Ablation of the second heart field in chick embryos causes conotruncal defects, 
including Tetralogy of Fallot and pulmonary atresia 34. Furthermore, co-
occurrence of conotruncal defects with malformations in the inflow tract in 
humans is consistent with their common second heart field origin 38. Importantly, 
conotruncal defects, which arise from disruptions in the heart looping and 
septation process, have the highest risk of embryonic lethality 39,40. Thus, second 
heart field development is critically relevant in addressing the etiology of 
congenital heart disease. 
 
Genetic causes of congenital heart disease 
 
The importance of cardiac progenitors and heart fields is reflected in our 
present knowledge of the molecular causes of congenital heart disease. 
Currently, mutations in over 60 genes have been causally linked to congenital 
heart disease in humans 10,28. Many of the human disease-causing mutations are 
in key cardiac transcription factors involved in the specification and differentiation 
of cardiac progenitor cells, both in the primary and second heart fields. 
 
Single gene mutations – TBX5 and the primary heart field 
 
In 1997, two groups described mutations in the T-box transcription factor 
TBX5 in patients with Holt-Oram Syndrome, a disease that manifests as a 
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spectrum of cardiac and upper limb defects 29,30. Through exon trapping 
experiments, these groups narrowed in on a previously described disease-
associated region of chromosome 12 and identified several mutations in TBX5 
that segregated with the disease in both familial and sporadic cases in an 
autosomal-dominant fashion. 
In situ and antibody staining analysis in chick, mouse, and human 
embryonic hearts revealed expression of TBX5 in the cardiac crescent and 
subsequent strong staining for TBX5 in the posterior regions of the linear heart 
tube 41. In chick and mouse, TBX5 expression becomes restricted to the atria and 
left ventricle in the looped heart, with little to no expression in the second heart 
field-derived right ventricle and outflow tract. Experiments in humans have 
suggested that TBX5 may be expressed in a broader domain including portions 
of the right ventricle in human embryos, however minimal expression was 
detected in the outflow tract segments 22,41. The phenotypes associated with 
Holt-Oram Syndrome reflect the restricted expression pattern of TBX5, with atrial 
septal defects, ventricular septal defects, and hypoplastic left heart syndrome 
being the predominant defects presenting in patients 41. 
Deletion studies in mice revealed critical roles of TBX5 in promoting 
growth and differentiation of the left ventricle and atria, classic derivatives of the 
primary heart field 20. While TBX5 is not required for development of the cardiac 
crescent or linear heart tube, its expression is essential for growth and 
development of the left ventricle and atria from the posterior regions of the heart 
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tube. In TBX5 knockout mice, arrested development of the posterior regions of 
the linear heart tube disrupt looping and lead to embryonic lethality by E10.5 20. 
In these mice, the second heart field-derived right ventricle and outflow tract 
develop independently of TBX5. Importantly, mice heterozygous for deletion of 
TBX5 phenocopy human Holt-Oram Syndrome, supporting a role for TBX5 in this 
disease process 20. 
Tbx5 synergistically interacts with Nkx2-5 to promote cardiomyocyte 
differentiation 42. Tbx5 target genes include cardiomyocyte structural genes, such 
as myosin and troponin, and differentiation-inducing signaling molecules, 
including Bmp4 43. Consistent with this, overexpression of TBX5 in embryonic 
stem cells causes increased expression of cardiac markers and early onset of 
beating in embryoid bodies 44. The TBX5-overexpressing embryoid bodies 
showed specific increased expression first heart field markers, including Nkx2-5 
and troponin, but no changes in expression of second heart field markers, such 
as Isl1 and Tbx20 44. These findings suggest that TBX5 is important in promoting 
first heart field cardiomyocyte differentiation. 
Since 1997, over 50 mutations in TBX5 have been reported in patients 
with Holt-Oram Syndrome 45. The overwhelming majority of these mutations are 
predicted to be loss-of-function or null-alleles. This led to a theory that Holt-Oram 
Syndrome may arise due to haploinsufficency of TBX5 29,45,46. However, at least 
one gain-of-function mutation in TBX5 has been described in Holt-Oram 
Syndrome, indicating that strict regulation of TBX5 activity is required for proper 
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development 47. Interestingly, while TBX5 mutations cause Holt-Oram Syndrome, 
individual mutations are not predictive of the disease presentation 29,46. For 
example, two patients in the same family sharing the same mutation in TBX5 
may exhibit differing types of cardiac and limb defects and variable severity of the 
disease. Mechanisms of how specific mutations manifest in variable phenotypes 
remain poorly understood. 
 
Microdeletions – 22q11.2 deletion syndrome and the second heart field 
 
While Holt-Oram syndrome cardiac defects primarily affect the septa and 
left side of the heart, other syndromes show arrays of defects focused on second 
heart field-derived structures. For example, 22q11.2 deletion syndrome is a 
disease characterized by cardiac, thymic, and craniofacial defects 48. Patients 
with 22q11.2 deletion syndrome exhibit cardiac defects predominately affecting 
the outflow tract, including Tetralogy of Fallot, pulmonary atresia, interrupted 
aortic arch, double outlet right ventricle, and transposition of the great arteries 48.  
This deletion syndrome, also known as DiGeorge Syndrome, is 
characterized by loss of a 1.5-3 Mb region of chromosome 22 48-50. Sequence 
analysis, mouse modeling, and gene rescue experiments suggest that loss of 
Tbx1 within this deleted region can account for many of the cardiac defects in 
DiGeorge Syndrome patients 50-54. Tbx1, a T-box family member, shows a 
complimentary expression pattern to Tbx5. While Tbx5 expression is robust in 
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the primary heart field-derived left ventricle, cardiac expression of Tbx1 is 
restricted predominately to the second heart field, including the pharyngeal 
mesoderm and cardiac outflow tract 55. Tbx1 is expressed in precursors of the 
right ventricle and outflow tract, structures commonly affected in DiGeorge 
Syndrome 55. 
Importantly, deletion of Tbx1 in mice using different Cre drivers revealed 
that the Tbx1 has separate but complementary roles in various cell types during 
development 53. They found that Tbx1 expression in the pharyngeal endoderm is 
required for septation of the outflow tract while expression in the second heart 
field is required for outflow tract alignment and truncal valve septation 53. These 
findings illustrate that a single protein can have both timing- and cell-type specific 
roles during cardiac development.  
Sequencing studies have identified several mutations in Tbx1 in patients 
with DiGeorge-like phenotypes but no accompanying deletion in chromosome 22 
51. As with Tbx5, the majority of identified Tbx1 mutations are believed to be loss-
of-function or null mutations 51,56. This is consistent with the shared phenotypes 
between patients with Tbx1 mutations and those with deletion of the Tbx1 
genomic region. However, several studies have also reported duplications or 
gain of function mutations in the Tbx1 locus in patients with DiGeorge-like 
phenotypes, suggesting that tight regulation of expression may be a critical factor 
in the disease process 57-59. 
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Signaling pathways – TGFβ1 and connective tissue disorders 
 
Beyond transcription factors, signaling pathways are critical for 
coordinating cell processes during heart development. Consistent with this, 
mutations in key signaling pathways are associated with congenital heart 
diseases, with mechanisms highlighting the important connections between 
extracellular signals, intracellular responses, and interactions between cells and 
the extracellular matrix. 
Loeys-Dietz Syndrome is classified as a connective tissue disorder, a type 
of condition affecting the formation or structure of the extracellular matrix 60. This 
disease is caused by mutations in Tgfβ2, the Tgfβ receptors, TGFBRI and 
TGFBRII, and the downstream effector Smad3 60-62. Affected patients exhibit 
cardiac defects including septal defects, bicuspid aortic valve and, most severely, 
aneurysms in the ascending aorta 60.  
In the heart, organized depositions of collagen, elastin, and other 
extracellular matrix components provide the vessels and valves with the 
structure, strength, and flexibility required for proper function 63-66. The 
extracellular matrix composition is intricately tied to signal transduction, through 
its interaction with receptors and sequestration or activation of growth factors, 
including Tgfβ 67,68. These growth factors, in turn, can regulate synthesis, 
deposition, and remodeling of the extracellular matrix 69. Mutations in Tgfβ 
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pathway genes in patients with Loeys-Dietz Syndrome can disrupt this 
relationship, altering signal transduction and extracellular matrix homeostasis. 
Related to this, mutations in genes encoding collagens and collagen-
related enzymes result in Ehlers-Danlos Syndrome, another connective tissue 
disorder 70,71. While this disease affects many organs, including the joints and 
skin, the most life-threatening complication is aortic dissection, resulting from 
weakened vessel walls. Similarly, mutations in fibrillin, a glycoprotein involved in 
elastin organization, cause Marfan Syndrome, a connective tissue disease 
associated with aortic aneurysm, among other defects 72,73. In both of these 
diseases, patients have shown elevated levels of Tgfβ, further supporting a link 
between Tgfβ, extracellular matrix, and connective tissue disease 61,74,75. This 
supports an established paradox in Tgfβ signaling, where functional analysis of 
TGFBRI and TGFBRII mutations found in patients with Marfan Syndrome or 
Loeys-Dietz Syndrome suggest that these mutations are functionally damaging, 
yet Tgfβ expression is elevated 76. This paradox implies complex regulation and 
activation of the Tgfβ pathway, which is not yet completely understood. 
Tgfβ receptor knockout mice have revealed important functions of Tgfβ 
signaling in regulating smooth muscle cell development and extracellular matrix 
organization 77. Loss of TGFBRII in SM22-positive cells is embryonic lethal 
between E14.5 and E18.5 77. This model deletes TGFBRII in the myocardium at 
E9.5, dorsal aorta at E11.5, and epicardium at E12.5 77. Embryos lacking 
TGFBRII in these cells exhibit abnormal shape and thickness of the aorta, with 
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an incomplete or absent elastin network, and, in some instances, aortic 
aneurysms. These defects were partially attributed to deficiency in synthesis and 
deposition of tropoelastin, associated with impaired expression and synthesis of 
fibulin 5 77.  
In addition to extracellular matrix defects, the TGFBRII-deficient aortic 
smooth muscle cells appeared round and disorganized, suggesting defective 
differentiation 77. This was most apparent in the descending thoracic aorta and 
less dramatic in the proximal aorta, suggesting regional differences in Tgfβ 
signaling requirements in aortic smooth muscle cells. Vascular smooth muscle 
cells arise from several lineages, including the neural crest, and second heart 
field in the proximal aortic arch, and the somites, and other stem cell sources in 
the descending aorta 78,79. Treatment of neural crest stem cells with Tgfβ induces 
expression of vascular smooth muscle contractile proteins, suggestive of a role of 
Tgfβ signaling in smooth muscle differentiation 80. Interestingly, vascular smooth 
muscle cells in culture responded to equal concentrations of Tgfβ in a lineage-
specific manner 80. Neural crest-derived vascular smooth muscle cells exhibited a 
4-8-fold higher transcriptional response to Tgfβ than mesodermal-derived 
vascular smooth muscle cells despite equal expression of Tgfβ receptors 80. This 
differential capacity to respond to Tgfβ may reflect lineage-specific differences in 
intracellular downstream effectors or chromatin states at the target promoters, 
which could either slow or amplify the response to receptor activation. 
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Beyond vessel integrity, Tgfβ signaling is implicated in valve development 
and disease. Bicuspid aortic valve is associated with connective tissue disorders, 
including Loeys-Dietz Syndrome and Marfan Syndrome 81,82. There is also 
correlation between bicuspid aortic valve and aortic aneurysms, suggesting a 
shared molecular mechanism or a cause-effect relationship 68,81,83. Patients with 
bicuspid aortic valve are at increased risk for developing aortic valve disease and 
calcification in adulthood 82. These adult aortic valve pathologies are associated 
with valve interstitial cell activation, extracellular matrix changes, and, 
interestingly, show induction of Tgfβ 65,84,85. The correlations between aortic 
aneurysm, bicuspid aortic valve, and calcific valve disease and the common 
involvement of Tgfβ dysregulation suggest a potential shared mechanism 
between congenital heart defects and acquired adult valve pathologies. 
 
Beyond the single gene – disease penetrance and modifier genes in 
congenital heart disease 
 
Despite identification of single genes and pathways as culprits for human 
congenital heart disease, the majority of cases appear to be multi-genic in origin. 
In humans, congenital heart disease is strongly associated with trisomy and 
monosomy disorders, including Down Syndrome (trisomy 21) and Turner 
Syndrome (females with a single X-chromosome) 86-88. In these cases, loss or 
gain of an entire chromosome leads to copy number changes in hundreds to 
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thousands of genes. However, in both Down Syndrome and Turner Syndrome, 
the prevalence of congenital heart disease is between 25% and 60% 86,87. This is 
well above the population-wide incidence of 1%, strongly suggesting that these 
syndromes predispose patients to congenital heart disease. However, the 
incomplete penetrance of cardiac phenotypes indicates that additional factors are 
required beyond the gain or loss of a single chromosome. In Down Syndrome, 
deletion of either Creld1 or Hey2, in conjunction with trisomy 21, increase the risk 
of congenital heart disease 89. These genes are believed to be modifier genes. 
Even among the “single gene” disorders discussed above, modifier genes 
may be important in influencing disease presentation. In both Holt-Oram and 
DiGeorge Syndromes, mutations in T-box transcription factors segregate with 
disease among families and occur in sporadic cases. However, there is a lack of 
concordance in type and severity of defects among patients sharing the same 
mutation 29,46,50,90. Therefore, although a mutation in TBX1 or TBX5 is indicative 
of disease, they are not predictive of clinical presentation, suggesting that the 
mechanism of disease development involves interaction of other genetic or 
environmental factors beyond the single gene mutation. 
Mouse models of congenital heart disease support the multi-genic etiology 
of congenital heart disease. For example, lethality of Tbx5 heterozygous mice is 
contingent upon genetic background, ranging from 40% to over 90% depending 
on mouse strain 20. In a 22q11.2 deletion mouse model, modulation of sonic 
hedgehog or retinoic acid signaling pathways influences phenotypic expression 
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91. These findings reveal that the molecular etiology of congenital heart disease is 
complex and requires further understanding of interacting pathways and 
transcriptions factors during cardiac development. 
 
Chromatin modifying enzymes in congenital heart disease 
 
Considering the complex molecular pathogenesis of congenital heart 
disease, recent work has focused on understanding chromatin structure and the 
role of chromatin-modifying enzymes in cardiac development and disease. These 
enzymes control gene regulation through their modification or remodeling of 
chromatin, including DNA and histone methylation, histone acetylation, 
ubiquitination, and sumoylation, thereby modulating DNA accessibility 92,93. 
However, many chromatin-modifying enzymes also have functions beyond the 
chromatin, covalently modifying transcription factors and other proteins or acting 
in multi-protein complexes or pathways to facilitate cellular processes 92,94. In 
these capacities, epigenetic enzymes facilitate gene expression, relay and 
interpret signals, and mediate cellular responses and behaviors, including those 
essential for development. 
One line of investigation into the involvement of chromatin-modifying 
enzymes in congenital heart disease is a search for mutations in histone-
modifying genes in patients with congenital heart disease. Recently, whole 
exome sequencing was conducted on over 300 patients with various congenital 
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heart defects, searching for novel mutations 95. Among the mutated genes 
identified in this study, the team found enrichment for histone-modification 
pathways, including H3K4 methylation and H3K27 acetylation, in the patient 
population. This suggests that disruption in histone-modifying pathways may be 
an important avenue of investigation into mechanisms of congenital heart 
disease. 
Indeed, mutations in several histone-modifying genes have been causally 
linked to congenital heart disease. One prominent example is CHD7, an ATP-
dependent chromatin-remodeling enzyme, which is mutated in patients with 
CHARGE syndrome 96-100. The acronym CHARGE describes this complex, multi-
organ disorder including: coloboma of the eye, heart defects, atresia choanae, 
retardation of growth and development, genital abnormalities, and ear 
abnormalities. Heart defects are present in 75% of CHARGE patients. 
Mechanisms of CHD7 function have been dissected using mouse models. 
Knockout of CHD7 in Mesp1-positive mesoderm cells results in cardiac defects 
that correlate well with cardiac abnormalities in humans with CHARGE Syndrome 
101. Interestingly, CHD7 appears to facilitate key cardiac developmental 
processes through non cell-autonomous pathways. For example, embryos with 
mesodermal deletion of CHD7 exhibit coronary vein anomalies that are not 
recapitulated by deletion specifically in the endothelial cells, which give rise to 
these veins 101. Likewise, the neural crest-derived neuronal axons are truncated 
in mesodermal CHD7 knockouts, despite retained expression of CHD7 in the 
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affected cells 101. In the case of the neural crest, CHD7 acts by regulating 
expression of semaphorins, which function as signaling guides for neural crest 
migration. CHD7 is enriched at the enhancer of Sema3c, expression of which is 
reduced in mesodermal CHD7 knockouts, possibly explaining the neuronal axon 
defects 101. CHD7 also interacts with other important cardiac enhancers, 
including the Nkx2-5 enhancer 102. In this case, CHD7 is required for BMP-
induced up-regulation of Nkx2-5. In response to active BMP signaling, CHD7 
interacts with regulatory Smads and localizes to the Nkx2-5 enhancer, where its 
histone binding and nucleosome remodeling activities are required to promote 
Nkx2-5 expression 102. In this ways, CHD7 demonstrates the importance of 
chromatin-modifying enzymes in facilitating a cell’s competence to respond to 
extracellular signals. 
In addition to their gene regulatory roles at enhancers, chromatin-
modifying enzymes have critical chromatin-independent roles during cardiac 
development. Like CHARGE Syndrome, Cornelia de Lange Syndrome is a rare 
genetic disease that causes developmental delays and physical abnormalities 
affecting multiple organ systems, including the heart 103. Congenital heart defects 
are present in 25-30% of patients with Cornelia de Lange Syndrome. Mutations 
in five genes involved in formation and function of the cohesin complex: NIPBL, 
SMC1A, SMC3, RAD21, and HDAC8, cause Cornelia de Lange Syndrome, with 
the presentation and severity of this disease correlating with the specific mutated 
gene 103. HDAC8, one of the genes mutated in Cornelia de Lange Syndrome, is a 
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chromatin-modifying enzyme which functions in a chromatin-independent 
manner, deacetylating SMC3 to facilitate the renewal of the cohesin complex 103-
106. This complex regulates the interaction between sister chromatids during cell 
division. Mutations in HDAC8 lead to a severe form of Cornelia de Lange 
Syndrome, illustrating the importance of HDAC8’s function in this context. 
 
The complex relationship between transcription factors and chromatin – 
illuminating mechanisms and therapeutic potential 
 
As seen in Cornelia de Lange Syndrome, mutations in any one of several 
genes can lead to overlapping phenotypes consistent with their participation in a 
shared biological process. Along the same lines, similar heart defects can be 
characteristic of seemingly unrelated disorders and investigation of these 
commonalities may reveal previously unknown connections between genes and 
pathways in cardiac development. For example, CHARGE Syndrome, caused by 
CHD7 mutations, shares clinical overlap with TBX1-associated DiGeorge 
Syndrome, which suggested a possible link between these two genes 107. 
Indeed, further studies in mice uncovered a genetic interaction between CHD7 
and Tbx1 that exists in mice 108.  
Along with investigating overlapping phenotypes to identify molecular 
interactions, understanding the relationships between transcription factors, 
chromatin, and chromatin-modifying enzymes in the context of normal heart 
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development can help to identify potential affected interactions in disease 
conditions. Going further, a precise molecular understanding of how an identified 
gene mutation or pharmaceutical agent specifically alters a protein’s activity or 
interactions can provide insight into how these disruptions result in disease and 
inform development of treatments to counter these detrimental effects. In pursuit 
of this understanding, model organisms and in vitro experiments are critical in 
probing molecular interactions and biological pathways. 
Many basic science studies have focused on determining how a missense 
mutation affects a protein’s stability and function. Such investigations into 
HDAC8 mutations associated with Cornelia de Lange Syndrome revealed 
predominately loss-of-function of mutant HDAC8 104-106. However, some of these 
mutants retained low levels of enzymatic activity 104. These observations lead a 
team to ask whether a specific small molecule activator of HDAC8, known as 
TM251, could rescue the activity of mutant HDAC8 104. Through in vitro activity 
assays, the team found that the enzymatic activity of HDAC8 mutants could be 
rescued by drug treatment 104. However, this rescue was only observed with 
mutants that had a measureable activity level at baseline. The activity of these 
catalytically inactive mutants could be enhanced; however catalytically-dead 
mutants were unresponsive to drug treatment 104. This suggests that molecular 
rescue of a mutant protein’s activity may be possible, with success dependent on 
the specific type of mutation involved. 
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Moving from a single-protein in vitro rescue to a disease-treatment model 
requires further understanding of both protein and drug interactions throughout a 
whole organism. It is well known that the state of chromatin can aid or hinder a 
transcription factor’s access to regulatory regions of the genome. However, the 
transcription factors, themselves, can assist in shaping this chromatin structure. 
For example, ChIP-seq analysis of Tbx1 and histone modifications in 
differentiating mesoderm revealed an association between Tbx1 binding sites 
and regions of chromatin enriched for H3K4 monomethylation and poor in H3K4 
acetylation 109. Interestingly, deletion of Tbx1 altered the methylation states of 
some of these regions. The researchers found that Tbx1 co-localizes and co-
immunoprecipitates with Kmt2 methyltransferases, possibly acting to recruit 
these methyltransferases to the chromatin 109. This suggests that transcription 
factors may have roles in shaping the chromatin structure of their target sites.  
Interaction between transcription factors and chromatin-modifying 
enzymes may have implications from a modifier gene perspective; chromatin-
modifying genes may alter disease presentation in predisposed genetic 
backgrounds. In DiGeorge Syndrome patients, whole exome sequencing 
discovered single nucleotide variations in histone-modification related genes, 
including KDM2B, JMJD1C, and RREB1, associated with phenotypic disease 
presentation 95. Further analysis revealed a disease association specifically with 
single nucleotide variations in genes related to active chromatin states and not 
with those in genes related to repressed chromatin 95. 
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Importantly, the interactions between Tbx1 and chromatin-modifiers open 
a potential therapeutic avenue to counteract mutations in transcription factors, 
such as Tbx1, by targeting chromatin-modification. Along this line, Fulcoli and 
colleagues treated pregnant mice with TCP, an inhibitor of Lsd1/2 histone 
demethylases, during the critical period for development of DiGeorge Syndrome 
phenotypes 109. TCP treatment, alone, had no obvious adverse affects on 
embryonic development, thus establishing a proof of principle that prenatal 
treatment targeting histone-modifying enzymes could have beneficial results in 
counteracting the effects of transcription factor mutations in congenital heart 
disease development 109. 
 
Chromatin-modifying enzymes as teratogenic drug targets 
 
While prenatal exposure to pharmaceuticals may be a future therapeutic 
avenue to lessen the burden of congenital malformations, pharmaceuticals can 
also function as teratogens. Teratogens, or agents that cause embryonic 
malformations, have been identified to be associated with increased risk of 
congenital heart disease. These include environmental toxins, pharmaceuticals, 
and factors from the maternal environment, such as infections or maternal 
diabetes 8. Importantly, many of these teratogens have been shown to modulate 
the epigenome. 
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One example of such a teratogen is sodium valproate, or valproic acid, 
which is a potent inhibitor of histone deacetylases. Valproic acid can induce 
hyper-acetylation in mouse embryos as quickly as one hour after treatment 110. 
First used in clinical trials for treatment of epilepsy as early as 1964, valproic acid 
was approved by the US Food and Drug Administration in 1978 111. Four years 
later, the first reports were published by the Centers for Disease Control 
describing teratogenic effects of maternal valproic acid treatment on developing 
embryos 111. Children exposed to valproic acid prenatally exhibit increased 
incidence of defects including neural tube defects, cleft palate and lip, and 
cardiac defects 112. Supporting the teratogenic effects of valproic acid, treatment 
of pregnant mice with valproic acid resulted in a dose-dependent increase in 
embryonic cardiac defects including ventricular septal defects 113. Administration 
of valproic acid at the time of cardiac crescent formation yielded the highest 
penetrance of cardiac defects, with 20% of all treated embryos affected 113. 
Furthermore, exposure to either valproic acid or trichostatin A (TSA), another 
Hdac inhibitor, resulted in gross developmental defects and embryonic lethality in 
zebrafish and Xenopus 114. Valproic acid analogs that do not inhibit Hdacs did not 
cause developmental defects 114. These findings, together, illustrate the 
detrimental impact of prenatal exposure to agents that alter the activity of 
chromatin-modifying enzymes. 
 
Histone deacetylases 
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The teratogenic effects of Hdac inhibitors suggest critical functions of 
Hdacs in cardiac development. In addition, as exemplified by the involvement of 
Hdac8 in Cornelia de Lange Syndrome, discussed above, Hdacs may also have 
mechanistic functions in genetic causes of congenital heart disease 106,115,116. 
Determining the biological functions of Hdacs during development could identify 
links to known genetic pathways in congenital heart disease pathogenesis and 
illuminate the specific mechanisms of teratogenic pharmaceutical effects, 
informing further drug design to specifically target therapeutic actions and 
minimize harmful side effects.  
Histone deacetylases are a class of enzymes that are responsible for 
removing acetyl groups from substrates, including histone tails. Unlike 
phosphorylation, which is regulated by over 500 kinases and more than 100 
phosphatases, the acetylome is written and erased by a set of only 18 
acetyltransferases and 18 deacetylases 117. 
The traditional function of histone deacetylases, as their name suggests, 
is to remove acetyl groups from histone tails. Histone acetylation, catalyzed by 
histone acetyltransferases, is associated with chromatin relaxation and active 
gene expression 117. Conversely, deacetylated histones are thought to condense 
chromatin and suppress gene expression. However, recent work examining the 
chromatin occupancy of histone deacetylases found enrichment for histone 
deacetylases at active promoters and a positive correlation between Hdac 
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occupancy and level gene expression 118. The authors of this study propose that 
Hdacs function to regulate acetylation levels at active promoters and may 
participate in maintaining promoters in primed states to allow for rapid activation 
of these genes in response to a stimulus 118. Additionally, Hdacs can regulate 
gene expression and cell behavior through mechanisms other than histone 
modification; Hdacs have been shown to deacetylate a variety of non-histone 
substrates, including transcription factors and cytoplasmic proteins, such as 
structural filaments 94,117. Thus, the biologic functions of Hdacs extend well 
beyond the classical model of histone deacetylation. 
Mammalian histone deacetylases are categorized into four classes based 
on their sequence homology 119. The predominately nuclear class I Hdacs (Hdac 
1, 2, 3, and 8) possess the major deacetylase activity within this gene family 
119,120. By contrast, class IIa Hdacs (Hdac 4, 5, 7, and 9) have up to 1000-fold 
less deacetylase activity than class I Hdacs due to the presence of a histidine 
residue rather than a tyrosine in the enzymatic active site 121. These catalytically 
inactive Hdacs are known to complex with their more active class I counterparts 
121. Hdac6, a class IIb Hdac, is primarily cytoplasmic, restricting its ability to 
deacetylate nuclear proteins, such as histones.120 
Consistent with their important roles as the major active deacetylase 
enzymes, global deletion of any of the class I Hdacs in mice leads to embryonic 
or perinatal lethality 119,122-126. This lethality also suggests a lack of redundancy 
between class I Hdacs during development. Therefore, it is critical to consider the 
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functions of each Hdac individually to determine the roles of Hdacs in the context 
of cardiac development and congenital heart disease. 
 
Hdac8 – a model for class I Hdac involvement in congenital heart disease 
 
As discussed above, mutations in Hdac8, a class I Hdac, are causatively 
linked to Cornelia de Lange Syndrome 103-106,115. This syndrome affects multiple 
organ systems, including the heart. In this context, Hdac8 participates in the 
cohesin complex, deacetylating SMC3, a non-histone protein, to facilitate 
recycling and renewal of complex components 103,104. The established connection 
between Hdac8 and congenital heart disease substantiates the potential 
importance of Hdacs in disease pathogenesis. 
Beyond its association with Cornelia de Lange Syndrome, very little is 
known about cardiac functions of Hdac8. First characterized in 2000, Hdac8 is 
expressed in several adult human tissues, including the heart 127. Hdac8 exhibits 
nuclear localization and intrinsic deacetylase activity, allowing for a possible role 
in transcriptional regulation 127. However, Hdac8 shares only 37% sequence 
homology with the other class I Hdacs and is believed to be the least closely 
related among this class 127. Unlike the other class I Hdacs, Hdac8 has not been 
found to act in a co-repressor complex and does not require cofactors or post-
translational modifications to facilitate its enzymatic activity 127. These differences 
suggest distinct functional roles of class I Hdacs. 
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Hdac1 and Hdac2 – partial redundancy among Hdacs 
 
The most closely related of all class I Hdacs, Hdac1 and Hdac2 are 83% 
identical and have been shown to have some functional redundancy 120,128,129. 
Deletion of Hdac1 and Hdac2 simultaneously in T-cells or ES cells reduces total 
Hdac activity by 50%, suggesting that these are major active deacetylases 130,131. 
Both of these Hdacs are found in the NuRD, CoREST, and Sin3a repressor 
complexes, which can associate with Hdac1 and Hdac2 heterodimers or 
homodimers. Disruption of any one of these complexes in mice leads to early 
embryonic lethality 132-134.  
Despite their suspected redundancy, 40% of Hdac1 exists independent of 
Hdac2 135. For example, the Sin3a complex in T-cells contains predominately 
Hdac1 homodimers 130. Interestingly, when Hdac1 is deleted in this T-cells, 
Hdac2 protein levels increase 2-fold and the mice exhibit only a mild increase in 
histone acetylation and no discernable T-cell phenotype 130. In contrast, deletion 
of one copy of Hdac2 in these Hdac1-null T-cells returns Hdac2 protein 
expression to wild-type levels, leading to a significant increase in histone 
acetylation and defects in T-cell differentiation 130. This demonstrates a retained 
compensatory relationship between Hdac1 and Hdac2, even in some cases 
when homodimers are dominant. However, this compensatory relationship is not 
absolute 130.  
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During embryonic development, Hdac1 is broadly expressed throughout 
the embryo, while Hdac2 shows a more restricted pattern, with strong expression 
in the heart and neural tube during mid-gestation 123,136. Hdac1 is strongly 
expressed in pluripotent stem cells and expression levels of Hdac1 fluctuate over 
the course of ES cell differentiation 137. Deletion of Hdac1, but not Hdac2, in ES 
cells affects expression of pluripotency genes and lineage commitment 138. 
Consistent with its developmental importance in ES cells, global deletion of 
Hdac1 in mice results in lethality by E10.5, with widespread proliferation defects 
and developmental arrest 129,136.  
Stem cell studies have revealed that non-redundant roles of Hdac1 impact 
cardiac differentiation. Hdac1-deficient embryonic stem cells develop into beating 
embryoid bodies with increased expression of cardiac and neuronal markers 138. 
These Hdac1-deficient ES cells show a significant reduction in deacetylase 
activity of the NuRD, CoREST, and Sin3a complexes and an increase in H3K56 
acetylation, indicative of an enzymatically-active role of Hdac1 in this context 138. 
Consistent with these findings, administration of Hdac inhibitors to differentiating 
embryonic carcinoma stem cells increased histone acetylation at the Nkx2-5 
locus and induced expression of Nkx2-5, a key transcription factor in cardiac 
lineage specification 139. Further investigation revealed that Hdac1 occupies the 
Nkx2-5 promoter and its expression and occupancy of the Nkx2-5 promoter 
decrease as the stem cells differentiate into cardiomyocytes. Knockdown of 
Hdac1 promoted Nkx2-5 transcription and cardiomyocyte differentiation while 
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overexpression of Hdac1 suppressed both changes. What’s more, Hdac1 was 
found to physically interact with and suppress the transcriptional activity of the 
Nkx2-5 protein 139. In this way, Hdac1 regulates differentiation of stem cells into 
cardiomyocytes by modulating both the expression and activity of Nkx2-5. 
As with Hdac1, Hdac2 has non-redundant functions relevant to cardiac 
development and disease. Global knockout of Hdac2 causes cardiac 
hypertrophy, with studies reporting either complete or partial neonatal lethality 
123,129. Interestingly, while Hdac2 knockout mice exhibit cardiac hypertrophy and 
decreased body size at birth compared to littermates, those knockouts that 
survive beyond the first month of life recover normal cardiac morphology and 
body size by the age of two months 123. Furthermore, at this stage Hdac2 
deficiency actually protects against hypertrophy and reactivation of the fetal gene 
program. Correspondingly, overexpression of Hdac2 in cardiomyocytes induced 
hypertrophy in the mature heart 123.  
In embryonic cardiomyocytes, Hdac2 functions together with Hopx to 
regulate proliferation 140. Combined deletion of Hdac2 and Hopx leads to 
complete perinatal lethality, with double knockout pups exhibiting ventricular 
septal defects, thickened ventricular walls, and a dramatic increase in 
cardiomyocyte proliferation 140. In this context, Hopx facilitates the interaction of 
Hdac2 with Gata4, a key cardiac transcription factor, allowing Hdac2 to 
deacetylate Gata4 and suppress its transcriptional activity. In doing so, the 
Hdac2/Hopx complex inhibits expression of Gata4-dependent cell cycle 
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regulatory genes, thereby controlling cardiomyocyte proliferation 140. These 
findings, together with the evidence for the role of Hdac2 in cardiac hypertrophy, 
suggest critical functions of Hdac2 in regulating the fetal and neonatal gene 
programs, both developmentally and in adult disease conditions. 
In contrast to global deletion, cardiac hypertrophy was not observed upon 
loss of Hdac2 in any single cardiac cell population, including cardiomyocytes, 
second heart field, smooth muscle, endothelium, or neural crest 129. This implies 
that multiple cell types are involved in the development of cardiac defects 
associated with Hdac2 deficiency. Similarly, mice lacking Hdac1 in 
cardiomyocytes, smooth muscle, endothelial cell, or neural crest are all viable 129. 
While cardiomyocyte specific deletion of either Hdac1 or Hdac2 is tolerated, 
combined deletion of both Hdac1 and Hdac2 in cardiomyocytes leads to lethality 
by P14 129. These double knockout mice exhibited cardiomyopathy and 
conduction defects, with increased expression of cardiac stress markers, 
consistent with heart failure. Hdac1 and Hdac2 were found to jointly regulate 
skeletal muscle and calcium channel genes as part of a repressive complex 129. 
In this context, Hdac1 and Hdac2 exhibit functional redundancy to regulate 
cardiac function. 
 
Hdac3 – deacetylase dependent and independent functions in development 
and disease 
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While Hdac1 and Hdac2 are found in shared complexes and show both 
independent and redundant functions, Hdac3 acts in complexes separate from 
the other class I Hdacs, with non-redundant functions. Hdac3 is enzymatically 
active, exhibits nuclear localization, and is ubiquitously expressed throughout the 
developing embryo 141-143. Global loss of Hdac3 in mice results in lethality by 
E9.5 due to defects in gastrulation, illustrating its developmental importance 124-
126. 
Although Hdac3 is known to be enzymatically active and most of its 
established roles involve deacetylation of substrates, including histones and 
transcription factors, recent evidence suggests that Hdac3 may have essential 
functions independent of its deacetylase capacity 144,145. Hdac3 is found in multi-
protein co-repressor complexes with N-CoR or SMRT 141,142,144,145. Such 
complexes are necessary for Hdac3’s recruitment to the chromatin, as Hdac3 
lacks DNA binding ability. In addition to chromatin recruitment, N-CoR and SMRT 
contain deacetylase-activating domains (DADs), which have been shown to be 
essential for stimulating the enzymatic activity of Hdac3 141,145. However, 
although global loss of Hdac3 is embryonic lethal, mice with homozygous 
mutations in the deacetylase-activating domains of both N-CoR and SMRT are 
viable and live to adulthood 145. In these mutants, chromatin recruitment of Hdac3 
is reduced by nearly 90 percent and immunoprecipitated Hdac3 also shows 
significantly impaired deacetylase activity 145. Viability of these mutant mice 
suggests that Hdac3’s enzymatic activity may be developmentally dispensable. 
	35 
Considering these findings, recent studies have begun to investigate both 
the deacetylase-dependent and deacetylase-independent functions of Hdac3 
during development and disease. One group generated a series of point 
mutations in Hdac3 that abolish Hdac3’s catalytic activity through a variety of 
mechanisms 144. They then attempted in vivo rescue of liver-specific Hdac3 
knockout phenotypes by viral introduction of wild type or deacetylase dead 
Hdac3. They found that interaction with N-CoR and SMRT was essential for 
rescuing liver phenotypes, but the catalytic activity of Hdac3 was dispensable 144. 
The deacetylase-dead mutants that retained interaction with N-CoR and SMRT 
could rescue the cellular and molecular defects of liver-specific Hdac3 knockout 
mice, revealing a deacetylase-independent function of Hdac3 in liver metabolism 
144. 
Hdac3 has also been shown to be important in muscle and heart 
development and function, though the deacetylase-dependence of these 
mechanisms has yet to be explored. During muscle development, Hdac3, 
stimulated by SMRT, interacts with and deacetylates the transcription factor 
Mef2d, inhibiting its activity and repressing myogenesis 146. In the context of 
heart development, Hdac3 is critical for promoting smooth muscle differentiation 
of neural crest cells within the cardiac outflow tract 147. Mice lacking Hdac3 in the 
neural crest exhibit outflow tract defects, including interrupted aortic arch, and 
have a lack of smooth muscle cells within the outflow tract 147. This smooth 
	36 
muscle differentiation defect is attributed to a reduction in expression of the 
Notch ligand Jagged1 upon loss of Hdac3 in the neural crest 147. 
Hdac3 has also been shown to play important roles in diseases processes 
affecting the postnatal heart. Mutations in Nkx2-5 are associated with congenital 
cardiac conduction defects in humans and haploinsufficiency of Nkx2-5 
phenocopies these defects in mice 148. Hdac3 was shown to be involved in 
regulating Nkx2-5 expression through its recruitment by Prox1 to the Nkx2-5 
enhancer in the adult cardiac conduction system 148. Disruption of Nkx2-5 activity 
leads to hypoplasia of Purkinje fibers and the atrioventricular node, the 
conduction components of the heart 148. 
While Hdac3 is involved in regulating Nkx2-5 in the cardiac conduction 
system, deletion of Hdac3 in cardiomyocytes produces no observable 
arrhythmias or conduction defects 149. Instead, Hdac3 has myocardial roles in 
regulating proliferation and cardiac metabolism. Mice with myocardial-specific 
deletion of Hdac3 are born in Mendelian ratios, but develop hypertrophy within 
four weeks which worsens until the mice succumb to heart failure and die by four 
months of age 149. This phenotype was accompanied by up-regulation of genes 
involved in fatty acid metabolism, which is linked to increased activity of PPARα 
149. Upon fasting, lipids accumulate within myocardium of Hdac3 knockout hearts, 
consistent with disrupted cardiac metabolism 149. Interestingly, postnatal deletion 
of Hdac3 in the cardiac and skeletal muscle does not recapitulate this lethal heart 
failure phenotype, suggesting a developmental importance for Hdac3 in 
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cardiomyocytes 150. Mice with postnatal deletion of Hdac3 in cardiac and skeletal 
muscle survive normally on a chow diet, but are sensitive to high fat diet-induced 
hypertrophic cardiomyopathy and heart failure 150. These mice die within weeks 
of switching to a high fat diet, exhibiting increased heart size, cardiac 
hypertrophy, and fibrosis, with down-regulation of genes associated with lipid 
metabolism 150. In this way, Hdac3 is important in mediating the cardiac 
metabolic response to changes in diet. 
Not only is loss of Hdac3 in damaging to cardiac health, but 
overexpression of Hdac3 in cardiomyocytes is also detrimental to cardiac 
development. Transgenic overexpression of Hdac3 in cardiomyocytes results in 
severe hyperplasia that nearly obliterates the ventricular lumens of murine hearts 
at birth 151. The thickened cardiac walls exhibit increased myocyte proliferation 
without altering myocyte cell size. Hdac3 acts within cardiomyocytes to regulate 
proliferation through suppression of the Cdkn1a, a cyclin-dependent kinase 
inhibitor 151. Interestingly, as is observed in the case of Hdac2 and cardiac 
hypertrophy, the cardiomyocyte proliferation and hyperplasia of Hdac3 transgenic 
hearts resolves by two months of age 151. Furthermore, trisomy 5q31.1q35.1, 
which involves duplication of the genomic region surrounding and including 
Hdac3, has been reported in a patient with complex congenital heart disease, 
including interrupted aortic arch and septal defects, suggesting a possible 
involvement of Hdac3 copy number in human congenital heart disease 152. 
Together, the current knowledge of Hdac3 in the heart suggests multiple cell 
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type, stage-specific, and dose-dependent requirements for Hdac3 in cardiac 
development and function.  
 
Aims of this work 
 
While its roles in the neural crest, conduction system, and myocardium 
have been investigated, developmental functions of Hdac3 within the 
mesodermal cardiac progenitor cells have not previously been explored. This 
thesis aims to fill in this gap in understanding by examining the roles of Hdac3 in 
the first heart field and second heart field progenitor cells. Distinct developmental 
and postnatal requirements for Hdac3 in cardiomyocytes argue that Hdac3 has 
evolving functions as an organism develops and matures. The work presented in 
this thesis expands on this theme, describing separate roles of Hdac3 in the 
primary heart field and second heart field. Furthermore, these findings reveal 
novel mechanisms for Hdac3 relevant to congenital heart disease etiology, 
including both deacetylase-dependent and deacetylase-independent functions of 
Hdac3. 
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Chapter II: Histone deacetylase 3 modulates Tbx5 activity to regulate early 
cardiogenesis 
 
Chapter II is adapted from a published manuscript to include supplemental data 
and is included with permission:  
 
Lewandowski SL, Janardhan HP, Smee KM, Bachman M, Sun Z, Lazar MA, 
and Trivedi CM. (2014). Histone deacetylase 3 modulates Tbx5 activity to 
regulate early cardiogenesis. Human Molecular Genetics, 23(14), 3801-3809. 
 
Author contributions: 
I provided all data shown in figure 2.1 A, D, E, and G-K, figure 2.2 A-D, figure 2.3 
A-C, figure 2.4 J, and figure 2.5 A, B, E, K, and N. In addition, I provided the 
model in figure 2.4 B, promoter analysis and primer design relevant to figure 2.2 
E-F, generated the TBX5 mutants used in figure 2.4 H-F, figure 2.5 C-D, G-H, 
and L-M, prepared lentiviruses relevant to figure 2.2 F-I, figure 2.3 D-F, and 
figure 2.4 K. I conducted the mouse breeding relevant to figure 2.2 E-I, figure 2.3 
D-F, and figure 2.4 K and provided the data in table 2.1 and table 2.2. Harish P. 
Janardhan developed the immunoprecipitation protocol used in figure 2.4 A, and 
C-I, and figure 2.5 C-D, F-H, and L-M. Kevin M. Smee performed the sequence 
analysis in figure 2.5 I and purified the HDAC3 protein used in figure 2.4 E. 
Marcos Bachman assisted in generating the HDAC3 terminal deletion constructs 
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used in figure 2.4 B-F. Zheng Sun and Mitchell A. Lazar provided the Hdac3 
ChIP-seq dataset seen in figure 2.2 A-E. Chinmay M. Trivedi performed the 
experiments in figure 2.1 B, C, and F, figure 2.2 E-I, figure 2.3 D-H, figure 2.4 A, 
C-I, and K, figure 2.5 C-D, F-H, and L-M, constructed the cartoon model in figure 
2.6, and supplied the data in tables 2.3 and 2.4. 
 
Abstract 
 
Congenital heart defects often result from improper differentiation of cardiac 
progenitor cells. Although transcription factors involved in cardiac progenitor cell 
differentiation have been described, the associated chromatin modifiers in this 
process remain largely unknown. Here we show that mouse embryos lacking the 
chromatin modifying enzyme histone deacetylase 3 (Hdac3) in cardiac progenitor 
cells exhibit precocious cardiomyocyte differentiation, severe cardiac 
developmental defects, up-regulation of Tbx5 target genes, and embryonic 
lethality. Hdac3 physically interacts with Tbx5 and modulates its acetylation to 
repress Tbx5-dependent activation of cardiomyocyte lineage-specific genes. 
These findings reveal that Hdac3 plays a critical role in cardiac progenitor cells to 
regulate early cardiogenesis.  
 
Introduction 
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Multipotent cardiac progenitor cells are specified during the early stages of 
gastrulation from lateral plate mesoderm in the murine embryo 153. Around 
embryonic day 7.0 (E7.0), these cells migrate to form the cardiac crescent, which 
contains two populations of cardiac progenitors, the first and second heart fields 
24. The cells of the cardiac crescent migrate medially to form a single linear heart 
tube, which subsequently gives rise to a four-chambered heart 25. During this 
process, multipotent cardiac progenitor cells differentiate into various endpoint 
lineages including cardiomyocytes, smooth muscle cells, endothelial cells, and 
specialized conduction cells 154-156. For instance, Nkx2-5-positive bipotent cardiac 
progenitor cells give rise to cardiomyocytes and smooth muscle cells 157.  
Despite recent progress in identifying cardiac progenitor cells, the 
epigenetic and chromatin modifiers regulating progenitor cell fate specification 
are poorly defined 158. Site-specific histone modifications, like acetylation and 
methylation, regulate chromatin structure and provide a signal to recruit lineage-
defining transcription factors 159. For instance, histone acetyltransferase (HAT)-
mediated acetylation of core-histones leads to relaxation of the chromatin 
structure and subsequent recruitment of transcription factors for gene activation. 
Conversely, histone deacetylase (Hdac)-dependent deacetylation leads to 
chromatin condensation and gene repression 119.  
The mammalian Hdacs are classified into four sub-families based on their 
conserved sequences and structure 160. Class I Hdacs (Hdac1, 2, 3, and 8) are 
ubiquitously expressed and play critical roles during development 119. For 
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example, we demonstrated that global loss of Hdac2 in mice causes severe 
cardiac developmental defects including cardiomyocyte hyperplasia 161. Global 
deletion of Hdac3 results in embryonic lethality around E9.5 124,125. In a tissue-
specific context, Hdac3 regulates lipid metabolism and mitochondrial functions in 
the adult heart 124,150.  
Hdacs lack intrinsic DNA binding ability and are recruited to target genes 
via their incorporation into large multi-protein transcriptional complexes as well as 
direct association with transcriptional activators or repressors 160. For instance, 
our recent findings show that Hdac2 interacts with Gata4 and inhibits its 
acetylation and transcriptional activity to regulate embryonic cardiomyocyte 
proliferation 140. Several evolutionarily conserved transcription factors from the T-
box, GATA, b-HLH, MADS box, and homeodomain families are expressed in 
cardiac progenitor cells and regulate various stages of cardiogenesis 162. With 
regards to the T-box family, Tbx5 gain or loss-of-function mutations can result in 
Holt-Oram syndrome, characterized by the presence of atrial and ventricular 
septal defects 20,30. Recent reports demonstrate that gain-of Tbx5 function in 
progenitor cells induces precocious differentiation into spontaneously beating 
cardiomyocytes, suggesting a lineage-defining role for Tbx5 during early 
cardiogenesis 44,163. However, how Tbx5 activity is regulated during 
cardiomyocyte lineage specification remains largely unknown.  
Here we show that cardiac progenitor cell-specific loss of Hdac3 in mice 
leads to complete embryonic lethality, precocious cardiomyocyte differentiation, 
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and severe cardiac developmental defects. Hdac3 regulates Tbx5 acetylation 
and activation of Tbx5-dependent cardiomyocyte lineage-specific genes. Our 
results suggest a novel cardiac progenitor cell-specific function of ubiquitously 
expressed Hdac3 during early developmental stages of cardiogenesis. 
 
Material and methods 
 
Mice - Transgenic Nkx2-5 Cre and Hdac3Flox mice have been previously 
described 164,165. Myh6-Cre (αMHC-Cre) mice were obtained from The Jackson 
Laboratory. The University of Massachusetts Medical School Institutional Animal 
Care and Use Committee approved all animal protocols. 
 
Cell culture, transient transfection and luciferase assays  - HEK293T cells 
were maintained in DMEM with 10% FBS, 100 µg/ml penicillin, and 100 µm/ml 
streptomycin in a 37C incubator with 5% CO2. Hearts from E8.5 mouse embryos 
were collected in DMEM with 10% FBS and plated on gelatin-coated dishes. 
Sub-confluent HEK-293T cells were transfected in 100-mm plates with 12.5µg of 
DNA and 25µl of Polyethylenamine, linear, in 10 ml of 10% FBS medium. 
Luciferase assays were conducted by transfecting sub-confluent HEK-293T cells 
in 6-well plates with 1µg of DNA and 2µl of Polyethylenamine, linear, in 2ml of 
10% FBS media. DNA amount was maintained constant using pcDNA3.1(-) or 
pLJM1-EGFP DNA. Cells were lysed with passive lysis buffer 16 hours after 
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transfection and lysates were analyzed using a dual luciferase reporter assay kit 
according to manufacturers guidelines. Luciferase activity was measured using 
an Omega microplate reader according to manufacturer’s guidelines. 
 
GST protein purification - Cultures of transformant E. coli were grown to an 
optical density at 600 nm (OD600) between 0.6 and 0.8. Transformants were 
induced upon reaching appropriate OD600 with 0.1 mM isopropyl-β-D-
thiogalactopyranoside (IPTG) for 2 hours at 37°C. Fusion proteins were bound to 
GST bead slurry and eluted by Thrombin cleavage for 16 hours at 22°C with 10 
units of Thrombin enzyme.   
 
In vitro acetylation assay  - TBX5 protein, purified from E. coli, was incubated 
with 600ng P300-HAT domain, 1mM Acetyl-CoA, 50µM TSA, and 50mM 
Nicotinamide in HAT Buffer (50nM Tris-HCl, pH8, 0.1mM DTT, 10% glycerol) for 
one hour at 30°C. Acetylated protein was resolved by SDS-PAGE and analyzed 
by Western blot. 
 
Plasmids and site-directed mutagenesis - To generate luciferase reporters, 
tandem repeats of Tbx5 (CTGAGGTGTGAG) or Nkx2-5 (CCACTTAA) 
consensus binding sites were subcloned from pIDT-SMART to pLuc-MCS using 
BglII and HindIII. HDAC3-Flag has been previously described 166. The TBX5 
lentiviral vector was generated by PCR-amplifying TBX5 cDNA from TBX5 
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PCMV-SPORT6 (Open Biosystems), subcloning into pCRII-TOPO (Life 
Technologies), and finally into pLJM1 (Addgene plasmid 19319) 167 using NheI 
and EcoRI. To construct GST-HA-TBX5 bacterial expression vector, HA- TBX5 
was PCR amplified from TBX5 PCMV SPORT6, cloned into pCRII-TOPO (Life 
Technologies), and subcloned to pGEX4T1 (GE Life Sciences) using EcoRI. The 
HDAC3 lentiviral vector was generated by subcloning Flag-HDAC3 cDNA to 
CSCGW2 using NheI and XhoI. Tbx5 and scrambled shRNA lentiviral vectors 
were obtained from the University of Massachusetts shRNA core facility. GFP 
lentiviral vector was obtained from Addgene (Addgene plasmid 15949) 168. 
Lentiviral packaging plasmids were obtained from Addgene: pCMV-dR8.2 
(Addgene plasmid 8455) and pCMV-VSVG (Addgene plasmid 8454) 169. EP300 
was obtained from Addgene (Addgene plasmids: 30489 and 10717). Nkx2-5 was 
obtained from Open Biosystems. Hdac1-Flag was obtained from Addgene 
(Addgene plasmid 13820) 143. KAT5 has been previously described 170. KAT2B 
was obtained from Addgene (Addgene plasmid 8941) 171. C-terminal deletions of 
TBX5 were generated by PCR amplification from HA-TBX5 pLJM1. An internal 
deletion of TBX5 was generated from HA-TBX5 pLJM1 by nested PCR. Deletion 
constructs were cloned into pCR2.1 TOPO and subcloned to pcDNA3.1(-) (Life 
Technologies). TBX5G125R and TBX5K157A, K159A were generated by site-
directed mutagenesis as per manufacturers protocol, using TBX5 pCRII-TOPO 
as a template. TBX5G125R was used as a template to generate TBX5G125R, 
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K157A, K159A by site-directed mutagenesis. All plasmids were verified by 
restriction analysis, sequencing, and Western blot analysis. 
 
Antibodies and reagents - The following antibodies were used in this study: 
Hdac3 (Abcam, Santa Cruz), Tbx5 (Santa Cruz), Myh7 (Santa Cruz), phospho-
histone H3 (Cell Signaling), cleaved caspase-3 (Cell Signaling), acetylated lysine 
(Cell Signaling, Millipore), HA (Santa Cruz), Troponin (Hybridoma bank, Iowa), 
Nkx2-5 (Abcam), Gapdh (Millipore), HRP-conjugated secondary antibodies 
(Santa Cruz), IRDye-conjugated secondary antibodies (Licor), and Alexa Fluor® 
488/546-conjugated secondary antibodies (Life Technologies). 
Paraformaldehyde, paraffin, Harris Modified Hematoxylin, and Eosin-Y were 
purchased from Fisher Scientific. Vectastain Elite ABC Kit, DAB Peroxidase 
Substrate Kit, and VectaShield Mounting Medium were purchased from Vector 
Laboratories. Donkey serum, fetal bovine serum, gelatin, nicotinamide, acetyl-
CoA, and magnetic anti-flag beads were purchased from Sigma. Horse serum, 
Trizol, Superscript First Strand Synthesis Kit, CellsDirectTM One-Step qRT-PCR 
Kit, Power SYBR Green PCR Master Mix, DMEM high glucose with Na pyruvate, 
and Pen/Strep were purchased from Life Technologies. QuikChange II XL Site-
Directed Mutagenesis Kit was purchased from Stratagene. Passive lysis buffer 
and dual-luciferase reporter assay kit were purchased from Promega. Agarose 
IgG and IgA bead slurry were purchased from Santa Cruz and Life Technologies. 
P300-HAT domain was purchased from Millipore. EZ-ChIP assay kit and 
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Trichostatin A (TSA) were purchased from Millipore. GST bead slurry was 
purchased from Qiagen. Polyethylenamine, linear was purchased from 
Polysciences. 
 
Histology, Immunohistochemistry, and Immunofluorescent staining  
Embryos were fixed overnight in 2% paraformaldehyde at 4°C, ethanol 
dehydrated, embedded in paraffin, and sectioned at 6 µm thickness using a 
microtome. Hematoxylin and eosin staining was conducted by deparaffinizing 
and rehydrating sections, two minute incubation in Harris Modified Hematoxylin 
and 30 second Eosin-Y stain. Slides were rinsed and dehydrated with ethanol 
and mounted using Vectashield mounting medium. For immunohistochemistry 
and immunofluorescent staining, sections were deparaffinized and pre-treated 
using heat antigen retrieval with 10mM sodium citrate, 0.05% Tween 20. 
Immunohistochemistry was performed using Vectastain Elite ABC Kit and DAB 
Peroxidase Substrate Kit according to manufacturers guidelines. Sections were 
incubated with primary antibodies against Hdac3 (1:500) or cleaved caspase-3 
(1:100) for one hour at room temperature. Slides were counter-stained with 
hematoxylin for two minutes and mounted with Vectashield mounting medium. 
For immunofluorescent staining, samples were blocked with 10% donkey serum 
and 0.3% Triton X- 100 in 1X PBS for one hour at room temperature. After 
washing with PBS, samples were incubated with Myh7 (1:50) and phospho-
histone H3 (1:100) antibodies for one hour at room temperature or Troponin 
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(1:25) and Nkx2-5 (1:50) antibodies for overnight at 4°C. The samples were 
washed with PBS and incubated for one hour with secondary antibodies: 1:500 
donkey anti-mouse, 1:500 donkey anti-rabbit, 1µg/mL Hoechst in 10% donkey 
serum. Slides were then washed with PBS and mounted with Vectashield 
mounting medium. 
 
Proliferation assay - Sections from three Hdac3Nkx2-5KO and three control 
E8.5 embryos were immunostained with Myh7 and phospho-histone H3 
antibodies and Hoechst nuclear stain. Images were taken of each heart section 
at 40X magnification and images were compiled using ImageJ. The total number 
of nuclei and phospho-histone H3-positive nuclei in Myh7-positive cells were 
counted using ImageJ; the percentage of Myh7-positive nuclei that were 
phospho-histone H3 positive was used as a proliferation index. 
 
Apoptosis assay - Five sections from three Hdac3Nkx2-5KO and three control 
E8.5 embryos were immunostained with cleaved caspase-3 antibody and 
counterstained with hematoxylin. Images of the hearts were taken at 20X 
magnification. The total number of nuclei and the number of cleaved caspase-3 
nuclei were counted in the heart wall. The number of cleaved caspase-3 positive 
nuclei per 1000 nuclei was used as an index of apoptosis. 
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Differentiation assay -  Sections from three Hdac3Nkx2-5KO and three 
control E8.5 embryos were immunostained with Myh7 or Troponin and Nkx2-5 
antibodies. Hoechst was used to stain the nuclei. Images were taken of each 
heart section at 40X magnification. Images were compiled using ImageJ. The 
number of Myh7-positive cells relative to the total number of nuclei in the cardiac 
wall was used as a differentiation index. The number of Nkx2-5+, Troponin-
negative cells relative to the total Nkx2-5+ cells in the cardiac wall was used as a 
differentiation index. 
 
Real Time quantitative PCR - Total RNA was isolated from cardiac cells using 
the CellsDirectTM One-Step qRT-PCR Kit according to manufacturers 
guidelines. Total RNA was isolated from dissected mouse heart using Trizol. 
RNA was reverse transcribed using random hexamers and the Superscript First 
Strand Synthesis Kit. Gene expression was measured by qRT-PCR using SYBR 
Green PCR Master Mix. Signals were normalized to their corresponding Gapdh 
controls, and ratios were expressed as relative expression compared to wild-type 
controls. PCR conditions and primer set sequences are available upon request. 
 
Western blotting - Tissue and cell lysates were prepared in lysis buffer 
consisting of 20mM Tris HCl (pH 7.5), 15mM NaCl, 1mM Na2EDTA, 1mM EGTA, 
1% Triton X-100, 1 µg/mL leupeptin, 2.5mM sodium pyrophosphate, 1mM 
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Na3VO4, and 1mM β-glycerophosphate; 1mM phenylmethylsulfonyl fluoride was 
added before use. Protein samples were resolved by 4-12% SDS-PAGE 
acrylamide gel and transferred to PVDF (poly-vinylidene difluoride) membranes. 
We used primary antibodies to Hdac3 (1:1000), Tbx5 (1:500), acetylated lysine 
(1:1000), and HA (1:1000). Primary antibodies were visualized by 
chemiluminescence with HRP-conjugated secondary antibodies or by infrared 
using IRDye®-conjugated secondary antibodies. Blots were stripped and 
reprobed with Gapdh (1:1000) as a loading control. 
 
Immunoprecipitation - Embryonic heart samples or 293T cells were 
homogenized in immunoprecipitation buffer (50mM Tris-HCl [pH 8.0], 150mM 
NaCl, 0.5% Nonidet P-40, 1mM EDTA, and 1mM DTT) containing 1mM PMSF, 
phosphatase inhibitors (Sigma), and protease inhibitors mixture (Sigma). The 
samples were sonicated using Branson 250 Digital Sonifier with 1s ON and 1s 
OFF pulses at 40% power amplitude for 15s. The lysates were collected by 
centrifugation at 16,000g for 10min at 4°C. Precleared lysates with beads were 
incubated with primary antibodies for 16hrs at 4°C. After incubation for 1hr at 4°C 
with beads, immune-complexes were collected, washed four times with 
immunoprecipitation buffer, and applied to 4-12% SDS-polyacrylamide gels for 
western blot analysis. Efficacy of immunoprecipitation was determined by 
western blot for the immunoprecipitated protein. To measure acetylation of TBX5, 
total cell lysates were prepared from isolated cardiac tissue or transfected 293T 
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cells (48hrs post-transfection) using acetylation assay buffer (20mM Tris-HCl [pH 
7.5], 150mM NaCl, 1mM Na2EDTA, 1mM EGTA, 1% Triton X- 100, 2.5mM 
sodium pyrophosphate, 1mM β-glycerophosphate, 1mM Na3VO4, 1µg/ml 
leupeptin, 1mM PMSF, and 20mM Na-butyrate). 
 
Lentiviral infection  - Subconfluent 293T cells were transfected in 100mm plates 
with 5µg of lentiviral cDNA, 5µg of pCMV-dR8.2, and 2.5µg of pCMV-VSVG, in 
10ml of 2% FBS media. Viral media was collected 48 hours after transfection and 
filtered through a 40 µm cell strainer. Isolated mouse embryonic hearts were 
infected with filtered viral media with 10µg/ml polybrene reagent. The volume of 
viral media was maintained constant using GFP viral media. Infected cells were 
harvested 24- hours post-infection. 
 
Binding site overlap of Hdac3 and cardiac transcription factors  - We 
identified consensus Hdac3 binding motif within 10kb upstream of the 
transcriptional start site of four cardiomyocyte-specific genes: Tnnt1, Tnnt2, 
Tnni2, and Myh7. Real-time PCR primers were designed for each of these Hdac3 
sites and binding of Hdac3 to these regions was evaluated by ChIP-qPCR from 
E8.5 mouse hearts. Regions of Hdac3 enrichment were mapped to the mm9 
mouse genome. We obtained ChIP-seq datasets for Tbx5, Nkx2-5, Gata4, Srf, 
and Mef2a from the NCBI Gene Expression Omnibus (GEO) website (accession: 
GSE21529) and aligned on the mm9 mouse genome and converted to the mm8 
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assembly using UCSC genome browser with liftOver tool to map along with 
regions of Hdac3 enrichment. To measure the degree of overlap between Hdac3 
and each transcription factor, we determined the percentage of Hdac3 
enrichment sites that overlapped with the transcription factor ChIP-seq peaks. 
 
Chromatin immunoprecipitation (ChIP) analysis - ChIP experiments were 
carried out as previously described 172-174. Briefly, isolated cardiac tissue or cells 
from E8.5 mouse embryos were cross-linked in cross-linking solution (1% 
formaldehyde, 1.5mM EGS, 20mM Na-butyrate, 10% FBS) for 15 min, followed 
by quenching with 125mM glycine solution for 5 min and two washes with 1X 
PBS. Chromatin fragmentation was performed by sonication in ChIP SDS lysis 
buffer (50mM Tris-HCl pH 8.0, 10mM EDTA, 1% SDS, 1X Protease Inhibitors), 
using the Branson Sonifier 250 (40% power amplitude, 110s). Proteins were 
immunoprecipitated in ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 
1.2mM EDTA, 16.7mM Tris-HCl pH 8.0, 167mM NaCl, 20mM Na-butyrate, 1X 
protease inhibitor) using IgG, Hdac3 or Tbx5 antibodies. IgG antibody was used 
to determine specificity of Hdac3 or Tbx5 antibodies at the relevant locus. 
Antibody-chromatin complexes were washed two times with low salt wash buffer 
(20 mM Tris-HCl pH 8.0, 150mM NaCl, 2mM EDTA, 0.1% SDS, and 1% Triton X-
100) followed by two washes with lithium chloride wash buffer (10mM Tris-HCl 
pH 8.0, 250mM LiCl, 1mM EDTA, 1% deoxycholate, and 1% Nonidet P-40) and 
TE buffer (10mM Tris-HCl pH 8.0, and 1mM EDTA). After removing wash buffer, 
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cross-linking was reversed overnight at 65°C using Proteinase K buffer (20mM 
Tris-HCl pH7.5, 5mM EDTA, 50mM NaCl, 1% SDS, 20mM Na-butyrate, 50µg/ml 
Proteinase K). The next day, DNA was purified using phenol/chloroform/isoamyl 
alcohol. Precipitated DNA was analyzed by real-time quantitative PCR as 
previously described 165,174,175. Enrichment of target sequences was measured by 
RT-PCR using primers designed against predicted Hdac3 binding motifs in the 
10 kb upstream of the transcription start site of four cardiomyocyte-specific 
genes: Myh7, Tnni2, Tnnt1, and Tnnt2. Relevant locus of Traf or Supth was used 
as a negative control for Tbx5 binding. Relevant locus of Supth was used as a 
negative control for Hdac3 binding. PCR conditions and primer set sequences 
are available upon request. 
 
Hdac3 ChIP-seq analysis  - ChIP-seq of HDAC3 in adult mouse heart was 
conducted as described previously 176. Briefly, hearts were grounded in liquid N2 
and cross-linked in 1% Formaldehyde for 20 min. Whole cell extracts were 
sonicated followed by immunoprecipitation with HDAC3 antibodies (Abcam). The 
precipitated DNA from independent ChIP of 4 difference mice were then pooled 
and amplified according to the guideline of Illumina, followed by deep sequencing 
on Illumina Genome Analyzer IIx. ChIP-seq results were mapped to mouse 
genome (mm8) using Bowtie v0.12.8. Peak calling was carried out by HOMER 
v4.2 (FDR 0.1%) using uniquely mapped reads. 
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Acetylation site prediction - The TBX5 cDNA sequence was retrieved from 
PubMed (accession: BC027942). A predicted protein product was generated 
using the MacVector translation tool. Acetylation site predictions were made 
using three software programs: PAIL, under medium stringency, Premod, and 
Phosida. For analysis using Premod, the sequence was split in two parts 
(residues 1-224 and 225-518). To assess conservation of predicted acetylation 
sites, cDNA sequences were retrieved from PubMed, translated using MacVector 
translation tool, and aligned using ClustalW in MacVector software. 
 
Statistical analysis - Statistical significance between groups was assessed 
using two-tailed Student’s t test or χ2 test. A P value of < 0.05 was considered 
significant. 
 
Results 
 
Loss of Hdac3 in cardiac progenitor cells results in embryonic lethality and 
severe cardiac developmental defects  
Hdac3 is ubiquitously expressed in the developing heart (Fig. 2.1A). 
Germline deletion of Hdac3 results in embryonic lethality at E9.5 125,177. To 
determine the function of Hdac3 during early cardiogenesis, we used Nkx2.5-
driven Cre recombinase to delete Hdac3 in cardiac progenitor cells (Hdac3Nkx2-
5KO). Hdac3Nkx2-5KO mice were not identified at birth (P0), indicating complete  
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Figure 2.1: Developmental myocardial defects due to loss of Hdac3 in 
Nkx2-5+ cardiac progenitor cells. (A) Hdac3 expression was determined in 
E8.5 murine embryo (top) and heart (bottom) by immunohistochemistry. Arrow 
indicates expression of ubiquitous Hdac3. (B) Hematoxylin and eosin-stained 
sections demonstrate membranous ventricular septal defect (top, arrow) and 
hypoplastic ventricular myocardium (middle, arrow) in Hdac3Nkx2-5KO E15.5 
hearts. Immunohistochemistry staining of Hdac3 shows loss of Hdac3 in cardiac 
cells derived from Nkx2-5+ progenitor cells (bottom, arrow). (C) Hematoxylin and 
eosin-staining section of the P0 hearts from Hdac3F/F and Hdac3F/F;αMHC-Cre 
mice demonstrate normal ventricular septum and myocardium (top, middle). 
Immunohistochemistry staining of Hdac3 shows loss of expression in 
differentiated cardiomyocytes (bottom, arrows). (D) Hematoxylin and eosin-
stained sections demonstrate abnormally hypoplastic ventricular myocardium in 
Hdac3Nkx2-5KO E8.5 hearts (top, arrow). Hdac3 immunohistochemistry shows loss 
of expression in Hdac3Nkx2-5KO E8.5 hearts (middle, arrow) compared to control. 
Precocious cardiomyocyte differentiation was assessed by Myh7 
immunofluorescent staining (green, bottom, arrow) in Hdac3F/F and Hdac3Nkx2-5KO 
E8.5 hearts. (E) Quantification of Myh7+ cells in Hdac3F/+ and Hdac3Nkx2-5KO E8.5 
hearts (mean ± SEM, n=3). (F) Transcripts for Myh7, Mybphl, Tnni2, Titin, Tnnt2, 
Tnnt1, and Tnnt3 were detected by real-time qPCR in Nkx2-5-Cre and Hdac3Nkx2-
5KO hearts derived from E8.5 embryos (mean ± SEM, n=3). (G) Cardiomyocyte 
(green, stained by Myh7) proliferation was assessed by phospho-histone H3 co-
staining (red, arrows) in Hdac3F/+ and Hdac3Nkx2-5KO E8.5 hearts. (H) 
Quantification of phospho-histone H3 positive, Myh7+ in Hdac3F/+ and Hdac3Nkx2-
5KO E8.5 hearts (mean + SEM, n=3). N.S., not significant. (I) Quantification of 
phospho-histone H3 positive, Myh7- cells in Hdac3F/+ and Hdac3Nkx2-5KO E8.5 
hearts (mean + SEM, n=3). (J) The population of undifferentiated cardiac 
progenitor cells (Nkx2-5+, Troponin-negative) was assessed by Troponin and 
Nkx2-5 co-immunostaining in Hdac3F/+ and Hdac3Nkx2-5KO E8.5 hearts. The 
number of Nkx2-5+, Troponin-negative cells relative to the total Nkx2-5+ cells in 
the cardiac wall was used as a differentiation index. 
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embryonic lethality (Table 2.1). Hdac3Nkx2-5KO embryos displayed 
significant lethality as early as E11.5 (Table 2.2, 2.3). However, some Hdac3Nkx2-
5KO embryos were identified until mid-gestation (Fig. 2.1B, Table 2.3). Hdac3Nkx2-
5KO embryos were characterized by cardiac defects such as hypoplastic 
ventricular walls and membranous ventricular septal defects (Fig. 2.1B-C). 
Interestingly, genetic deletion of Hdac3 using αMHC-Cre, which is expressed in 
differentiated cardiomyocytes at E9.5 178, did not reveal any embryonic lethality 
or developmental cardiac defects (Fig. 2.1D, Table 2.4) 124. Together, these data 
suggest a primary role of Hdac3 in cardiac progenitor cells during early 
cardiogenesis.  
Cardiomyocyte marker immunostaining revealed a significant increase in 
precociously differentiated cardiomyocytes (Fig. 2.1C, 2.1E). Consistent with 
these findings, we observed robust precocious expression of cardiomyocyte 
lineage-specific genes, including Myh7, Tnni2, Tnnt1, and Tnnt2, in E8.5 
Hdac3Nkx2-5KO hearts compared to control (Fig. 2.1F). We did not observe 
proliferation or apoptosis defects in differentiated Hdac3Nkx2-5KO cardiomyocytes 
at E8.5 (Fig. 2.1G-K). These results suggest that Hdac3 represses differentiation 
of cardiac progenitor cells and expression of cardiomyocyte lineage-specific 
genes during early cardiogenesis.  
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Hdac3 represses Tbx5-dependent transactivation during early 
cardiogenesis 
We next explored the mechanism of cardiomyocyte lineage-specific gene 
regulation by Hdac3 during early cardiogenesis. We identified chromatin 
occupancy of Hdac3 in the conserved noncoding regions within 10 kb upstream 
of Myh7, Tnni2, Tnnt1, and Tnnt2, using an Hdac3 ChIP-seq dataset (Fig. 2.2A-
D, unpublished). ChIP-qPCR analysis confirmed 13 sites occupied by Hdac3 in 
E8.5 wild-type hearts (Fig. 2.2A-D). Comparison with a recent ChIP-seq dataset 
of core cardiac transcription factors revealed significant overlap (>61%) between 
Tbx5 enriched regions and Hdac3 occupied sites 179. ChIP-qPCR analysis 
showed that 11 sites are occupied by both Hdac3 and Tbx5 (Fig. 2.2A-E). To 
determine whether Tbx5 recruits Hdac3 to chromatin in the developing heart, we 
expressed Tbx5-shRNA in E8.5 cultured cardiac cells. Hdac3 ChIP-qPCR 
analysis revealed a significant decrease in Hdac3 enrichment in Tbx5-shRNA 
expressing compared to control cardiac cells at all overlapping regions (Fig. 
2.2F). Tbx5 is known to activate expression of cardiomyocyte-specific genes 
43,44,163. Hence, we examined the requirement of Tbx5 for aberrant expression of 
cardiomyocyte-specific genes in Hdac3Nkx2-5KO hearts. Loss of Hdac3 resulted in 
significant activation of Myh7, Tnni2, and Tnnt2, and this activation was largely 
abolished by Tbx5 knockdown (Fig. 2.2G-I). 
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Figure 2.2:  Hdac3 localizes to a subset of Tbx5-bound cardiomyocyte-
specific enhancers. Tbx5 recruits Hdac3 to enhancer regions of 
dysregulated cardiomyocyte-specific genes. Aberrant expression of 
cardiomyocyte-specific genes in Hdac3-null hearts requires Tbx5 
transcriptional activity. (A-D) Genome browser images showing sites of Hdac3 
enrichment and Tbx5 enrichment in E8.5 mouse hearts along with ChIP-seq 
datasets of core cardiac transcription factors (He et al. 2011) and Hdac3 
upstream of cardiomyocyte-specific genes: (A) Tnnt1, (B) Tnni2, (C) Myh7, and 
(D) Tnnt2. (E) Hdac3 localizes to a subset of Tbx5-bound cardiomyocyte-
specific enhancers. ChIP qPCR analysis of Hdac3 and Tbx5 recruitment to 
promoter-proximal regions of dysregulated cardiomyocyte-specific genes 
performed in wild-type E8.5 hearts (mean ± SEM, n=3). Supth promoter-proximal 
region served as a control. *P < 0.05 by Student’s two-tailed t test. (F) Tbx5 
recruits Hdac3 to enhancer regions of dysregulated cardiomyocyte-specific 
genes. ChIP-qPCR analysis of Hdac3 recruitment to Tbx5-bound sites 
interrogated in scramble (Sc) shRNA or Tbx5 shRNA expressing cultured cardiac 
cells derived from wild-type E8.5 hearts (mean ± SEM, n=3). Traf promoter-
proximal region served as a control. N.S., not significant. (G-I) Aberrant 
expression of cardiomyocyte-specific genes in Hdac3-null hearts requires 
Tbx5 transcriptional activity. Transcripts for Myh7 (G), Tnni2 (H), and Tnnt2 (I) 
were detected by real-time qPCR in Hdac3F/F and Hdac3Nkx2-5KO cultured cardiac 
cells, derived from E8.5 embryos, expressing scramble (Sc) shRNA or Tbx5 
shRNA (mean ± SEM, n=3). 
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To determine the effect of Hdac3 gain-of-function on Tbx5-dependent 
transactivation, we generated a Tbx5-luciferase reporter construct containing five 
consensus Tbx5-binding sites. Transfection of Tbx5 resulted in an approximate 
15-fold activation of the Tbx5-luciferase reporter and this activation was 
significantly inhibited by co-transfection of Hdac3, but not by Hdac1 (Fig. 2.3A-
C). Likewise, Hdac3 gain-of-function repressed Tbx5-mediated activation of 
Myh7, Tnni2, and Tnnt2 in developing cardiac cells (Fig. 2.3D-F). Importantly, 
Tbx5 mRNA and protein levels were unaltered in Hdac3Nkx2-5KO hearts (Fig. 2.3G-
H).  
 
Hdac3 and Tbx5 physically interact  
Immunoprecipitation of endogenous Hdac3 protein from E8.5 heart 
lysates, followed by immunoblotting for Tbx5, indicates that Hdac3 and Tbx5 
proteins interact in vivo (Fig. 2.4A). Hdac3 and Tbx5 also interact in transfected 
HEK-293T cells (Fig. 2.4B). Deletion analysis indicates that the interaction 
between Hdac3 and Tbx5 requires the partial T-box domain of Tbx5 and is 
specific (Fig. 2.4B-G). Approximately 40 different genetic mutations of Tbx5 have 
been identified in human patients with Holt-Oram syndrome 45,180. Interestingly, 
the human TBX5G125R gain-of-function mutation 47 coincides with the T-box 
domain required for interaction with Hdac3 (Fig. 2.4B-G). We found that the 
TBX5G125R mutation affects its interaction with Hdac3 (Fig. 2.4H-I). This finding 
had functional implications, as Hdac3 failed to repress TBX5G125R-mediated 
	64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	65 
Figure 2.3: Hdac3 represses Tbx5-dependent transcriptional activity during 
early cardiogenesis. (A) Tbx5-Luciferase reporter construct was transfected in 
293T cells with or without TBX5 and HDAC3 expression constructs. The 
induction is represented as fold-induction over the normalized luciferase activity 
in the control-transfected cells (mean ± SEM, n=3). (B) Hdac1 does not inhibit 
Tbx5-dependent transactivation. Tbx5-Luciferase reporter construct was 
transfected in 293T cells with or without Tbx5 and Hdac1 expression constructs. 
(mean ± SEM, n=3). N.S. – not significant. (C) Hdac3 does not inhibit Nkx2-5-
dependent transactivation. Nkx2-5-Luciferase reporter construct was transfected 
in 293T cells with or without Nkx2-5 and Hdac3 expression constructs. The 
induction is represented as fold-induction over the normalized luciferase activity 
in the control transfected cells (mean ± SEM, n=3). (D-F) Transcripts for Myh7 
(D), Tnni2 (E), and Tnnt2 (F) were detected by real-time qPCR in TBX5 and/or 
HDAC3 cDNA expressing cultured cardiac cells derived from E8.5 embryos 
(mean ± SEM, n=3). N.S., not significant. (G) Tbx5 transcripts were detected by 
real-time qPCR from E8.5 Nkx2-5-Cre and Hdac3Nkx2-5KO hearts (mean ± SEM, 
n=3). (H) Western blot analysis was performed on total lysates from E8.5 Nkx2-5-
Cre and Hdac3Nkx2-5KO hearts. Gapdh is shown as a loading control. 
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activation of the Tbx5-luciferase reporter construct and transcription of Myh7, 
Tnni2, and Tnnt2 in developing cardiac cells (Fig. 2.4J-K). These results suggest 
that Hdac3 interacts with Tbx5 to repress its transcriptional activity during early 
cardiogenesis.  
 
Hdac3 and EP300 regulate Tbx5 acetylation 
Post-translational modifications such as acetylation and deacetylation regulate 
the activity of cardiac transcription factors 140,181. We examined the ability of 
various Tbx5-associated HATs to modify Tbx5-dependent activation of the Tbx5-
luciferase reporter construct 182,183. TBX5 activity was significantly augmented by 
co-transfection of EP300 but not by KAT5 or KAT2B (Fig. 2.5A-B). Transfection 
experiments in 293T cells followed by TBX5 immunoprecipitation and acetyl 
lysine immunoblotting revealed that acetylated TBX5 levels are markedly 
enhanced by co-transfection of EP300 (Fig. 2.5C-D). Transfection of mutant 
TBX5G125R alone results in a significant increase of the acetylated signal 
compared to wild-type TBX5 (Fig. 2.5C-D). However, co-transfection of mutant 
TBX5G125R with EP300 does not augment the acetylation signal (Fig. 2.5C-D). An 
in vitro acetylation assay confirmed that EP300 acetylates TBX5 (Fig. 2.5E). 
Immunoprecipitation experiment revealed that Tbx5 is significantly acetylated in 
E9.5 wild-type hearts (Fig. 2.5F). Co-transfection with HDAC3 significantly 
diminished acetylated-TBX5 but not acetylated-TBX5G125R (Fig. 2.5G-H).  
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Figure 2.4: Hdac3 interacts with Tbx5. (A) Total lysates from E8.5 wild-type 
hearts were immunoprecipitated by Hdac3 antibody, and western blot was 
performed using Tbx5 antibody. Tbx5, Hdac3 and Gapdh are shown as an input 
control. (B) Schematic representation of TBX5 showing posttranslational 
modification sites and deletion constructs. Tbx5 acetylation sites Lys157 and 
Lys159 throughout human T-box family proteins and between various different 
vertebrate species. A gain-of-function TBX5 mutation, Gly125Arg, is associated 
with Holt-Oram syndrome. (C-G) Total lysates from TBX5 or various TBX5 
deletion constructs transfected 293T cells were immunoprecipitated with anti-HA 
antibody, and western blot analysis was performed with anti-Hdac3 antibody to 
detect Hdac3. (H) Total lysates from Flag-HDAC3 and TBX5 or TBX5G125R cDNA 
expressing 293T cells were immunoprecipitated by Flag antibody to 
immunoprecipitate HDAC3, and western blot was performed with Tbx5 antibody 
to detect TBX5. (I) TBX5 was quantified and normalized to total input Gapdh 
using ImageJ software (mean ± SEM, n=4).	(J) Tbx5-Luciferase reporter 
construct was transfected in 293T cells with or without TBX5, TBX5G125R and 
HDAC3 expression constructs. The induction is represented as fold-induction 
over the normalized luciferase activity in the control-transfected cells (mean ± 
SEM, n=3). (K) Transcripts for Myh7, Tnni2, and Tnnt2 were detected by real-
time qPCR in TBX5G125R and/or HDAC3 cDNA expressing cultured cardiac cells 
derived from E8.5 embryos (mean ± SEM, n=3). N.S., not significant. 
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We identified Lys157 and Lys159 as conserved acetylation sites of TBX5 using 
three independent acetylation site prediction software programs (Fig 2.5I-K).  
Replacement of lysines with alanine to mimic deacetylation resulted in a mutant 
form of TBX5, TBX5K157A-K159A, that could only weakly transactivate the Tbx5-
luciferase reporter (Fig. 2.5K). EP300 failed to enhance TBX5K157A-K159A activity 
(Fig. 2.5K). Furthermore, co-transfection of TBX5K157A-K159A with EP300 showed 
significantly reduced acetylation signal compared to wild-type TBX5 (Fig. 2.5L-
M). We sought to determine whether loss of hyperacetylation of human mutant 
TBX5G125R modulates its activity. We generated a mutant form of TBX5, 
TBX5G125R-K157A-K159A, in which lysine residues 157 and 159 are mutated to 
alanine. This mutant form of TBX5 could not be robustly acetylated by EP300 
and failed to transactivate the Tbx5-luciferase reporter (Fig. 2.5L-N). Taken 
together, these results suggest that Hdac3 functions to deacetylate Tbx5 and 
thus regulate transcriptional activity and differentiation of cardiac progenitor cells 
during early cardiogenesis (Fig. 2.6). 
 
Discussion 
 
Recent studies identified a population of multipotent cardiac progenitor 
cells that progressively become lineage restricted and differentiate into various 
cardiac cell types in a developmental stage-specific manner 184. However, 
epigenetic and chromatin modifiers regulating fate specification of cardiac 
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Figure 2.5: Hdac3 regulates Tbx5 acetylation. (A) EP300 induces TBX5-
dependent transactivation. Tbx5-Luciferase reporter construct was transfected in 
293T cells with or without TBX5 and EP300 expression constructs. Induction is 
represented as fold-induction over the normalized luciferase activity in the 
control-transfected cells (mean ± SEM, n=3). (B) KAT5 and KAT2B do not induce 
TBX5-dependent transactivation. Tbx5-Luciferase reporter  construct was 
transfected in 293T cells with or without TBX5 and KAT5 or KAT2B expression 
constructs. The induction is represented as fold-induction over the normalized 
luciferase activity in the control transfected cells (mean ± SEM, n=3). (C) EP300 
acetylates TBX5 in vivo. Total lysates from TBX5, TBX5G125R and/or EP300 
cDNA expressing 293T cells were immunoprecipitated by TBX5 antibody. 
Acetylated TBX5 was detected by western blot analysis using acetyl lysine 
antibody. (D) Acetylated TBX5 was quantified and normalized to total TBX5 using 
ImageJ software (mean ± SEM, n=3). N.S. – not significant. (E) EP300 acetylates 
TBX5 in vitro. Purified GST/HA-tagged TBX5 was subjected to in vitro acetylation 
using purified EP300. Western blot analysis was performed to determine 
acetylated TBX5 using acetyl lysine antibody. HA-TBX5 is shown as a loading 
control. (F) Tbx5 is acetylated in developing myocardium. Total lysates from E9.5 
wild-type hearts were immunoprecipitated by Tbx5 antibody, and western blot 
was performed using acetyl lysine antibody to detect acetylated Tbx5. Western 
blot for Tbx5 and Gapdh is shown as an input control. (G) HDAC3 deacetylates 
TBX5. Total lysates from TBX5, TBX5G125R and/or HDAC3 cDNA expressing 
293T cells were immunoprecipitated by TBX5 antibody and acetylated TBX5 was 
detected by western blot analysis using acetyl lysine antibody. (H) Acetylated 
TBX5 was quantified and normalized to total TBX5 using ImageJ software (mean 
± SEM, n=3). (I) Conservation of Tbx5 acetylation sites Lys157 and Lys159 
throughout human cardiac T-box family proteins. (J) Conservation of Tbx5 
acetlyation sites 157 and 159 across vertebrate species. (K) Lys157 and Lys159 
are required for EP300-dependent transactivation of Tbx5. Tbx5-Luciferase 
reporter construct was transfected in 293T cells with or without EP300 and TBX5 
or TBX5K157A, K159A expression constructs. The induction is represented as 
fold-induction over the normalized luciferase activity in the control transfected 
cells (mean ± SEM, n=3) (L) EP300 acetylates TBX5 at Lys157 and Lys159. 
Total lysates from TBX5, TBX5G125R, TBX5K157A, K159A, TBX5G125R, K157A, K159A 
and/or EP300 cDNA expressing 293T cells were immunoprecipitated by TBX5 
antibody, and acetylated TBX5 was detected by western blot analysis using 
acetyl lysine antibody. (M) Acetylated TBX5 was quantified and normalized to 
total TBX5 using ImageJ software (mean ± SEM, n=3). (N) Lys157 and Lys159 
acetylation modulate TBX5-dependent transactivation. Tbx5-Luciferase reporter 
construct was transfected in 293T cells with or without TBX5, TBX5G125R, 
TBX5K157A, K159A, and TBX5G125R, K157A, K159A expression constructs. The induction 
is represented as fold-induction over the normalized luciferase activity in the 
control-transfected cells (mean ± SEM, n=3). 
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Figure 2.6: Proposed model depicting Hdac3 interacting with Tbx5 to 
repress cardiomyocyte lineage-specific genes in Nkx2-5+ cardiac 
progenitor cells during early cardiogenesis. 
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progenitor cells remain elusive. Our present work suggests that ubiquitously 
expressed Hdac3 plays a critical role in cardiac progenitor cells during early 
stages of cardiogenesis. Mice lacking Hdac3 in cardiac progenitor cells exhibit 
complete embryonic lethality and precocious differentiation into the 
cardiomyocyte lineage. The resulting hearts show hypoplastic ventricular walls 
and membranous ventricular septal defects. Cardiomyocyte lineage-specific 
genes are upregulated. Our data suggest that this is due, at least in part, to 
enhanced Tbx5 transcriptional activity, which in turn is due to Tbx5 hyper-
acetylation.  
We observed that Hdac3 binds at a subset of Tbx5-bound sites within 
regulatory regions of cardiomyocyte lineage-specific genes. Moreover, Tbx5 is 
able to recruit Hdac3 to chromatin. The available data suggest that several 
transcription factors synergistically interact with Tbx5 to promote early 
cardiogenesis 185. For example, Tbx5 associates with Nkx2-5 to promote 
cardiomyocyte differentiation 42. In contrast, our findings support a model in 
which Hdac3 interacts with Tbx5 to block the Tbx5-dependent activation of 
cardiomyocyte lineage-specific genes in cardiac progenitor cells. Consistent with 
our findings, recent work demonstrates that Tbx5 gain-of-function is sufficient to 
induce cardiomyocyte lineage specification from cardiac mesoderm 163. 
Conversely, loss of Tbx5 function results in early embryonic lethality due to 
impaired cardiac differentiation 20. Of note, Hdac3 gain-of-function failed to inhibit 
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Nkx2-5-dependent transactivation, suggesting that the functional relationship 
between Hdac3 and Tbx5 is specific (Fig. 2.3C). 
TBX5, the causative gene in Holt-Oram Syndrome, was the first identified 
single-gene mutation giving rise to congenital heart defects (CHDs) 29,30. Several 
pathogenic mutations of TBX5, located within the highly conserved T-box 
domain, have been reported in patients with or without Holt-Oram Syndrome 45. 
Further studies demonstrated that several of these mutations cause, at least in 
part, defective interactions between TBX5 and NKX2-5 or GATA4 to affect 
cardiac gene expression and lead to CHDs 20,186. Our studies revealed that the 
human TBX5G125R mutation, located within the T-box domain, disrupts interaction 
between TBX5 and HDAC3. Furthermore, HDAC3 fails to repress the 
transcriptional activity of TBX5G125R, resulting in activation of cardiomyocyte 
lineage-specific genes in cardiac progenitor cells. Consistent with our findings, 
TBX5G125R mutation results in gain-of-function in human patients with Holt-Oram-
Syndrome 47.  
Recent reports demonstrate that acetylation of cardiac transcription 
factors modulate their activity 181. Acetylation of Tbx5 has not been reported, 
however, there are reports suggesting cooperation between Tbx5 and histone 
acetyltransferases 182,183. We show that EP300 directly acetylates TBX5 to 
enhance its transcriptional activity. Further, we identified conserved acetylation 
sites of TBX5, Lys157 and Lys159, that are important for EP300-mediated 
acetylation and transcriptional activation. Although Lys157 and Lys159 are 
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conserved among various TBX genes, functional acetylation targets could be 
different within TBX family. Indeed, we observed that Lys234, conserved among 
TBX family, was not required for TBX5 acetylation or activity (not shown). Future 
mass spectrometry analysis will be needed to identify all the acetylated lysine 
residues within TBX5.  
HDACs regulate gene expression by deacetylating histone and non-
histone proteins 119. Our data suggest that Tbx5 is a novel non-histone catalytic 
target of Hdac3 in the embryonic heart. Overall, our findings support a model in 
which Hdac3 deacetylates Tbx5 and represses Tbx5-dependent transcriptional 
activity to maintain the multipotent state of cardiac progenitor cells. Loss of 
Hdac3 removes this brake to precociously activate cardiomyocyte lineage-
specific genes in progenitor cells, likely explaining precocious differentiation of 
cardiomyocytes in Hdac3Nkx2-5KO embryos. This is consistent with the model 
where transient binding of HDACs maintain a low level of acetylation and prevent 
activation of primed genes in pluripotent cells 118. However, alternate functions of 
Hdac3, related to proliferation, histone deacetylation, or chromatin remodeling, 
remain as plausible causes of precocious differentiation observed in Hdac3Nkx2-
5KO heart. Indeed, transient proliferation arrest of undifferentiated cardiac cells 
could explain, in part, precocious differentiation and hypoplastic ventricular walls 
in E8.5 Hdac3Nkx2-5KO hearts (Fig. 2.2G-J). Recent studies have suggested that 
functions unrelated to catalytic activity of Hdac3 may also exist and may require 
nuclear compressor corepressor NCoR 144,187. Thus, it will be critical in future 
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experiments to determine whether the catalytic activity of Hdac3 and NCoR is 
required for its normal function during early cardiogenesis.   
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Abstract 
 
About two-thirds of human congenital heart disease (CHD) involves second heart 
field (SHF) derived structures. Histone-modifying enzymes, histone deacetylases 
(HDACs), regulate the epigenome; however, their functions within the second 
heart field remain elusive.  Here we demonstrate that histone deacetylase 3 
(Hdac3) orchestrates epigenetic silencing of Tgfβ1, a causative factor in CHD 
pathogenesis, in a deacetylase-independent manner to regulate development of 
SHF-derived structures. In murine embryos lacking Hdac3 in the SHF, increased 
Tgfβ1 bioavailability is associated with ascending aortic dilatation, outflow tract 
malrotation, overriding aorta, double outlet right ventricle, aberrant semilunar 
valve development, bicuspid aortic valve, ventricular septal defects, and 
embryonic lethality. Activation of Tgfβ signaling causes aberrant endothelial-to-
mesenchymal transition (EndMT) and altered extracellular matrix homeostasis in 
Hdac3-null outflow tracts and semilunar valves and pharmacological inhibition of 
Tgfβ rescues these defects. Hdac3 physically recruits methyltransferase Ezh2 to 
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the Ncor complex to enrich trimethylation of lys27 on histone H3 at the Tgfβ1 
regulatory region and thereby maintains epigenetic silencing of Tgfβ1 specifically 
within the SHF-derived mesenchyme. Wild-type Hdac3 or catalytically-inactive 
Hdac3 expression rescue aberrant EndMT and epigenetic silencing of Tgfβ1 in 
Hdac3-null outflow tracts and semilunar valves. These findings reveal that 
epigenetic dysregulation within the SHF is a predisposing factor for CHD. 
 
Introduction 
 
Congenital heart disease is the most common of all birth defects, the 
leading cause of infant mortality 188. Cardiac morphogenesis in the mouse begins 
at around embryonic day 7.0 (E7.0), when subset of cells derived from antero-
lateral mesoderm forms the cardiac crescent 153. This crescent contains first and 
second heart field cardiac progenitor cells 24. The first heart field progenitor cells 
are the principal contributor to the primary heart tube, the left ventricle, AV canal 
and atria 189. The second heart field progenitor cells extensively contribute to the 
outflow tract, semilunar valves, atria, right ventricle, primary atrial septum, and 
ventricular septum 31-33,190,191. Indeed, ablation or genetic manipulation of second 
heart field progenitor cells and their derivatives leads to outflow tract malrotation, 
overriding aorta, double outlet right ventricle, aberrant semilunar valve 
development, and ventricular septal defects 34,192,193. In humans, about two-thirds 
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of congenital cardiac defects involve the outflow tract, semilunar valves or 
ventricular septum 7.  
 Patterning of the second heart field requires several signaling pathways 
and their interaction with transcriptional regulators 194. Transforming growth 
factor-β (Tgf-β) family members are among the pioneer signaling molecules that 
induce endothelial-to-mesenchymal transition (EndMT) to form semilunar valve 
cushions in the developing outflow tract 195-197. Subsequent elongation, 
expansion and extracellular matrix remodeling transform these cushions into the 
mature semilunar valves 66,85,198. During these valvular remodeling processes, 
regulation of TGF-β bioavailability appears to be crucial. For instance, patients 
with semilunar valve pathologies, such as semilunar valve stenosis, regurgitation, 
and aberrant deposition of myofibroblasts and extracellular matrix, display 
elevated TGF-β levels 84,199,200. Indeed, exogenous Tgf-β transforms cultured 
valvular interstitial cells into myofibroblasts and promotes excessive secretion of 
extracellular matrix 201-203. Elevated Tgf-β level is also implicated in the 
pathogenesis of connective tissue disorders such as Marfan syndrome, Ehlers-
Danlos syndrome and Loeys-Dietz syndrome 61,74,75. Interestingly, patients with 
these syndromes frequently display congenital cardiovascular anomalies, such 
as aortic dilatation, outflow tract defects, bicuspid aortic valve, semilunar valve 
stenosis, and ventricular septal defects 60,204,205. How the second heart field 
progenitor cells interpret elevated TGF-β at the chromatin level in these 
connective tissue disorders remains to be elucidated. 
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 Extracellular matrix tightly regulates the bioavailability of active TGF-β 206. 
For instance, extracellular matrix proteoglycans, such as decorin (Dcn), biglycan 
(Bgn), and fibromodulin (Fmod), sequester Tgf-β to limit its activity 207. Mice 
lacking Dcn, Bgn or Fmod display elevated Tgf-β activity and phenotypes 
observed in Marfan syndrome or Ehlers-Danlos syndrome 208-210. Indeed, 
proteoglycan deficiencies have been demonstrated in patients with these 
syndromes 211. Proteoglycans expressed in the developing outflow tract and 
semilunar valves also play a key role in the assembly of collagen fibers in the 
extracellular matrix 210,212. Patients with collagen deficiency, such as COL3A1 
mutations in Ehlers-Danlos syndrome, show elevated TGF-β levels 75.  How 
extracellular matrix homeostasis is regulated remains an area of intense 
research.  
 The active form of TGF-β binds to TGFBR2 and TGFBR1, which in turn 
phosphorylate Smad2/3 (R-Smads) to promote assembly of heteromeric complex 
with Smad4. Activated SMAD complex accumulates in the nucleus, where it 
recruits transcription co-factors and chromatin modifiers to regulate the 
expression of target genes 206. Several factors, in addition to TGF-β, play critical 
roles to trigger activation and amplification of intracellular TGF-β signaling 
pathway at multiple levels 206. For instance, transcription factor Snai1 interacts 
with Smad3/4 to repress endothelial gene expression and thereby augments 
TGF-β mediated mesenchymal transition 213. EndMT, a specialized form of EMT, 
is the complex biological process in which endothelial cells trans-differentiate into 
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mesenchymal cell types, including smooth muscle-like and fibroblast-like cells. 
EndMT has been implicated in several pathological processes including fibrotic 
disorders and cardiac valvular diseases. A complex orchestration of several 
signaling pathways, including TGF-β signaling, initiates and promotes EndMT. 
However, the molecular and epigenetic mechanisms regulating termination of 
EndMT remain elusive.  
Histone deacetylases (HDACs) are chromatin-modifying enzymes that 
regulate the epigenome 160. The mammalian HDACs are classified into five 
subfamilies based on their phylogenetic analysis and sequence homology. Class 
I HDACs (Hdac1, Hdac2, Hdac3, and Hdac8) play critical roles at various stages 
of development 119. For instance, global loss of Hdac1 or Hdac3 results in early 
embryonic lethality around E9.5 119. Similarly, mice lacking Hdac2 or Hdac8 
display lethality at birth 123,214,215. Our group and others, using gene inactivation 
studies in mice, have demonstrated vital functions for Class I Hdacs in 
cardiomyocyte proliferation, differentiation and hypertrophy 123,140,151,216. 
However, functions of Hdacs in second heart field development remain 
undefined. 
Hdacs lack intrinsic DNA-binding domains but are recruited to the 
chromatin via their interaction with transcription factors, co-factors, and large 
multiprotein transcriptional complexes 160. For instance, Hdac3 is an integral part 
of nuclear receptor corepressor (Ncor) or its homologue silencing mediator of 
retinoic and thyroid receptors (SMRT). Interaction of Hdac3 with the deacetylase 
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activating domain of Ncor/SMRT is required for its enzyme activity. Interestingly, 
recent evidences suggest that enzymatic activity of Hdac3 is dispensable, but its 
interaction with Ncor/SMRT is essential for transcriptional repression. However, 
molecular mechanisms that mediate the deacetylase-independent function of 
Hdac3 remain to be defined. Recent study shows that Hdac4 controls histone 
methylation in response to elevated cardiac overload, suggesting Hdacs may 
recruit histone methyltransferases to the chromatin.  
In this study, we demonstrate a deacetylase-independent role for Hdac3 
as an epigenetic-silencer of Tgf-β1 within the second heart field with direct 
implications for human Tgf-β pathway-associated cardiovascular anomalies. As a 
part of the Ncor complex, Hdac3 recruits enhancer of zeste homologue 2 (Ezh2), 
the major histone methyltrasferase of the polycomb repressor complex 2 (PRC2), 
to mediate epigenetic silencing of TGF-β1 specifically within the second heart 
field-derived mesenchymal cells and thereby promotes termination of EndMT. 
Genetic deletion of Hdac3 in the murine second heart field results in increased 
Tgf-β bioavailability within mesenchymal cells, perpetual activation of 
mesenchymal cells, aberrant EndMT, and altered extracellular matrix 
homeostasis, observed in patients with semilunar valve pathologies. Together, 
these results uncover that epigenetic silencing mediated by Hdac3 in a 
deacetylase-independent manner orchestrates second heart field development, 
which may be a molecular target in human cardiovascular anomalies.  
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Materials and Methods 
 
Mice - Transgenic Mef2C-AHF-Cre, Cdh5-Cre, Hdac3flox and knock-in Isl1-Cre 
mice were previously described 165,190,217,218. Tagln-Cre (Sm22α-Cre), Myh6-Cre 
(αMhc-Cre), and R26R-LacZ mice were obtained from The Jackson 
Laboratories. The University of Massachusetts Medical School Institutional 
Animal Care and Use Committee approved all animal protocols. 
 
Histology - Tissue samples were fixed in 2% paraformaldehyde at 4°C 
overnight, ethanol dehydrated, embedded in paraffin and sectioned at 6-8 micron 
thickness using a microtome. 
 
Antibodies and reagents - The following antibodies were used in this study: 
Hdac3 (Abcam and Santa Cruz), phospho-Hdac3 (S424) (Cell Signaling), Tgf-β 
pan specific polyclonal antibody (R&D Systems), Smad2/3 (Santa Cruz), 
phospho-Smad2/3 (Ser 423/425) (Santa Cruz), Vimentin (Santa Cruz), PECAM1 
(BD Pharmingen), Troponin T (Hybridoma Bank, Iowa), MF-20 (Hybridoma Bank, 
Iowa), cleaved caspase-3 (Cell Signaling), RNA polymerase II (Abcam), Ezh2 
(Abcam), Ncor1 (Abcam), H3K27ac (Abcam), H3K27me3 (Abcam), IgG (R&D 
Systems), Gapdh (R&D Systems), Flag (Sigma), α-tubulin (Sigma), IRDye-
conjugated secondary antibodies (Licor), Alexa Fluor® 546-conjugated 
secondary antibody (Life Technologies), and biotinylated universal pan-specific 
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antibody (Horse anti-mouse/rabbit/goat IgG) (Vector Laboratories). Recombinant 
Tgf-β was purchased from R&D Systems. Alcian blue, alkaline alcohol, Orcein, 
alcoholic hematoxylin, ferric chloride, Lugol’s Iodine, Woodstain Scarlet-Acid 
Fuchsin, phosphotungstic acid, Saffron, Bouin’s fixative, Weigert’s Iron 
Hematoxylin A, Weigert’s Iron Hematoxylin B, phosphomolybdic acid-
phosphotungstic acid, Aniline blue, and Van Gieson’s solution were purchased 
from Electron Microscopy Sciences. Harris Modified Hematoxylin, Eosin-Y, 
ethanol, Xylenes, glacial acetic acid, paraformaldehyde, paraffin, potassium 
ferricyanide, potassium ferrocyanide, and deoxycholic acid were purchased from 
Fisher Scientific. Polyethylenamine, linear, was purchased from Polysciences. X-
gal was purchased from 5 Prime. VectaShield Mounting Medium, Vectastain Elite 
ABC Kit, and DAB Peroxidase Substrate Kit were purchased from Vector 
Laboratories. RNeasy Mini Kit and GST bead slurry were purchased from 
Qiagen. Power SYBR Green PCR Master Mix, Superscript First Strand Synthesis 
Kit, TOPO-TA Cloning Kit, DMEM high glucose with NA pyruvate, Pen/Strep, and 
horse serum were purchased from Invitrogen. CellsDirectTM One-Step qRT-PCR 
Kit, insulin-transferrin-selenium (ITS), Epoxy M-450 dynabeads, and Trizol were 
purchased from Life Technologies. Rat tail collagen type I was purchased from 
BD Biosciences. iScript reverse transcription supermix was purchased from 
BioRad. Sandwich ELISA assay kit for Tgfβ1 was purchased from R&D Systems. 
Sandwich ELISA assay kit for phospho-Smad2/3 was purchased from Cell 
Signaling. QuikChange II XL Site-Directed Mutagenesis Kit was purchased from 
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Stratagene. Passive lysis buffer and dual-luciferase reporter assay kit were 
purchased from Promega. Fetal bovine serum, donkey serum, gelatin, and 
magnetic anti-flag beads were purchased from Sigma. Agarose IgG and IgA 
bead slurry were purchased from Santa Cruz and Life Technologies. EZ-ChIP 
assay kit was purchased from Millipore. TaKaRa DNA ligation kit was purchased 
from Clontech. 
 
Hematoxylin and eosin staining - Hematoxylin and eosin staining was 
performed by deparaffinizing sections in Xylenes, rehydrating through an ethanol 
gradient, 30 second or 2 minute stain with 30% or 100% Harris Modified 
Hematoxylin, and a 30 second counter-stain with Eosin-Y. Slides were rinsed 
and dehydrated with ethanol, cleared with Xylenes, and mounted with 
Vectashield mounting medium. 
 
Movat’s pentachrome staining - Movat’s pentachrome staining was conducted 
by deparaffinizing and rehydrating slides, followed by a 20 minute stain in Alcian 
blue, 1 hour differentiation in alkaline alcohol, 20 minute stain in Orcein-Verhoeff 
solution (Orcein, alcoholic hematoxylin, ferric chloride, and Lugol’s Iodine), 2 
minute stain with Woodstain Scarlet-Acid Fuchsin, rinse in acetic acid, and 10 
minute differentiation in 5% phosphotungstic acid, followed by a 15 minute stain 
in Saffron. Sections were dehydrated in ethanol, cleared in Xylenes, and 
mounted with Vectashield mounting medium. 
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Masson’s trichrome staining - Masson’s trichrome staining was performed by 
deparaffinizing and rehydrating sections through an ethanol gradient followed by 
a 1 hour mordant in Bouin’s fixative at 56C. Samples were then washed and 
stained for 5 minutes in a solution of Weigert’s Iron Hematoxylin A and Weigert’s 
Iron Hematoxylin B. Following washing, samples were differentiated in 
phosphomolybdic acid-phosphotungstic acid for 15 minutes, stained in Aniline 
blue solution for 20 minutes, and differentiated in 1% acetic acid for 3 minutes. 
Samples were then dehydrated in ethanol, cleared in Xylenes, and mounted with 
Vectashield mounting media. 
 
Modified Verhoeff Elastic-Van Gieson stain - Modified Verhoeff Elastic-Van 
Gieson stain was conducted by deparaffinizing and rehydrating sections, staining 
for 7 minutes in Verhoeff working solution (1.8% alcoholic hematoxylin, 0.8% 
ferric chloride, 20% Lugol’s iodine), washing in running water, differentiating for 1 
minute in 0.4% ferric chloride, and counterstaining for 3 minutes in Van Gieson’s 
solution. Samples were then ethanol dehydrated, cleared with Xylenes, and 
mounted with Vectashield mounting media. 
 
LacZ staining - Tissue samples were dissected in PBS, and then fixed in 2% 
paraformaldehyde for 30 minutes at 4C. After washing in PBS at room 
temperature, samples were stained overnight in LacZ staining solution (5 mM 
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potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM MgCl2, 0.01% 
deoxycholic acid, 0.04% NP-40, 0.1% X-gal, in 1X PBS) at 37C in the dark. 
Samples were then washed in PBS and fixed overnight in 4% paraformaldehyde. 
 
Plasmids and site-directed mutagenesis - Flag-HDAC3 pcDNA3.1(-) and the 
Flag-HDAC3 lentiviral vector were previously described 216. GFP lentiviral vector 
and lentiviral packaging plasmids were obtained from Addgene: pLOVE-GFP 
(Addgene plasmid 15949), pCMV-dR8.2 (Addgene plasmid 8455) and pCMV-
VSVG (Addgene plasmid 8454). Lentiviral plasmids expressing Hdac3-shRNA, 
Ezh2-shRNA, Ncor1-shRNA, and scrambled-shRNA control were obtained from 
the University of Massachusetts shRNA Core Facility. Flag-HDAC3H134A/H135A was 
generated by site-directed mutagenesis as per manufacturer’s protocol, using 
Flag-HDAC3 pcDNA3.1(-) as a template and subcloned to CSCGW2. To 
generate the Tgf-β1 luciferase construct, a 1309bp promoter-proximal region 
immediately upstream of the translational start site of Tgf-β1 was PCR amplified 
from mouse genomic DNA, gel-purified, and cloned into pCR2.1 TOPO (Life 
Technologies) following the manufacturer’s protocol. The promoter was 
subcloned from pCR2.1 TOPO to pGL3-basic (Promega). An Hdac3 binding site, 
identified using published ChIP-seq data and confirmed by ChIP-qPCR from 
murine valve tissue, was deleted from the 3’ end of the Tgf-β1 promoter-proximal 
region by PCR amplification using the Tgf-β1 luciferase vector as a template. The 
Tgf-β1 deletion promoter was gel-purified, cloned into pCR2.1 TOPO, and 
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subcloned into pGL3-basic. All generated plasmids were verified by restriction 
analysis and sequencing. 
 
Immunohistochemistry - For immunohistochemistry, sections were 
deparaffinized in Xylenes and pre-treated using heat antigen retrieval in sodium 
citrate buffer (10mM sodium citrate, 0.05% Tween 20, pH 6). 
Immunohistochemistry was conducted using Vectastain Elite ABC Kit and DAB 
Peroxidase Substrate Kit according to manufacturers guidelines. Sections were 
incubated with cleaved caspase-3 antibody (1:100) for one hour at room 
temperature or Hdac3 antibody (1:250) or phospho-Smad2/3 antibody (1:50) 
overnight at 4oC. Biotinylated universal pan-specific antibody (horse anti-
mouse/rabbit/goat IgG) was used for phospho-Smad2/3 immunostaining in place 
of the Vectastain Elite ABC Kit secondary antibody according to manufacturer’s 
guidelines. For counter-staining, slides were rinsed and then incubated with 30% 
hematoxylin for 30 seconds after DAB developing. All slides were ethanol 
dehydrated, cleared with Xylenes, and mounted with Vectashield mounting 
medium. For immunofluorescent staining, sections were deparaffinized and 
rehydrated through xylenes and an ethanol gradient. Slides were rinsed in PBS 
and antigen retrieval was performed in sodium citrate buffer (10mM sodium 
citrate, 0.05% Tween 20, pH 6.0) for 10 minutes at 95C. After rinsing, sections 
were blocked in 10% donkey serum, 0.3% Triton X-100 in PBS for one hour at 
room temperature. Sections were then washed in PBS and incubated with 
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smooth muscle actin antibody (1:100) in 10% donkey serum and PBS for one 
hour at room temperature or MF-20 (1:50) or Troponin (1:25) antibodies in 10% 
donkey serum in PBS overnight at 4C. Finally, slides were washed in PBS, 
incubated in secondary antibody (donkey anti-mouse 546, 1:500, with Hoechst, 
1:1000, in 10% donkey serum, PBS) for one hour at room temperature, rinsed in 
PBS, and mounted with Vectashield mounting media. 
 
Biometric analysis - Aortic diameter was measured from 2X images of 
dissected hearts at three levels (tubular aortic trunk, proximal aortic arch, and 
intermediate aortic arch) using NIS-Elements analysis software (Nikon). 
Ventricular wall thickness and valve area measurements were made from 2X and 
10X images, respectively, of position-matched hematoxylin and eosin-stained 
sections using NIS-Elements analysis software (Nikon). Nuclei numbers per 
section in the valves were counted manually in 10X hematoxylin and eosin-
stained sections using ImageJ counting tools. Differences between groups were 
compared using Student’s t tests. 
 
Real Time quantitative PCR - Total RNA was extracted and reverse transcribed 
using iScript reverse transcription supermix (BioRad) or CellAmp whole 
trascriptome amplification kit (Takara) according to the manufacturer’s 
guidelines. Transcript expression was measured by qRT-PCR using SYBR 
Green PCR Master Mix. Signals were normalized to corresponding Gapdh 
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controls, and represented as relative expression ratios of experimental samples 
relative to Hdac3F/F controls. Primer sequences are available upon request. 
 
Apoptosis assay - Sections of aortic and pulmonic valves from five Hdac3Isl1KO 
and five control E13.5 hearts were immunostained with cleaved caspase-3 
antibody and counter-stained with hematoxylin. Images of the aortic and 
pulmonic valves were taken at 20X magnification. The total number of nuclei and 
the number of cleaved caspase-3 positive nuclei within the valve cusp were 
manually counted for each sample. The aortic and pulmonic valves were 
compared separately. The number of cleaved caspase-3 positive nuclei per 1000 
nuclei served as an apoptosis index. 
 
Microarray analysis - Heart tissue was dissected from E9.5 mouse embryos 
and snap frozen in liquid nitrogen. RNA was extracted from pools of Hdac3Isl1KO 
or Hdac3F/F control hearts using an RNeasy Mini Kit. Microarray analysis was 
performed in triplicate from pooled samples by the University of Massachusetts 
Genomics Core Facility using Affymetrix Mouse Gene 2.0 ST arrays (Affymetrix). 
Raw microarray data were annotated using bioconductor and oligo packages in 
R 219-221. Significance of expression differences between Hdac3Isl1KO and 
Hdac3F/F samples were determined using Student’s t test. Heatmaps of 
microarray data were generated using the pheatmap package in R 222. Relative 
expression of each transcript is reported as log-transformed expression value for 
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each sample, normalized to the median expression value of the transcript across 
all six samples. MIAME-compliant full microarray datasets can be accessed at 
the Gene Expression Omnibus (GEO, GSE73666). 
 
Ingenuity pathway analysis - Microarray data from E9.5 Hdac3Isl1KO and control 
hearts were analyzed using Ingenuity Pathway Analysis (IPA). IPA Diseases and 
Functions utility was employed to investigate phenotypes associated with the 
molecular changes. Hierarchical heatmaps were generated using both Diseases 
and Biological Functions categories and Tox Functions categories of the 
Diseases and Functions utility. Plots of phenotypically-relevant categories were 
constructed based on subcategory P-values. The Upstream Regulators utility 
was employed to determine potential regulators of differentially-expressed genes. 
Significant regulators were sorted by significance and by number of associated 
genes. Differentially-expressed genes associated with the upstream regulator 
Tgfβ1 were exported and a clustered heatmap was generated using R software. 
 
Lentiviral infection - Lentiviral media was generated by transfecting 100mm 
plates of subconfluent 293T cells with 5µg of lentiviral cDNA, 5µg of pCMV-
dR8.2, and 2.5µg of pCMV-VSVG, in 10ml of 2% FBS media. Media was 
changed to fresh 10ml of 2% FBS media 24 hours after transfection. Viral media 
was collected 24 hours later and filtered through a 40µm cell strainer. Isolated 
mouse embryonic heart tissue was infected with filtered viral media 
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supplemented with 10µg/ml polybrene reagent. GFP viral media was used to 
maintain a constant viral media volume. Infected cells were harvested for 
analysis 24 or 48 hours after infection. 
 
Cell culture, transient transfection, and luciferase assay – HEK293T cells 
and murine endothelial cells were maintained in DMEM with 10% FBS, 100 
mg/ml penicillin and 100 mM/ml streptomycin in a 37°C incubator with 5% CO2. 
HEK293T cells were transfected in sub-confluent 100 mm plates with 2.5 µg of 
DNA and 5 µl of polyethylenamine, linear, in 10 ml of 10% FBS media. Luciferase 
assays were conducted by transfecting subconfluent murine endothelial cells in 
6-well plates with 1µg of DNA and 2µl of polyethylenamine, linear, in 2 ml of 10% 
FBS media. DNA amount was maintained constant using pcDNA3.1(-) or pLJM1-
EGFP DNA. Cells were lysed with passive lysis buffer 16 h after transfection, and 
lysates were analyzed using a dual luciferase reporter assay kit according to the 
manufacturer’s guidelines. Luciferase activity was measured using a Berthold 
microplate reader according to manufacturer’s guidelines.  
 
Immunoprecipitation - Tissue samples were homogenized in 
immunoprecipitation buffer (50mM Tris-HCl [pH 8.0], 150mM NaCl, 0.5% Nonidet 
P-40, 1mM EDTA, and 1mM DTT) containing 1mM PMSF, phosphate inhibitors 
(Sigma), and protease inhibitors mixture (Sigma). The homogenized samples 
were sonicated using Branson 250 Digital Sonifier with 1s ON and 1s OFF pulses 
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at 40% power amplitude for 15s. Precleared lysates with beads were incubated 
with primary antibodies for 16hrs at 4°C. After incubation for 1hr at 4°C with 
beads, immune-complexes were collected, washed four times with 
immunoprecipitation buffer, and applied to 4-12% SDS-polyacrylamide gels for 
western blot analysis.  
 
Western blotting - Tissue lysates were prepared in lysis buffer (20mM Tris HCl 
(pH 7.5), 15mM NaCl, 1mM Na2EDTA, 1mM EGTA, 1% Triton X-100, 1µg.mL 
leupeptin, 2.5mM sodium pyrophosphate, 1mM Na3VO4, and 1mM β-
glycerophosphate; 1mM phenylmethylsulfonyl fluoride was added before use). 
Protein samples were resolved on 4-12% SDS-PAGE acrylamide gel before 
transferring to PVDF (poly-vinylidene difluoride) membranes. We used primary 
antibodies to Hdac3 (1:1000) and Flag (1:1000). Primary antibodies were 
visualized by chemiluminescence using HRP-conjugated secondary antibodies or 
by infrared with IRDye®-conjugated secondary antibodies. Blots were probed 
with α-tubulin (1:1000) or Gapdh (1:1000) for loading control. 
 
ELISA assay - Sandwich ELISA assay were performed according to the 
manufacturer’s protocol. Briefly, for phospho-Smad2/3 or phospho-Hdac3 ELISA, 
samples were prepared using 100µl using 1x cell lysis buffer (20 mM Tris, pH 
7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium 
pyrophosphate, 1mM β-glycerophosphate, 1 mM Na3VO4, 1µg/ml leupeptin). 100 
	95 
µl of sample diluet was added per 100 µl of sample (1:1 ratio). Samples were 
incubated overnight at 4°C. After four washes with 1X wash buffer, samples were 
incubated with detection antibody for 1 hour at 37°C. Samples were visualized 
using HRP-detection method at 450 nm. For phospho-Hdac3 ELISA assay, 
microtiter plate was coated with Hdac3 antibody (5 µg / ml) in 
carbonate/bicarbonate buffer (pH9.6). Sandwich ELISA for Tgf-β1 was performed 
according to the manufacturer’s protocol. Briefly, samples were prepared using 
assay diluent buffer RD1-21. Samples were incubated for 2 hours at RT. After 
four washes with 1X wash buffer, samples were incubated with 100 µl of Tgf-β1 
conjugate for 2 hour at RT. After four washes with 1X wash buffer, samples were 
incubated with 100 µl of substrate solution (protected from light) for 30 minutes at 
RT. After addition of 100 µl of stop solution, reactions were visualized at 450 nm 
and 540 nm. Readings at 540 nm were subtracted from readings at 450 nm to 
correct for optical imperfections in the plate. 
 
Outflow tract explant assay - The outflow tract explant cultures were performed 
as previously described 223,224. Briefly, a solution of rat tail collagen type I (1.5 
mg/ml) containing NaOH to a final concentration of 15 mmol/L was dispensed 
into 24-well microculture dishes. Subsequently, gels were placed in a 37°C tissue 
culture incubator at 5% CO2 and allowed to polymerize. After 30 min, collagen 
gels were washed several times with DMEM containing 10% fetal bovine serum, 
0.1% insulin-transferrin-selenium (ITS) and 100 mg/ml penicillin and 100 mM/ml 
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streptomycin. Outflow tracts were carefully dissected from control and Hdac3Isl1KO 
E9.5 or E10.5 or E14.5 embryonic hearts. The outflow tracts were placed 
endocardium face down onto collagen gels and allowed to adhere for 8h at 37°C, 
5% CO2. Eight hours after attachment, medium was added and expants were 
cultured for up to 24 or 48 or 72 hours. Radial migration was measured from 4X 
images of outflow tract explants at 45° intervals using NIS-Elements analysis 
software (Nikon). Explants were treated with Tgf-β antibody (1µg / ml) for 24 or 
48 hours or recombinant Tgf-β (10ng / ml) for 24 or 48 hours. Explants were also 
detached, trypsinized, and incubated with anti-vimentin (mesenchymal marker) 
antibody conjugated or PECAM-1 (endothelial marker) conjugated epoxy M-450 
dynabeads as per manufacturer’s guidelines to isolate cells. 
 
Chromatin immunoprecipitation (ChIP) analysis - ChIP experiments were 
preformed as previously described 216. Briefly, isolated cardiac tissue or explants 
from E9.5 mouse embryos were cross-linked for 15 minutes in cross-linking 
solution (1% formaldehyde, 1.5mM EGS, 20mM Na-butyrate, 10% FBS), then 
quenched with 125mM glycine solution for 5 minutes followed by two washes 
with 1X PBS. Chromatin fragmentation was carried out by sonication in ChIP 
SDS lysis buffer (50mM Tris-HCl pH 8.0, 10mM EDTA, 1% SDS, 1X protease 
inhibitors), using the Branson Sonifier 250 (40% power amplitude, 110s). 
Proteins were immunoprecipitated in ChIP dilution buffer (0.01% SDS, 1.1% 
Triton X-100, 1.2mM EDTA, 16.7mM Tris-HCl pH 8.0, 167mM NaCl, 20mM NA-
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butyrate, 1X protease inhibitor) using IgG or Hdac3 or Ncor1 or Ezh2 or 
H3K27me3 or H3K27ac or PolII antibody. Specificity of Hdac3 or Ncor1 or Ezh2 
or H3K27me3 or H3K27ac or PolII antibody at the relevant loci was determined 
using IgG control antibody. Specificity of Hdac3 antibody at the relevant loci was 
also determined using Hdac3-null hearts compared to wild-type control. 
Immunoprecipitated antibody-chromatin complexes were washed twice with low 
salt wash buffer (20mM Tris-HCl pH 8.0, 150mM NaCl, 2mM EDTA, 0.1% SDS, 
and 1% Triton X-100) followed by two washes with lithium chloride wash buffer 
(10mM Tris-HCl pH 8.0, 250 mM LiCl, 1mM EDTA, 1% deoxycholate, and 1% 
Nonidet P-40) and TE buffer (10mM Tris-HCl pH 8.0, and 1mM EDTA). After 
removing wash buffer, cross-linking was reversed at 65C overnight in Proteinase 
K buffer (20mM Tris-HCl pH 7.5, 5mM EDTA, 50mM NaCl, 1% SDS, 20mM Na-
butyrate, 50µg/ml Proteinase K). The following day, DNA was purified using 
phenol/chloroform/isoamyl alcohol. Purified precipitated DNA was analyzed by 
qRT-PCR as previously described. Enrichment of target sequences was 
determined by qRT-PCR using primers designed against Hdac3 consensus 
binding sites within the proximal 10kb upstream of the transcription start site of 
genes of interest: Tgf-β1, Kpnb1, Sumo1, and Smad4. Primer sequences are 
available upon request. 
 
Statistical analysis - Statistical significance between groups was determined 
using two-tailed Student’s t test or χ2 test. A P-value < 0.05 was considered 
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significant. 
 
Results 
 
HDAC3 Is Required in the Second Heart Field for Cardiac Development 
Germ line deletion of ubiquitously expressed HDAC3 results in embryonic 
lethality at E9.5 125,177. To determine the function of HDAC3 in the second heart 
field, we deleted HDAC3 in the second heart field progenitor cells using two Cre 
lines, Isl1-Cre (Hdac3Isl1KO) (Fig. 3.1A–C) and Mef2C-Cre (Hdac3Mef2CKO) 
190,217. Hdac3Isl1KO embryos were identified at E18.5 (Table 3.1). However, 
Hdac3Isl1KO pups displayed complete lethality at birth (P0) (p < 0.01; Table 3.1). 
Hdac3Isl1KO embryos were characterized by malrotation of outflow tract, 
overriding aorta, double outlet right ventricle, membranous ventricular septal 
defect, ascending aortic dilatation (21–35%, p < 0.02), and normal outflow tract 
septation at E18.5 (Table 3.2 and Fig. 3.1D–I). Hdac3Isl1KO embryos displayed 
aberrant distribution and expression of collagen in all layers of ascending aortic 
and pulmonary arterial walls (Fig. 3.1J–L). In addition, elastin fibers appeared 
fragmented, probably explaining aortic dilatation in Hdac3Isl1KO embryos (Fig. 
3.1K-L). Isl1-Cre is a knock-in allele; however, we did not observe genetic 
interaction between HDAC3 and ISL1 (Tables 3.1 and 3.2). Hdac3Mef2CKO 
embryos revealed similar developmental cardiac defects, including double outlet 
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Figure 3.1: Hdac3 functions within the second heart field to regulate 
cardiac morphogenesis. (A-C) Hdac3 immunostaining of LacZ-stained 
Hdac3Isl1KO; R26R-LacZ+/- and control embryos shows that Hdac3 protein 
expression (black arrows) is lost (grey arrows) in the Isl1-Cre expression domain 
in (A) E9.5 and (B-C) E13.5 Hdac3Isl1KO hearts, including in semilunar valves (C). 
(D) Dissected and fixed E18.5 hearts show malrotation of the outflow tract in 
Hdac3Isl1KO hearts. (E) Tracings of outflow tract vessels demonstrate abnormal, 
parallel orientation of the aorta and pulmonary artery in Hdac3Isl1KO hearts. (F) 
Hematoxylin- and eosin-stained sections demonstrate double outlet right 
ventricle, with membranous ventricular septal defect (arrow) and an overriding 
aorta in Hdac3Isl1KO E18.5 hearts. (G) Hematoxylin- and eosin-stained cross-
sections show malrotation, but complete septation, of the aorta and pulmonary 
artery in E18.5 Hdac3Isl1KO hearts. (H-I) Cartoon diagram of proximal aorta 
showing three levels: Level 1 – tubular aortic trunk, Level 2 – proximal aortic 
arch, Level 3 – intermediate aortic arch (H). Comparison of aorta diameter in 
Hdac3Isl1KO and control hearts, measured at three levels from dissected, fixed 
hearts (I). (J) Masson’s trichrome-stained sections of aorta and pulmonary artery 
demonstrate disorganized collagen (blue) in the vessel walls of Hdac3Isl1KO E18.5 
hearts. (K) Verhoeff-Van Gieson-stained sections of aorta and pulmonary artery 
demonstrate disorganized collagen (arrows, red) and fragmented elastin (arrows, 
black) in the vessel walls of Hdac3Isl1KO E18.5 hearts. (L) Cartoon model of 
disorganized outflow vessel wall morphology. (M) Hematoxylin- and eosin-
stained sections demonstrate double outlet right ventricle with aortic valve 
overriding a membranous ventricular septal defect (arrow) in Hdac3Mef2CKO E18.5 
hearts. (N) Quantification of aortic diameter shows dilation of E18.5 Hdac3Mef2CKO 
aortas at three levels: Level 1 – tubular aortic trunk, Level 2 – proximal aortic 
arch, and Level 3 – intermediate aortic arch. (O-P) Hematoxylin- and eosin-
stained sections show normal primary atrial septum (arrow) in (O) Hdac3Isl1KO 
and (P) Hdac3Mef2CKO E18.5 hearts. RA = right atrium, LA = left atrium, A = aorta, 
AV = aortic valve, PA = pulmonary artery, PV = pulmonic valve, RV = right 
ventricle, LV = left ventricle, BA = brachiocephalic artery, LCA = left common 
carotid artery, PAS = primary atrial septum. 
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right ventricle, ascending aortic dilatation (22–32%, p < 0.002), and perinatal 
lethality (Tables 3.2 and 3.3 and Fig. 3.1M-N). Primary atrial septum and right 
ventricle, in part derived by the second heart field progenitor cells, appeared 
normal in both Hdac3Isl1KO and Hdac3Mef2CKO hearts (Fig. 3.1O-P) (data not 
shown). Cardiomyocyte differentiation was unaffected in early Hdac3Isl1KO 
embryos (data not shown). 
 
HDAC3 Is Essential for Semilunar Valve Development 
The second heart field progenitor cells are required for conotruncal 
cushion development, which contributes to the semilunar valves and outflow tract 
septum (5, 6, 8–10). Hdac3Isl1KO embryos demonstrated dysmorphic, thickened 
(1.59–3-fold, p < 0.02), and hyperplastic (1.31–3.14-fold, p < 0.02) semilunar 
valves at E18.5 (Table 3.2 and Fig. 3.2A–N). Interestingly, aortic valves were 
bicuspid in Hdac3Isl1KO hearts (Table 3.2 and Fig. 3.2E). The outflow tract 
septum and atrioventricular valves appeared normal in these embryos at E18.5 
(Figs. 3.1G and 3.2O). Similarly, Hdac3Mef2CKO embryos revealed defects in 
semilunar valve development, but not in atrioventricular valve development, at  
E18.5 (Table 3.2 and Fig. 3.2P–T).  
The mature semilunar valves are composed of extracellular matrix, 
valvular interstitial cells, and endothelial cells. Remodeling of valvular interstitial 
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Figure 3.2: Hdac3 is required for semilunar valve development. (A) 
Hematoxylin- and eosin-stained sections demonstrate thick, hyperplastic, and 
dysmorphic aortic valve in Hdac3Isl1KO E18.5 hearts. (B) Quantification of aortic 
valve area, measured from frontal sections of E18.5 hearts. (C) Quantification of 
number of nuclei per aortic valve section, counted from hematoxylin- and eosin-
stained frontal sections of E18.5 hearts. (D) Quantification of width of junction 
between aortic valve and cardiac wall, measured from frontal sections of E18.5 
hearts. (E) Hematoxylin- and eosin-stained sections demonstrate thick, 
hyperplastic, dysmorphic, and bicuspid aortic valve in Hdac3Isl1KO E18.5 hearts. 
(F) Quantification of aortic valve area, measured from cross-sections of E18.5 
hearts. (G) Quantification of number of nuclei per aortic valve section, counted 
from hematoxylin- and eosin-stained cross sections of E18.5 hearts. (H) 
Hematoxylin- and eosin-stained sections demonstrate thick, hyperplastic, and 
dysmorphic pulmonic valve in Hdac3Isl1KO E18.5 hearts. (I) Quantification of 
pulmonic valve area, measured from frontal sections of E18.5 hearts. (J) 
Quantification of number of nuclei per pulmonic valve section, counted from 
hematoxylin- and eosin-stained frontal sections of E18.5 hearts. (K) Width of 
hinge region in pulmonic valve measured from frontal sections of E18.5 hearts. 
(L) Hematoxylin- and eosin-stained sections demonstrate thick, hyperplastic, 
dysmorphic, and tricuspid pulmonic valve in Hdac3Isl1KO E18.5 hearts. (M) 
Quantification of pulmonic valve area, measured from cross-sections of E18.5 
hearts. (N) Quantification of number of nuclei per pulmonic valve section, 
counted from hematoxylin- and eosin-stained cross sections of E18.5 hearts. (O) 
Hematoxylin- and eosin-stained sections demonstrate normal tricuspid and mitral 
valve morphology in Hdac3Isl1KO E18.5 hearts. (P-Q) Hematoxylin- and eosin-
stained sections show thickened, hyperplastic (P) aortic and (Q) pulmonic valves 
in E18.5 Hdac3Mef2CKO hearts. (R) Hematoxylin- and eosin-stained sections show 
hyperplastic, bicuspid aortic valve in E18.5 Hdac3Mef2CKO E18.5 hearts. (S) 
Hematoxylin- and eosin-stained sections show hyperplastic, tricuspid pulmonic 
valve in E18.5 Hdac3Mef2CKO hearts. (T) Hematoxylin- and eosin-stained sections 
demonstrate normal mitral and tricuspid valves in E18.5 Hdac3Mef2CKO hearts. RA 
= right atrium, LA = left atrium, A = aorta, AV = aortic valve, PA = pulmonary 
artery, PV = pulmonic valve, RV = right ventricle, LV = left ventricle, MV = mitral 
valve, TV = tricuspid valve. 
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cells and extracellular matrix, mainly collagens, proteoglycans, and elastin, is 
essential for maturation of the semilunar valves 65. Hdac3Isl1KO hearts displayed 
loss of extracellular matrix trilaminar stratification and valvular interstitial cell 
compartmentalization in the semilunar valves at various stages of development 
(Fig. 3.3A–F, L, and M). Specifically, loss of HDAC3 resulted in aberrant 
expression of collagen and proteoglycan in all layers, probably explaining 
enlarged and thickened semilunar valves (Fig. 3.3A–F, L, and M). Elastin fibers 
appeared disorganized and fragmented in Hdac3Isl1KO semilunar valves (Fig. 
3.3, A, B, E, F, L, and M). Similarly, Hdac3Mef2CKO embryos revealed aberrant 
expression of collagen and proteoglycan in all layers of the semilunar valves (Fig. 
3.3G-H). Remodeling of the semilunar valves is associated with an increase in 
apoptosis 198. Hdac3Isl1KO semilunar valve interstitial cells displayed a 55– 65% 
decrease in apoptosis compared with controls (p < 0.02) during valve remodeling 
(Fig. 3.3I–K).  
 
HDAC3 Regulates TGF-β Signaling Pathway 
Transcriptional analysis of early embryonic Hdac3Isl1KO hearts revealed 
significant expression changes indicative of the congenital heart defects 
observed in late stage Hdac3Isl1KO embryos (Fig. 3.4A-B). Upstream regulator 
analysis identified marked changes in TGF- β1 pathway genes (Fig. 3.4C–E). 
Positive regulators of the TGF- β1 pathway, including Sumo1, Nrp2, Smad4, 
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Figure 3.3: Hdac3 is required for extracellular matrix homeostasis and 
remodeling of semilunar valves. (A) Movat’s pentachrome staining of 
remodeling aortic valve shows an increase in proteoglycans (arrows, blue) from 
E13.5 to E18.5 in Hdac3Isl1KO aortic valves with a reduction and remodeling of 
proteoglycans in control valves. (B) Movat’s pentachrome staining of remodeling 
pulmonic valve shows an increase in proteoglycans (arrows, blue) from E13.5 to 
E18.5 in Hdac3Isl1KO pulmonic valves with a reduction and remodeling of 
proteoglycans in control valves. (C) Masson’s trichrome staining demonstrates 
disorganized collagen expression (arrow, blue) in Hdac3Isl1KO E18.5 aortic valve. 
(D) Masson’s trichrome staining demonstrates disorganized collagen expression 
(arrow, blue) in Hdac3Isl1KO E18.5 pulmonic valve. (E) Verhoeff-Van Gieson 
(VVG) staining shows disorganized collagen expression (arrow, red) in 
Hdac3Isl1KO E18.5 aortic valve. (F) Verhoeff-Van Gieson (VVG) staining shows 
disorganized collagen expression (arrow, red) in Hdac3Isl1-KO E18.5 aortic valve. 
(G) Movat’s pentachrome-stained sections show increased proteoglycans (blue) 
in aortic valve cusps of E18.5 Hdac3Mef2CKO hearts. (H) Movat’s pentachrome 
staining reveals increased proteoglycans (blue) in E18.5 Hdac3Mef2CKO pulmonic 
valve. (I) Representative images of cleaved caspase-3 immunostaining in E13.5 
semilunar valves. Arrows indicate positive staining. (J) Quantification of cleaved 
caspase-3 positive cells in E13.5 control and Hdac3Isl1KO aortic valves. (K) 
Quantification of cleaved caspase-3 positive cells in E13.5 control and 
Hdac3Isl1KO pulmonic valves. (L) Cartoon model depicting disorganized 
extracellular matrix and reduced apoptosis in Hdac3Isl1KO E13.5 semilunar valves. 
(M) Cartoon model showing hyperplastic, enlarged, and disorganized Hdac3Isl1KO 
E18.5 semilunar valves. 
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Snai1, Tgf- β1, and Kpnb1 were 3–9- fold up-regulated (p < 0.02) in 
Hdac3Isl1KO hearts (Fig. 3.4F). ChIP-qPCR analysis confirmed chromatin 
occupancy of HDAC3 (0.15–0.5%, p < 0.002) on identified sites in the conserved 
noncoding regions within 10 kb upstream of TGF-β pathway genes, including 
Smad4, Sumo1, Tgf- β1, and Kpnb1 (Fig. 3.4G–J). We also observed ~3.5-fold 
higher TGF-β levels in Hdac3Isl1KO outflow tracts compared with control (p < 
0.015; Fig. 3.4K). Loss of HDAC3 resulted in ~2.7-fold activation of SMAD2/3 
phosphorylation (p < 0.02), suggesting enhanced TGF-β signaling (Fig. 3.4L-M). 
These results suggest that HDAC3 represses TGF-β signaling pathway during 
early cardiogenesis. 
 
TGF-β Mediates Aberrant EndMT and Extracellular Matrix Remodeling in 
Hdac3Isl1KO Heart 
TGF-β signaling and its downstream target genes, such as Snai1, are 
critical factors that induce EndMT in the developing outflow tract cushions 213. 
EndMT is characterized by loss of endothelial markers, such as TEK, and gain of 
mesenchymal markers, such as TAGLN 206. Hdac3Isl1KO hearts exhibited robust 
down-regulation of Tek and up-regulation of Snai1 and Tagln (Figs. 3.4F and 
3.5A). Hdac3Isl1KO outflow tract cushion explants showed ~3-fold induction of 
EndMT (p < 0.005; Fig. 3.5B-C), and these changes were largely abolished by 
TGF-β-neutralizing antibody (p < 0.009; Fig. 3.5B–F). Aberrant TGF-β signaling  
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Figure 3.4: Hdac3 is a critical regulator of Tgf-β  signaling pathway. (A-E) 
Ingenuity Pathway Analysis (IPA) of microarray data from E9.5 Hdac3Isl1KO 
hearts. (A) Cardiovascular development and functions subcategories significantly 
dysregulated in E9.5 Hdac3Isl1KO hearts, sorted by significance, from IPA 
diseases and functions analysis. (B) Classes of congenital heart anomalies 
affected in E9.5 Hdac3Isl1KO hearts, sorted by significance, from IPA diseases and 
functions analysis. (C) Top 30 most significant upstream regulators from IPA 
upstream analysis of E9.5 Hdac3Isl1KO microarray data. (D) Clustered heatmap of 
differentially-expressed genes related to upstream regulator Tgf-β1 from IPA 
upstream analysis of Hdac3Isl1KO microarray data. (E) Top 30 upstream 
regulators, based on number of associated genes differentially-expressed in E9.5 
Hdac3Isl1KO hearts from IPA upstream analysis. (F) Transcripts for Sumo1, Nrp2, 
Smad4, Snai1, Tgf-β1, and Kpnb1 were detected by real-time qPCR in Hdac3F/F 
and Hdac3Isl1KO outflow tract with right ventricle derived from E9.5 embryos 
(mean ± SEM, n=3). (G-J) ChIP-qPCR analysis of Hdac3 recruitment to 
promoter-proximal regions of Tgf-β pathway genes performed in wild-type E9.5 
outflow tract (mean ± SEM, n=3). (K-L) ELISA for Tgf-β1 (K) and phospho-
Smad2/3 (L) was performed in Hdac3F/F and Hdac3Isl1KO outflow tracts (mean ± 
SEM, n=3 (K), n=4 (L)). (M) Phospho-Smad2/3 immunostaining (arrows) in E9.5 
Hdac3Isl1KO; R26R-LacZ+/- hearts. 
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activates valvular interstitial cells, which in turn, express smooth muscle genes 
and produce extracellular matrix scaffold proteins to remodel valvular matrix 201. 
Hdac3Isl1KO hearts revealed significant expression changes in smooth muscle 
and extracellular matrix genes (Fig. 3.5A and 3.5G–M). Smooth muscle genes, 
including Tagln, Myh11, and Cnn2, were up-regulated in Hdac3Isl1KO hearts 
and semilunar valves (Fig. 3.5A and 3.5G-H). Simultaneously, expression of 
proteoglycans, including Dcn, Bgn, Fmod, and Vcan, and collagens, including 
Col2a1, Col11a2, Col9a2, Col1a2, and Col3a1, were significantly altered in 
Hdac3Isl1KO hearts and semilunar valves (Fig. 3.5A and 3.5I–M). We next 
examined the requirement of TGF-β for aberrant expression of extracellular 
matrix genes in Hdac3Isl1KO valvular interstitial cells. Loss of HDAC3 resulted in 
6–10-fold expression changes in proteoglycans, collagen, and smooth muscle 
genes (p < 0.006), and these changes were largely abolished by TGF-β-
neutralizing antibody (Fig. 3.5H–M). Taken together, these results suggest that 
aberrant EndMT and extra- cellular matrix remodeling in Hdac3Isl1KO hearts are 
mediated by TGF-β signaling. 
 
HDAC3 Functions within Mesenchymal or Smooth Muscle Cells to Regulate 
Semilunar Valve and Outflow Tract Development 
The second heart field progenitor cells give rise to cardiomyocytes, 
endothelial cells, and mesenchymal cells or smooth muscle cells 156,225. Genetic 
	114 
 
 
 
 
 
 
 
	115 
Figure 3.5: Tgf-β mediates aberrant expression of EndMT and extracellular 
matrix genes in Hdac3Isl1KO heart. (A) Heatmap of microarray data shows 
differential expression of extracellular matrix, smooth muscle, and endothelial-
related genes in Hdac3Isl1KO E9.5 hearts. (B) EndMT assay of Tgf-β antibody-
treated or IgG antibody-treated outflow tract cushion explants 24 hours after 
isolation from Hdac3Isl1KO and Hdac3F/F E10.5 hearts. (C) Quantification of 
average radial migration, measured in 8 directions, from Tgf-β antibody-treated 
or IgG antibody-treated outflow tract cushion explants from Hdac3Isl1KO and 
Hdac3F/F E10.5 hearts, measured 24 hours after isolation. (D-F) Transcripts for 
Snai1 (D), Tagln (E), and Tek (F) were detected by real-time qPCR in IgG or Tgf-
β antibody treated control and Hdac3Isl1KO outflow tract explants derived from 
E9.5 hearts (mean ± SEM, n=3). (G) Immunostaining for smooth muscle actin in 
Hdac3Isl1KO and control E18.5 aortic valves (AV). (H-M) Transcripts for Tagln (H), 
Dcn (I), Bgn (J), Lum (K), Col1a2 (L), and Col2a1 (M) were detected by real-time 
qPCR in IgG or Tgf-β antibody treated control and Hdac3Isl1KO proximal outflow 
tract explants with semilunar valves derived from E14.5 embryos (mean ± SEM, 
n=3). 
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deletion of Hdac3 using Cdh5-Cre (Hdac3Cdh5KO), which is expressed in 
differentiated endothelial and endocardial cells at E8.0 218, and Myh6-Cre 
(Hdac3Myh6KO), which is expressed in differentiated cardiomyocytes at E8.5 178, 
did not reveal malrotation of outflow tract, overriding aorta, double outlet right 
ventricle, or valve defects observed in Hdac3Isl1KO or Hdac3Mef2CKO embryos 
(Fig. 3.6A–O). Importantly, genetic deletion of Hdac3 using Tagln- Cre 
(Hdac3TaglnKO), which is expressed in differentiated mesenchymal or smooth 
muscle cells at E8.5 226, recapitulated outflow tract malrotation, overriding aorta, 
double outlet right ventricle, aberrant semilunar valve development, membranous 
ventricular septal defect, disorganized collagen, and fragmented elastin in great 
vessel walls and showed hyperplastic semilunar valves with expanded 
proteoglycans and aberrant collagen deposition, as observed in Hdac3Isl1KO 
and Hdac3Mef2CKO embryos (Fig. 3.7A–L). Expression of positive regulators of 
TGF-β pathway genes, smooth muscle markers, proteoglycans, and collagens 
were 4 –20-fold up-regulated in Hdac3TaglnKO semilunar valves (p < 0.03; Fig. 
3.7M). Hdac3TaglnKO outflow tract cushion explants displayed an ~3-fold 
increase in EndMT (p < 0.03) and ~20 – 40-fold expression changes in 
proteoglycans and smooth muscle genes (p < 0.004; Fig. 3.7N–Q). Importantly, 
these changes were largely abolished by TGF-β-neutralizing antibody (p < 
0.004), suggesting that aberrant EndMT and extracellular matrix remodeling in 
Hdac3TaglnKO hearts are mediated by TGF-β signaling (Fig. 3.7N–Q). Together, 
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these data suggest a primary role of HDAC3 in the second heart field-derived 
mesenchymal or smooth muscle cells during early cardiac development. 
 
HDAC3 Epigenetically Silences TGF-β1 within Mesenchymal Cells by 
Recruiting EZH2 to the NCOR Complex 
During EndMT, endothelial cells lose their endothelium-specific markers and 
morphology and acquire a mesenchymal cell-like phenotype 206. In this process, 
endothelium-derived mesenchymal cells displayed >90% repression of TGF-β1 
expression compared with endothelial cells (p < 0.003); however, this repression 
was completely absent in mesenchymal cells lacking HDAC3 (Fig. 3.8A-B). We 
observed ~0.6 –1.8% enrichment of HDAC3 at a regulatory region upstream of 
TGF-β1 within mesenchymal cells compared with endothelial cells (p < 0.02; Fig. 
3.8C-D). We evaluated chromatin occupancy of various histone marks to 
determine the regulatory mechanism of the HDAC3-enriched region upstream of 
TGF-β1 within mesenchymal cells. ChIP-qPCR analysis revealed loss of 
trimethylation of Lys-27 on histone H3 (H3K27me3) and ~8% enrichment of 
acetylation of Lys-27 on histone H3 (H3K27ac) at the TGF-β1 regulatory region 
in Hdac3Isl1KO semilunar valves compared with control (p < 0.04, Fig. 3.8E-F). 
Consistent with these findings, Hdac3Isl1KO semilunar valves displayed ~0.9 –
3% enrichment of RNA polymerase II and CREBBP (p < 0.006) and abolished 
occupancy of EZH2, EED, and SUZ12, the H3K27 methyltransferase 
components of PRC2 complex, at the TGF-β1 regulatory region (Fig. 3.8G–K). 
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NCOR1 was required for recruitment of HDAC3 to the TGF-β1 locus (Fig. 3.8L). 
Interestingly, NCOR1 occupancy remained unchanged at this locus in 
Hdac3Isl1KO semilunar valves, suggesting that HDAC3 is not required for 
NCOR1 recruitment to the TGF-β1 regulatory region (Fig. 3.8M). Co-ChIP-qPCR 
analysis revealed co-occupancy of HDAC3 with either EZH2, H3K27me3, or 
NCOR1 at the TGF-β1 locus in wild-type semilunar valves (Fig. 3.8N). HDAC3 
interacts with EZH2 within mesenchymal cells of semilunar valves (Fig. 3.8O). 
Importantly, EZH2 and NCOR1 are required for deposition of the H3K27me3 
mark at the TGF-β1 locus within valvular mesenchymal cells (Fig. 3.8P). These 
data suggest that HDAC3 is required to mediate epigenetic silencing of TGF-β1 
within mesenchymal cells of semilunar valves. 
 
Deacetylase Activity of HDAC3 Is Dispensable for EndMT and Epigenetic 
Silencing of TGF-β1 
Approximately 10% of mammalian enzymes are catalytically inactive 227. 
These “dead” enzymes or pseudoenzymes are biologically functional; however, 
their enzyme-independent functions remain largely undefined. A recent study 144 
describes a deacetylase-independent function of HDAC3 in lipid metabolism. To 
determine whether deacetylase activity of HDAC3 is required to regulate EndMT, 
expression of Tgf-β1, and recruitment of EZH2 to the TGF-β1 locus, we 
generated a previously described mutant form of HDAC3 in which two highly 
conserved tandem His residues, 134 and 135, are mutated to alanine 
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Figure 3.6: Endocardial or myocardial Hdac3 is dispensable for 
morphogenesis of second heart field-derived structures. (A-D) Hdac3Cdh5KO 
hearts appear normal at birth. (A) Position of aorta and pulmonary artery appear 
normal in Hdac3Cdh5KO mice hearts at birth (P0). (B-D) Hematoxylin, eosin and 
LacZ stained sections of hearts from control and Hdac3Cdh5KO mice. (B) Aortic 
valve, (C) pulmonic valve, (D) tricuspid valve, and mitral valve appear normal in 
size and shape Hdac3Cdh5KO hearts. (E-G) Hdac3Myh6KO hearts appear normal at 
birth. (E) Position of aorta and pulmonary artery appear normal in Hdac3Myh6KO 
hearts at birth. (F-G) Hematoxylin- and eosin-stained sections of hearts from 
control and Hdac3Myh6KO mice. (F) Aortic valves and (G) pulmonic valves appear 
normal in size and shape in Hdac3Myh6KO hearts as compared to control. (H-I) 
Movat’s pentachrome staining show normal extracellular matrix organization in 
Hdac3Cdh5KO P0 (H) aortic valves and (I) pulmonic valves. (J-O) Hdac3Myh6KO 
extracellular matrix appears normal. (J-K) Masson’s trichrome staining of (J) 
aortic valve and (K) pulmonic valve, (L-M) Movat’s pentachrome staining of (L) 
aortic valve and (M) pulmonic valve, and (N-O) Verhoeff-van Gieson staining of 
(N) aortic valve and (O) pulmonic valve show normal extracellular matrix in 
semilunar valve cusps of P0 Hdac3Myh6KO hearts. A = aorta, PA = pulmonary 
artery, RA = right atrium, LA = left atrium, RV = right ventricle, LV = left ventricle, 
PV = pulmonic valve, AV = aortic valve, TV = tricuspid valve, MV = mitral valve. 
Scale bars are 50µm respectively. 
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Figure 3.7: Hdac3 functions within mesenchymal or smooth muscle cells to 
regulate outflow tract and semilunar valve development. (A) Dissected, fixed 
P0 hearts show malrotation of the aorta and pulmonary artery in Hdac3TaglnKO 
hearts. (B) Hematoxylin- and eosin-stained sections show double outlet right 
ventricle with aortic valve (AV) overriding a ventricular septal defect (arrow) in 
Hdac3TaglnKO P0 hearts. (C) Masson’s trichrome staining of P0 aortic vessel wall 
shows collagen on the outer surface of control aortic walls (white arrow, blue 
staining) and aberrant collagen expression throughout the vessel wall (black 
arrow, blue staining) in Hdac3TaglnKO aortic walls. (D) Verhoeff-Van Gieson (VVG) 
staining of P0 aortic vessel wall shows thick, continuous elastin fibers (white 
arrow, grey staining) in control aortas and thin, fragmented elastin fibers (black 
arrow, grey staining) in Hdac3TaglnKO aortas. (E) Masson’s trichrome staining of 
P0 pulmonic artery wall shows collagen on the outer surface of control pulmonic 
artery walls (white arrow, blue staining) and aberrant collagen expression 
throughout the vessel wall (white arrow, blue staining) in Hdac3TaglnKO pulmonic 
artery walls. (F) Verhoeff-Van Gieson (VVG) staining of P0 pulmonic artery wall 
shows thick, continuous elastin fibers (white arrow, grey staining) in control 
aortas and thin, fragmented elastin fibers (white arrow, grey staining) in 
Hdac3TaglnKO pulmonic arteries. (G) Movat’s pentachrome staining of P0 aortic 
valve shows expanded proteoglycans (arrow, blue) in Hdac3TaglnKO aortic valve 
compared to Hdac3F/+ control. (H) Movat’s pentachrome staining of P0 pulmonic 
valve shows expanded proteoglycans (arrow, blue) in Hdac3TaglnKO pulmonic 
valve compared to Hdac3F/+ control. (I) Masson’s trichrome staining of P0 aortic 
valves shows disorganized collagen expression (arrow, blue) in Hdac3TaglnKO 
aortic valve. (J) Masson’s trichrome staining of P0 pulmonic valves shows 
disorganized collagen expression (arrow, blue) in Hdac3TaglnKO pulmonic valve. 
(K) Verhoeff-Van Gieson (VVG) stain of P0 aortic valves demonstrates 
disorganized collagen expression (arrow, red) in Hdac3TaglnKO aortic valve. (L) 
Verhoeff-Van Gieson (VVG) stain of P0 pulmonic valves demonstrates 
disorganized collagen expression (arrow, red) in Hdac3TaglnKO pulmonic valve. 
(M) Relative mRNA levels of Tgf-β1, Snai1, Smad4, Sumo1, Tagln, Lum, and 
Col2a1 show increased expression in Hdac3TaglnKO E14.5 hearts. (N) EndMT 
assay of Tgf-β antibody-treated or IgG antibody-treated outflow tract cushion 
explants from Hdac3TaglnKO and Hdac3F/F E10.5 hearts, 24 hours after isolation. 
(O) Quantification of average radial migration, measured in 8 directions, from 
Tgf-β antibody-treated or IgG antibody-treated outflow tract cushion explants 
from Hdac3TaglnKO and Hdac3F/F E10.5 hearts, measured 24 hours after isolation. 
(P-Q) Transcripts for Tagln (P) and Lum (Q) were detected by real-time qPCR in 
IgG or Tgf-β antibody treated control and Hdac3TaglnKO outflow tract cushion 
explants derived from E10.5 hearts (mean ± SEM, n=3). 
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(HDAC3H134A,H135A). These mutations do not affect its expression (Fig. 3.9A-
B), chromatin recruitment, and interaction with NCOR1 144; however, they render 
HDAC3 completely inactive (Fig. 3.9C). HDAC3-null outflow tract cushion 
explants showed an ~2-fold increase in EndMT (p < 0.05), and these changes 
were largely rescued by either wild-type HDAC3 or HDAC3H134A,H135A 
expression (p < 0.04; Fig. 3.9D-E). Similarly, either wild-type HDAC3 or 
HDAC3H134A,H135A rescued aberrant Tgf-β1 transcription within cultured 
HDAC3-null semilunar valve mesenchymal cells (p < 0.0004; Fig. 3.9F). Hence, 
we generated a mutant TGF-β1 promoter luciferase reporter lacking the HDAC3 
enriched regulatory region (-42 to -1 upstream of ATG). Transfection of HDAC3 
or HDAC3H134A,H135A resulted in >90% repression of the wild-type TGF-β1 
reporter (p < 0.002); however, it failed to repress the mutant TGF-β1 reporter 
(Fig. 3.9G). The mutant TGF-β1 promoter luciferase reporter displayed 
transcriptional activity similar to control (Fig. 3.9G). Interestingly, valvular 
mesenchymal cells expressing HDAC3H134A,H135A showed similar levels of 
H3K27ac at the TGF-β1 locus compared with those expressing wild-type 
HDAC3, although HDAC3H134A,H135A lacks the ability to actively deacetylate 
histones (Fig. 3.9H). Either wild-type HDAC3 or HDAC3H134A,H135A 
expression restored chromatin occupancy of EZH2, EED, and SUZ12 and 
thereby deposition of the H3K27me3 mark at the TGF-β1 locus in cultured 
HDAC3- null semilunar valve mesenchymal cells (Fig. 3.9I–L). Taken together, 
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Figure 3.8: Hdac3 epigenetically silences Tgf-β1 within valvular 
mesenchymal cells by recruiting Ezh2 to the Ncor complex. (A) Relative 
mRNA levels of Tgf-β1 in isloated cardiac endothelial cells (EC) or cardiac 
mesenchymal cells (MC) from E10.5 Hdac3F/F outflow tract cushion explants, 
infected either with CRE or GFP control lentivirus. (B) Relative mRNA levels of 
Tgf-β1 in isolated cardiac endothelial cells (EC) or dissected semilunar vales (SL) 
derived from Hdac3Isl1KO and Hdac3F/F E14.5 hearts. (C) ChIP-qPCR analysis of 
Hdac3 occupancy upstream of Tgf-β1 in isolated cardiac endothelial cells (EC) or 
cardiac mesenchymal cells (MC) from E10.5 outflow tract cushion explants. (D) 
ChIP-qPCR analysis of Hdac3 occupancy upstream of Tgf-β1 in isolated cardiac 
endothelial cells (EC) or dissected semilunar valves (SL) from E14.5 hearts. (E-
K) ChIP-qPCR analysis of (E) H3K27 tri-methylation, (F) H3K27 acetylation, (G) 
RNA polymerase II, (H) Crebbp, (I) Ezh2, (J) Eed, and (K) Suz12 upstream of 
Tgf-β1 in Hdac3Isl1KO and control E14.5 semilunar valves. (L) ChIP-qPCR 
analysis of Hdac3 occupancy upstream of Tgf-β1 in E14.5 valvular mesenchymal 
cells infected with either control shRNA (sc-shRNA), Ezh2-shRNA, or Ncor1-
shRNA. (M) ChIP-qPCR analysis of Ncor1 upstream of Tgf-β1 in Hdac3Isl1KO and 
control E14.5 semilunar valves (N) Co-ChIP for Hdac3 and either Ezh2, Ncor1, 
H3K27me3, H3K27ac, or Pol II upstream of Tgf-β1 in E14.5 wild-type dissected 
semilunar valves. (O) Total lysates from E14.5 wild-type pooled semilunar valves 
were immunoprecipitated by Ezh2 antibody, and western blot was performed 
using Hdac3 antibody. α-tubulin is shown as an input control. Hdac3 was 
quantified and normalized to total input α-tubulin using ImageJ software (mean ± 
SEM, n=3). (P) ChIP-qPCR analysis of H3K27me3 upstream of Tgf-β1 in E14.5 
valvular mesenchymal cells infected with either control shRNA (sc-shRNA), 
Ezh2-shRNA, or Ncor1-shRNA. 
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these findings demonstrate that HDAC3-mediated epigenetic silencing of TGF-β1 
within second heart field-derived mesenchymal cells is essential for termination 
of EndMT (Fig. 3.10A-B). In the absence of HDAC3, aberrant expression of TGF-
β within mesenchymal cells leads to perpetual activation of mesenchymal cells to 
myofibroblasts, altered extracellular matrix homeostasis, and enhanced EndMT, 
which in turn, leads to congenital cardiac anomalies resembling those seen in 
patients with mutations causing activation of the TGF-β signaling pathway (Fig. 
3.10A-B). 
 
Discussion 
 
Previous studies from our group and others have demonstrated that 
HDACs are critical regulators of various develop- mental processes, including 
cardiogenesis 122,216. Among class I HDACs (HDAC1, -2, -3, and -8), global loss 
of HDAC2 or HDAC8 in mice does not affect morphogenesis of second heart 
field-derived structures at birth 123,140,215. Interestingly, murine embryos lacking 
HDAC1 within the second heart field (Hdac1Isl1KO) display normal 
cardiogenesis, including development of the outflow tract and semilunar valves 
(Z. Milstone and C.M. Trivedi, unpublished results). Similarly, second heart field-
derived structures appear normal in mice lacking class II HDACs, such as 
HDAC4, -5, -6, or -9 at birth 119. Taken together, our data reveal a unique and a 
specific role for HDAC3 in regulation of second heart field morphogenesis. 
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Figure 3.9: Hdac3 functions in a deacetylase-independent manner to 
regulate EndMT and epigenetic silencing of Tgf-β1. (A) HDAC3-Flag and 
HDAC3H134A,H135A-Flag expression constructs were transfected in HEK-293T 
cells. Expression was detected by western blot from whole cell lysates using Flag 
antibody. Gapdh is shown as a loading control. (B) HDAC3-Flag and 
HDAC3H134A,H135A-Flag expression was quantified and normalized to total input 
Gapdh using ImageJ software (mean ± S.D., n=3). (C) HDAC activity of HDAC3-
Flag and HDAC3H134A,H135A-Flag expression was quantified against a 
pseudosubstrate. (D) EndMT assay of control- or Cre-infected E10.5 Hdac3F/F 
outflow tract cushion explants co-infected with GFP, HDAC3-Flag, or 
HDAC3H134A,H135A-Flag lentiviruses, imaged 24 hours after isolation. (E) 
Quantification of average radial migration, measured in 8 directions, of control- or 
Cre-infected E10.5 Hdac3F/F outflow tract cushion explants co-infected with GFP, 
HDAC3-Flag, or HDAC3H134A,H135A-Flag lentiviruses, measured 24 hours after 
isolation (mean ± SEM, n=3). (F) Relative mRNA levels of Tgf-β1 in control- or 
Cre-infected E14.5 Hdac3F/F valvular mesenchymal cells co-infected with control, 
HDAC3-Flag, or HDAC3H134A,H135A-Flag lentiviruses (mean ± SEM, n=3). (G) A 
1309bp Tgf-β1 promoter luciferase reporter (WT) or a truncated, 1267bp Tgf-β1 
promoter luciferase reporter, lacking a Hdac3 enriched region (mutant) were 
transfected in murine endothelial cells with and without an Hdac3 or 
HDAC3H134A,H135A expression plasmid. Induction is represented as a ratio of firefly 
and renilla luciferase activity. (H-J) ChIP-qPCR analysis of (H) H3K27 
acetylation, (I) H3K27 tri-methylation, and (J) Ezh2 upstream of Tgf-β1 in control- 
or Cre-infected E14.5 Hdac3F/F valvular mesenchymal cells co-infected with 
control, HDAC3-Flag, or HDAC3H134A,H135A-Flag lentiviruses (mean ± SEM, n=3).  
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Figure 3.10: Summary of phenotypes and proposed model of Hdac3 
function within second heart field progenitor cells and second heart field-
derived mesenchymal cells. (A) Loss of Hdac3 in second heart field progenitor 
cells leads to outflow tract and semilunar valve pathologies. Strikingly, genetic 
deletion of Hdac3 in differentiated mesenchymal and smooth muscle cells 
(Hdac3TaglnKO) recapitulates the majority of these phenotypes. However, deletion 
of Hdac3 in differentiated cardiomyocytes (Hdac3Myh6KO) or endothelial cells 
(Hdac3Cdh5KO) did not recapitulate the cardiovascular defects observed in 
Hdac3Isl1KO embryos. (B) Hdac3Isl1KO hearts exhibit disorganized collagen and 
elastin within dilated aortic walls and hyperplastic semilunar valves containing 
activated myofibroblasts and disorganized extracellular matrix. In both control 
and Hdac3Isl1KO cardiac endothelial cells, the upstream regulatory region of Tgf-
β1 is occupied by RNA polymerase II and Crebbp and exhibits H3K27 
acetylation, concomitant with Tgf-β1 expression. In control semilunar valves, 
endothelial cells undergo EndMT to become mesenchymal cells. In these 
mesenchymal cells, Ncor1, Hdac3, and PRC2 complex (Ezh2, Eed, and Suz12) 
are recruited to the upstream regulatory region of Tgf-β1, which becomes tri-
methylated on histone H3K27, and Tgf-β1 expression is epigenetically silenced. 
In Hdac3Isl1KO hearts, Ezh2, Eed, and Suz12 are not recruited to the Tgf-β1 
regulatory region, RNA polymerase II and Crebbp are present, and histone 
H3K27 remains acetylated, favoring aberrant expression of Tgf-β1 in 
mesenchymal cells. Tgf-β1 activates mesenchymal cells to become 
myofibroblasts, which perpetuate EndMT and activation of mesenchymal cells 
through continued induction of Tgf-β1 and aberrant expression of extracellular 
matrix, including proteoglycans and collagen.  
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Second heart field progenitor cells progressively and restrictively 
differentiate into various cardiac cell types, including cardiomyocytes, endothelial 
cells, and mesenchymal or smooth muscle cells 24. Genetic ablation of HDAC3 in 
the second heart field progenitor cells using either Isl1-Cre or Mef2c-AHF-Cre 
resulted in ascending aortic dilatation, outflow tract malrotation, overriding aorta, 
double outlet right ventricle, semilunar valve stenosis, bicuspid aortic valve, and 
membranous ventricular septal defects that closely resembled those seen in 
patients with congenital cardiovascular diseases. Strikingly, genetic deletion of 
HDAC3 in mesenchymal or smooth muscle cells (Hdac3TaglnKO) recapitulated 
the cardiovascular anomalies observed in Hdac3Isl1KO and Hdac3Mef2CKO 
embryos; however, genetic deletion of HDAC3 in differentiated cardiomyocytes 
(Hdac3Myh6KO) or endothelial cells(Hdac3Cdh5KO) did not recapitulate these 
defects. These observations define a spatiotemporal function of HDAC3 within 
mesenchymal or smooth muscle cells of second heart field-derived structures 
that is required for arterial pole morphogenesis (Fig. 3.10A-B). 
The anterior part of the second heart field contributes to the arterial pole of 
the heart, myocardial, and endothelial layers of the outflow tract, right ventricle, 
ventricular septum, and endocardial cushion mesenchyme of the outflow tract. 
The posterior part of the second heart field contributes to the venous pole of the 
heart, atria, dorsal mesenchymal protrusion, and atrial septum 189. Isl1Cre marks 
both the anterior and posterior part of the second heart field 24. However, genetic 
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deletion of ubiquitously expressed HDAC3 in the Isl1Cre expression domain only 
affected morphogenesis of the anterior heart field-derived structures. Indeed, 
embryos lacking HDAC3 in the anterior second heart field (Mef2C-AHF-Cre) 
recapitulated these defects. Thus, HDAC3 mainly functions within the anterior 
part of the second heart field. Interestingly, embryos lacking HDAC3 in the 
second heart field display normal ventricular myocardium (data not shown). 
Previously, we demonstrated that HDAC3 is required in the primary heart field 
(Nkx2-5 enhancer-Cre) for development of the ventricular myocardium at the 
early stages of cardiogenesis 216. Taken together, these findings suggest that 
once the primary heart field progenitors have adopted a cardiac fate to form the 
nascent heart tube, the second heart field-derived ventricular myocardium can 
develop independently of HDAC3. This is consistent with prior evidence that the 
ventricular myocardium remains unaffected after genetic manipulations or 
ablation of the second heart field progenitor cells 34,192. 
Outflow tract malrotation in tandem with ventricular septal defect is one of 
the most common cyanotic congenital heart defects at birth 7. Proper alignment, 
orientation, and septation of the cardiac outflow tract into the aorta and the 
pulmonary artery require intricate coordination and interaction among multiple 
cell types, including neural crest and second heart field 228. Cardiac neural crest 
cell-dependent processes, such as outflow tract septation and distal outflow tract 
morphogenesis, appeared normal in embryos lacking HDAC3 in the second heart 
field (Fig. 3.1G). Previously, we demonstrated that neural crest-specific genetic 
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deletion of HDAC3 resulted in anomalous outflow tract septation and distal 
outflow tract morphogenesis; however, outflow tract rotation and semilunar valve 
development were unaffected 147. Instead, second heart field-derived 
myocardium at the base of the outflow tract governs the normal outflow tract 
rotation 229. Prior studies also suggest that aberrant EndMT and remodeling of 
the outflow tract cushions give rise to structural outflow tract defects, particularly 
outflow tract malrotation 228. Our data establish that loss of HDAC3 triggers 
EndMT in the outflow tract cushion that can be markedly reduced by inhibiting 
TGF-β. Indeed, TGF-β and its downstream target genes are critical regulators of 
EndMT 197. In particular, TGF-β-activated SMAD proteins directly stimulate the 
expression of zinc finger transcription factor Snai1 within the outflow tract 
cushion 213. Studies in chicken and mice have shown that transcriptional 
repressor Snai1 is both sufficient and required for EndMT 230. Consistent with 
these findings, embryos lacking HDAC3 in the second heart field or valvular 
mesenchymal cells display a marked increase in Snai1 expression within the 
developing outflow tract and semilunar valves. Overall, our data demonstrate that 
genetic deletion of HDAC3 in the second heart field or in valvular mesenchymal 
cells augments TGF-β bioavailability, which, in turn, promotes aberrant EndMT 
and remodeling of the outflow tract cushion, and this, in part, may modulate 
outflow tract rotation. Importantly, our results highlight the underlying fact that 
outflow tract rotation and septation are independent processes regulated by 
distinct second heart field and cardiac neural crest lineages. 
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Our data reveal that HDAC3 is a critical regulator of extracellular matrix 
homeostasis within the second heart field-derived structures. Aberrant 
extracellular matrix is often an underlying pathology in semilunar valve stenosis, 
bicuspid aortic valve, and aortic dilatation 62,85,211. Patients with connective tissue 
disorders often exhibit altered composition and distribution of extracellular matrix 
within thickened semilunar valves and ascending aorta, resembling those seen in 
Hdac3Isl1KO and Hdac3Mef2CKO embryos. We demonstrate that HDAC3 is 
required to maintain proper composition of both proteoglycans and collagen in 
the developing semilunar valves and ascending aorta. The small leucine-rich 
proteoglycans, such as biglycan, decorin, and fibromodulin, sequester TGF-β to 
limit its bioavailability and thereby regulate proper remodeling of the hinge region 
of the semilunar valves and ascending aorta 210,212. Without this sequestration, an 
increase of TGF-β bioavailability manifests as dilatation of ascending aorta, 
bicuspid aortic valves, and thickened semilunar valves in connective tissue 
disorders. Consistent with this model, our data demonstrate that genetic deletion 
of HDAC3 in the second heart field or valvular mesenchymal cells leads to 
significant down-regulation of biglycan, decorin, and fibromodulin, probably 
explaining increased TGF-β bioavailability, enlarged hinge region of semilunar 
valves, bicuspid aortic valves, and dilation of ascending aorta in Hdac3Isl1KO 
and Hdac3Mef2CKO embryos. Interestingly, we observed striking up-regulation 
of lumican, a small leucine-rich proteoglycan, in the outflow tract and developing 
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semilunar valves of Hdac3Isl1KO embryos, probably explaining thickened 
semilunar valves. Patients with bicuspid aortic valve, the most common 
congenital heart defect, are at increased risk for ascending aortic dilatation 231. 
Proteoglycans facilitate collagen assembly and synthesis, a critical process for 
the development of semilunar valves and ascending aorta 210. Indeed, patients 
with mutations in collagen genes, such as Col1a2 or Col3a1, are often 
predisposed to bicuspid aortic valves and aortic dilatation. Consistent with these 
observations, significantly reduced expression of Col1a2 and Col3a1 in 
Hdac3Isl1KO embryos might explain bicuspid aortic valves and ascending aortic 
dilatation. 
Recent elegant studies 232 clearly demonstrate that in addition to their 
complex roles in early development, TGF-β signaling pathways are involved in 
many human diseases as a result of mutations in components of the pathways or 
aberrant regulation of signaling. Our study identifies HDAC3 as a novel and 
specific regulator of the TGF-β signaling pathway at the extra- cellular, 
membrane, cytoplasmic, and nuclear levels. For instance, our data demonstrate 
that loss of HDAC3 augments expression of extracellular agonist ligands of the 
TGF-β pathway, such as TGF-β1. Simultaneously, expression of extracellular 
antagonists of these ligands, such as decorin, biglycan, fibromodulin, and 
collagen, is strikingly diminished in the absence of HDAC3, probably explaining 
increased TGF-β bioavailability in Hdac3Isl1KO embryos. Similarly, gain of 
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NRP2, SUMO1, KPNB1, and SMAD4 expression in Hdac3Isl1KO embryos would 
probably explain amplification of TGF-β signaling at the membrane, cytoplasmic, 
and nuclear levels. 
Our findings demonstrate that HDAC3 is required to maintain quiescence 
of valvular mesenchymal cells, the most prevalent cells of valvular cusps. 
Pathologic conditions promote activation and differentiation of valvular interstitial 
cells into myofibroblasts, smooth muscle-like fibroblasts that are observed in 
patients with semilunar valve disease 202. Myofibroblasts express smooth 
muscle-specific genes and secrete strikingly higher levels of TGF-β, 
proteoglycans, and collagen that alter the composition of the extracellular matrix 
85. Hence, semilunar valve pathologies augment TGF-β bioavailability, which in 
turn promotes aberrant EndMT and transcriptional activation of smooth muscle 
and extracellular matrix genes within the myofibroblasts 201. TGF-β activation and 
aberrant extracellular matrix further promote the activation and differentiation of 
new valvular mesenchymal cells derived via EndMT 202. Consistent with these 
observations, our data demonstrate that loss of HDAC3 leads to strikingly higher 
expression of TGF-β1, smooth muscle genes, and aberrant expression of 
extracellular matrix genes within the valvular mesenchymal cells, and these 
changes were largely abolished by TGF-β-neutralizing antibody. Taken together, 
our findings support a model in which HDAC3-mediated repression of TGF-β1 
within valvular mesenchymal cells is required to prevent perpetual activation of 
EndMT and to maintain extracellular matrix homeostasis in the semilunar valves. 
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Catalytically inactive enzymes or “pseudoenzymes” are clearly 
widespread, occurring in most enzyme families, including HDACs 227. For 
instance, class II HDACs, such as HDAC4, -5, -7, and -9, lack deacetylase 
activity due to a His substitution at the key Tyr residue 233. These 
pseudoenzymes function as scaffolding proteins to recruit various co-factors in a 
signal-de- pendent manner 119. Similarly, HDAC1 and -3, class I HDACs, and 
their deacetylase-dead mutants have the same degree of in vivo effect on 
cardiomyopathy 92. During endothelial-to-mesenchymal transition, epigenetic 
mechanisms regulating gene activation and silencing remain largely undefined 
234. The present study provides the mechanistic basis of a deacetylase-
independent function of HDAC3 as a scaffold to recruit methyltransferase 
components of PRC2 (polycomb repressive complex 2) to epigenetically silence 
TGF-β1. Repressor complex-mediated gene silencing is critical to maintain 
cellular identity of differentiated cells through multiple divisions 121. Recent 
evidence suggests that PRC2-mediated epigenetic silencing is maintained for 
many cell generations. EZH2, the major H3K27 methyltransferase of the PRC2 
complex, supported by EED and SUZ12, catalyzes methylation of H3K27 to 
mediate chromatin compaction and thereby regulate differentiation and cell 
identity 235. Consistent with this model, our data demonstrate that HDAC3 recruits 
EZH2, EED, and SUZ12 to the NCOR complex in a deacetylase-independent 
manner and thereby mediates epigenetic silencing of TGF-β1 within valvular 
mesenchymal cells. In the absence of HDAC3, the NCOR complex fails to recruit 
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PRC2 complex, resulting in aberrant recruitment of CREBBP, which catalyzes 
acetylation of H3K27 to mediate activation of TGF-β1 expression, which in turn 
promotes perpetual transdifferentiation of valvular mesenchymal cells to 
myofibroblasts. Subsequently, activated myofibroblasts secrete higher levels of 
extracellular matrix proteins and promote aberrant EndMT. Future investigations 
dissecting the modes of interaction among HDAC3, EZH2, EED, and SUZ12 will 
be important to determine PRC2-independent functions of HDAC3. Similarly, 
murine models expressing catalytically inactive HDAC3 would further define 
deacetylase-independent functions of HDAC3 during cardiogenesis. 
Elucidation of the role of HDAC3 in the second heart field is directly 
relevant to human congenital heart disease. Marfan syndrome, Ehlers-Danlos 
syndrome, and Loeys-Dietz syndrome, caused by mutations and activation of 
TGF-β signaling genes, are associated with congenital cardiovascular anomalies 
resembling those seen in Hdac3Isl1KO, Hdac3Mef2CKO, or Hdac3TaglnKO 
embryos. Our data suggest that many of these cardiovascular defects, such as 
aortic dilatation, outflow tract defects, bicuspid aortic valve, semilunar valve 
stenosis, and membranous ventricular septal defects, are likely to be caused by 
defective morphogenesis of the second heart field and aberrant extracellular 
matrix as a result of anomalous epigenetic silencing of TGF-β. 
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Chapter IV: Discussion and future directions 
 
Despite the prevalence and severity of congenital heart disease, the 
molecular mechanisms of normal and pathogenic cardiac development are not 
well understood. Recent studies highlighting roles of chromatin-modifying 
enzymes and related teratogens, including Hdac inhibitors, in congenital heart 
disease pathogenesis stressed the importance of investigating basic functions of 
epigenetic enzymes in cardiac progenitor cells 112-114,236. This thesis aimed to 
determine the functions of Hdac3 in the major mesodermal cardiac progenitor 
populations: the primary heart field and the second heart field.  
Prior to this work, Hdac3 was shown to have developmental roles in the 
cardiac neural crest and cardiac conduction system and distinct developmental 
and postnatal functions cardiomyocytes 147-150. Deletion studies in murine 
cardiomyocytes demonstrated that loss of Hdac3 in cardiomyocytes 
embryonically lead to postnatal defects in cardiac metabolism and lethal cardiac 
hypertrophy by four months of age 177. Conversely, under normal diet conditions, 
postnatal deletion of Hdac3 in cardiomyocytes produced no phenotype or 
lethality 150. Metabolic deficiencies and heart failure were only observed in these 
mice in response to high fat diet. This divergence in phenotype between prenatal 
and postnatal loss of Hdac3 in the same cell type hinted at stage-specific 
requirements for Hdac3 during cardiac development. Our work extended this 
investigation of stage-specific functions of Hdac3 back to the mesoderm-derived 
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first heart field and second heart field progenitor cells. The findings presented in 
this thesis demonstrate clear embryonic requirements for Hdac3 in both of these 
early progenitor populations. Importantly, these progenitor-specific functions of 
Hdac3 offer new insights into potential mechanisms underlying multiple forms of 
human congenital heart disease, including Holt-Oram Syndrome, connective 
tissue disorders, and teratogenic effects of Hdac inhibition. Such findings could 
inform clinical efforts to treat or prevent cardiac defects. 
 
Stage-specific importance of Hdac3 in cardiomyocyte differentiation 
 
In support of the stage-specific nature of Hdac3 function in cardiac 
development, we found that Hdac3 has roles in the primary heart field distinct 
from those in the second heart field or differentiated cardiac lineages. Loss of 
Hdac3 in the primary heart field results in precocious differentiation of cardiac 
progenitors into cardiomyocytes. The affected hearts exhibit ventricular septal 
defects and hypoplastic walls, leading to mid-gestational embryonic lethality.  
The precocious cardiomyocyte differentiation and hypoplastic wall 
phenotype observed in Hdac3Nkx2-5KO hearts were not observed upon loss of 
Hdac3 in either differentiated cardiomyocytes or second heart field progenitors. 
This implies that although Hdac3 is required in primary heart field progenitor cells 
for cardiomyocyte differentiation, once this initial specification event has 
occurred, the second heart field can differentiate appropriately in the absence of 
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Hdac3. The specific requirement for Hdac3 in primary heart field, but not second 
heart field, cardiomyocyte differentiation provides a new example of a difference 
in regulation between these two progenitor pools. 
Within the primary heart field progenitor cells, we showed that Hdac3 
interacts with, deacetylates, and suppresses the activity of the primary heart field 
transcription factor Tbx5. Tbx5 is known to promote differentiation of primary 
heart field progenitors, inducing expression of cardiac differentiation genes, 
including those aberrantly expressed in Hdac3Nkx2-5KO hearts 42,44. The 
deacetylase function of Hdac3 opposes EP300, an acetyltransferase, which we 
showed acetylates Tbx5 in vitro and in vivo and enhances its transcriptional 
activity. In this manner, Hdac3 functions as a brake, tempering the activation of 
Tbx5-induced cardiac differentiation genes. Loss of Hdac3 allows for increased 
Tbx5 acetylation and aberrant induction of its target genes. Mutating suspected 
acetylation sites in TBX5 abolishes its transcriptional activity, supporting the 
correlation between TBX5 acetylation and activity. Importantly, these findings 
showed, for the first time, acetylation of a T-box protein and regulation of T-box 
protein activity by a histone deacetylase, thereby establishing a novel post-
translational regulatory mechanism for T-box proteins. Further mass-
spectrometry experiments could more precisely describe the post-translational 
modifications of Tbx5 and allow for more in-depth investigation into regulation of 
Tbx5 activity. 
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T-box proteins are critical developmental regulators in nearly every organ 
system, including cardiac, limb, and craniofacial development 237. Within the 
heart, T-box genes show specific, overlapping expression patterns from the time 
of cardiac specification through late stages of cardiac remodeling 237. These 
proteins are conserved through evolution and expression patterns of Tbx5 are 
correlated with chamber septation, suggesting an evolutionary role of Tbx5 in the 
development of the four-chambered heart and dual circulatory systems 11,237. The 
importance of T-box proteins in cardiac development is further evidenced by the 
causative links between mutations in T-box genes, including Tbx1 and Tbx5, and 
human congenital heart disease 29,30,50,52. The proposed acetylation sites that we 
identified in TBX5 are conserved across the T-box family and throughout 
evolution. This suggests that other T-box family members may share a similar 
mechanism of regulation by acetylation, as described between Tbx5, Hdac3, and 
EP300 in this dissertation. Further investigation into regulation of other T-box 
proteins, such as Tbx1, by acetylation is thus warranted. 
More than 40 TBX5 mutations have been identified in patients with Holt-
Oram Syndrome, one of which is believed to result in a gain-of-function 45,47. 
Deletion analysis revealed that this gain-of-function mutation, TBX5G125R, lies 
within a critical domain for interaction with Hdac3. Notably, this point mutation 
disrupts the physical interaction between HDAC3 and TBX5. TBX5G125R exhibits 
increased acetylation and transcriptional activity that cannot be efficiently 
suppressed by Hdac3. Mutation of suspected acetylation sites ameliorates this 
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aberrant activity. This suggests a potential mechanistic role of TBX5 acetylation 
and disrupted interaction between HDAC3 and the TBX5G125R gain-of-function 
mutant relevant to congenital heart disease, highlighting the importance of post-
translational modifications in insuring proper protein function. Fulcoli and 
colleagues have demonstrated proof of principle for prenatal pharmaceutical 
interventions for congenital heart disease in mice, specifically DiGeorge 
Syndrome, by targeting proteins involved in post-translational modification of 
Tbx1 109. The disruption in acetylation and interaction with Hdac3 by the 
TBX5G125R gain-of-function mutation presents a novel therapeutic target for 
prenatal treatment of Holt-Oram Syndrome. 
 
Hdac3 functions in second heart field-derived lineages 
 
In contrast to the primary heart field, deletion of Hdac3 in the second heart 
field progenitors leads to later lethality, around the time of birth, with no obvious 
ventricular wall hypoplasia. Instead, deletion of Hdac3 in second heart field 
progenitors results in outflow tract rotation defects, double outlet right ventricle, 
ventricular septal defect, and semilunar valve defects, including pulmonary valve 
hyperplasia, aortic valve hyperplasia, and bicuspid aortic valve. These defects 
are highly penetrant in second heart field Hdac3 knockouts. Importantly, loss of 
Hdac3 in differentiated endothelial or myocardial cells do not recapitulate these 
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defects, however loss of Hdac3 in mesenchymal smooth muscle cells manifests 
as a similar spectrum of outflow tract defects and semilunar valve hyperplasia. 
We determined that Hdac3Isl1KO semilunar valves fail to undergo normal 
remodeling, instead exhibiting excessive EndMT, reduced apoptosis, and 
expanded, disorganized extracellular matrix deposition. Within valvular 
mesenchymal cells, Hdac3 suppresses expression of Tgfβ1 and Tgfβ1 pathway 
components, which are known to regulate valve development and extracellular 
matrix organization 238-241. Upon loss of Hdac3, Tgfβ1 expression increases, the 
Tgfβ1 pathway is activated, and valvular mesenchymal cells take on a 
pathogenic myofibroblast phenotype. This is accompanied by extracellular matrix 
disorganization within the outflow tract vessels and semilunar valves. The 
disorganized extracellular matrix and dilatation of the aorta in Hdac3Isl1KO hearts 
resemble cardiac phenotypes observed in humans with connective tissue 
disorders such as Marfan Syndrome, Ehlers-Denlos Syndrome, and Loeys-Dietz 
Syndrome 60-62,70-73. Patients with these syndromes often show elevated Tgfβ1 
expression levels, consistent with observations in Hdac3Isl1KO hearts 61,74,75.  
Our model proposes that Hdac3 acts at the Tgfβ1 promoter in 
mesenchymal cells to epigenetically regulate Tgfβ1 transcription. We show that 
Hdac3 and the N-CoR complex are required to recruit the PRC2 
methyltransferase complex to the Tgfβ1 promoter, resulting in histone H3K27 tri-
methylation and transcriptional repression. In the absence of Hdac3, the Tgfβ1 
promoter becomes occupied by Crebbp and polymerase, and exhibits histone 
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H3K27 acetylation, all hallmarks of gene activation. Indeed, increased Tgfb1 
gene expression is observed in Hdac3 knockout semilunar valves and outflow 
tracts, along with gene expression changes and protein expression indicative of 
Tgfb1 pathway activation. This is accompanied by changes in cell behavior, 
including enhanced EndMT and an activated myofibroblast phenotype of valve 
interstitial cells. 
Importantly, we found that Hdac3’s recruitment of the PRC2 complex and 
epigenetic repression of Tgfβ1 does not require Hdac3’s catalytic activity. A 
catalytically dead point mutant version of Hdac3, HDAC3H134A, H135A could rescue 
PRC2 complex recruitment, Tgfβ1 promoter H3K27 tri-methylation, and EndMT 
defects in explant experiments. These findings support a new, deacetylase-
independent role for Hdac3 as a scaffold to coordinate gene regulation in second 
heart field development.  
Clinically, these discoveries establish a novel mechanism for regulation of 
Tgfβ1 expression that could serve as a therapeutic target for treatment of 
disorders involving aberrant Tgfβ1 expression. Tgfβ1 expression is elevated in 
patients with connective tissue disorders, such as Marfan Syndrome, Ehlers-
Denlos Syndrome, and Loeys-Dietz Syndrome, and reactivation of Tgfβ1 in 
valvular interstitial cells is associated with adult valve disease 61,74,75,197,201,242,243. 
Pharmaceutical interventions targeting Tgfβ1 expression and activation are in 
clinical trials for treatment of such diseases 243. We propose that suppression of 
Tgfβ1 expression that occurs naturally in mesenchymal cells during development 
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requires recruitment of the PRC2 complex to the Tgfβ1 promoter, facilitated by 
Hdac3. Strategies to suppress Tgfβ1 expression in patients with connective 
tissue disorders or adult valve pathologies may explore targeting Hdac3-
mediated recruitment of the PRC2 complex, Tgfβ1 promoter methylation, or 
Tgfβ1 promoter deacetylation as alternate strategies to induce suppression of 
pathogenic Tgfβ1 expression. 
Although bicuspid aortic valve is the most prevalent congenital cardiac 
defect, animal models with highly penetrant bicuspid aortic valve phenotypes 
have not been established. We show, for the first time, a genetic mouse model 
that reproducibly exhibits bicuspid aortic valve. This model will facilitate 
investigations into the cellular and molecular etiologies of this common human 
malformation. 
Interestingly, while mesenchymal cell deletion of Hdac3 partially 
recapitulated the outflow tract defects and valve hyperplasia observed in 
Hdac3Isl1KO hearts, these hearts did not exhibit bicuspid aortic valve (Appendix 
A). In fact, neither mesenchymal, myocardial, nor endothelial deletion of Hdac3 
resulted in bicuspid aortic valve (Appendix A). This implies that the mechanism of 
bicuspid aortic valve development is independent of the aortic valve hyperplasia 
and outflow tract rotation defects observed in Hdac3Isl1KO, Hdac3Mef2cKO, and 
Hdac3TaglnKO hearts. Furthermore, the mechanism of bicuspid aortic valve 
development in Hdac3Isl1KO and Hdac3Mef2cKO requires Hdac3 function either 
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specifically within the second heart field progenitor cells or in multiple interacting 
derivative cell types. 
In humans, bicuspid aortic valve arises either due to fusion of two adjacent 
cusps or due to developmental abnormalities resulting in a failure of one cusp to 
form 65,82,244,245. Previous work has suggested that separate genetic mechanisms 
are responsible for different subtypes of bicuspid aortic valve 245. Preliminary 
analysis of the developing aortic valve in Hdac3Isl1KO hearts suggests abnormal 
formation of the noncoronary cusp, with morphology mimicking the right-
noncoronary bicuspid aortic valve subtype (data not shown). Further investigation 
into this phenotype, its developmental origins, cellular basis, and molecular 
mechanism will define additional functions of Hdac3 in aortic valve biology and 
may provide insights into the causes of human bicuspid aortic valve development 
and associated pathologies. 
 
Future directions – expanding investigation into early roles of Hdac3 in 
cardiac development 
 
This thesis described critical, stage-specific roles of Hdac3 in mesoderm-
derived cardiac progenitors: the primary heart field and second heart field, with 
important human disease associations. These findings, together with prior work 
demonstrating separate embryonic and postnatal requirements for Hdac3 in 
cardiomyocytes, clearly established that the essential functions of Hdac3 evolve 
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as development progresses from the primary and second heart field progenitors 
to the differentiated postnatal lineages 150,177. 
Extending this investigation one step further back in development, 
preliminary analysis of mesodermal knockouts of Hdac3 (Hdac3Mesp1KO) suggests 
requirements for Hdac3 in cardiogenic mesoderm distinct from those in the 
primary heart field, second heart field, or differentiated cardiac cells (Appendix 
B). Hdac3Mesp1KO embryos exhibit embryonic lethality prior to E12.5, earlier than 
the lethality of any of the Hdac3 knockouts described in this thesis. These 
embryos show heart looping defects, hypoplastic endocardial cushions, 
extracellular matrix disorganization, and gene expression changes in 
developmental signaling pathways and cell lineage markers (Appendix B).  
These preliminary findings warrant further analysis, including phenotypic 
and molecular characterization of Hdac3Mesp1KO embryos at earlier developmental 
time points to determine the origin of the observed defects and identify the 
mechanisms of Hdac3’s functions at these earliest stages of cardiac 
development. Tracing the differences in gene expression observed by microarray 
analysis at E9.5 back to their time of onset would help to distinguish primary from 
secondary changes in gene expression in response to loss of Hdac3, facilitating 
the identification of the direct gene targets for Hdac3 in cardiogenic mesoderm. 
Dual-staining and in situ analyses of early embryos could investigate the specific 
effects of mesodermal Hdac3 deletion on individual derivative populations, such 
as the primary heart field or second heart field progenitors. Such work, combined 
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with the existing literature on cardiac roles of Hdac3, including the work in this 
dissertation, would provide a more complete picture of the important functions of 
Hdac3 from cardiac specification through maintenance of cardiac health in the 
mature, adult heart. 
 
Regulation of Hdac3 activity – key to stage specific functions? 
 
Considering the evolving roles of Hdac3 throughout cardiac development, 
interactions and regulation of Hdac3 activities must be dynamically regulated as 
development progresses through progenitor stages and into differentiated 
cardiac cell types. Hdac3 appears ubiquitously expressed throughout the heart 
and body during the period of cardiac development, which argues against 
transcriptional regulation of Hdac3 as a mechanism for differences in 
requirements across stages of differentiation. Interestingly, expression of 
interacting factors, for example co-expression of Hdac3 and Tbx5, may not be 
sufficient for their interaction.  
While we observed interaction between Hdac3 and Tbx5 in E8.5 hearts by 
endogenous co-IP, a recent Tbx5 interactome study conducted in E9.5 hearts did 
not identify Hdac3 as a binding partner of Tbx5, despite overlapping cardiac 
expression of both proteins at this stage 246. The interactome study utilized an 
Avitag Tbx5 mouse model, but reported no adverse affects of the genetic 
manipulation on embryonic development, suggesting conserved function of 
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Avitag Tbx5. This raises the question of whether the interaction between Hdac3 
and Tbx5 is developmentally transient. Hdac3 acts as a suppressor of Tbx5 
activity in cardiac progenitor cells, preventing activation of myocardial 
differentiation genes. A lifting of this repression by dissociation of Hdac3 and 
Tbx5 may be required to allow differentiation to proceed at the appropriate 
developmental stage. Regulation of this interaction may, therefore, be important 
in directing the correct timing of differentiation. Further study into the mechanism 
regulating Hdac3 interaction with Tbx5 could reveal whether this interaction 
serves as a downstream effector of a differentiation signal to induce 
cardiomyocyte differentiation. 
Much like the interaction between Hdac3 and Tbx5, Hdac2 has been 
shown to interact with, deacetylate, and functionally repress Gata4 in embryonic 
cardiomyocytes 140. This interaction is dependent on the phosphorylation status 
of Hdac2. Although a phospho-mutant version of Hdac2 retains deacetylase 
activity comparable to that of wild-type Hdac2, it exhibits an 87% reduction in its 
interaction with Gata4 and is unable to repress Gata4 activity 140. Studies in other 
systems have described post-translational regulation of Hdac3 by 
phosphorylation 247,248. Investigation into the role of post-translational 
modifications of either Tbx5 or Hdac3, such as Hdac3 phosphorylation, on their 
association with one another could provide insight into the regulation of stage-
specific roles of Hdac3 during cardiac development. 
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Concluding remarks  
 
Overall, the work presented here expands our understanding of the 
developmental roles of histone deacetylases, specifically Hdac3, in cardiac 
progenitor cells. We show that Hdac3 is required in cardiac progenitor cells for 
survival of the embryo and describe clinically relevant interactions that may serve 
as therapeutic targets for congenital heart disease or related conditions. For 
example, we found that Hdac3 interacts with and deacetylates Tbx5, a 
relationship that is disrupted by a point mutation in Tbx5 found in patients with 
congenital heart disease. This disrupted regulatory relationship between Hdac3 
and Tbx5 highlights the relevance of Hdac3 activities in human disease etiology. 
Furthermore, this mechanism establishes a novel therapeutic target for a subset 
of Holt-Oram Syndrome patients, with the potential for similar mechanisms 
among other T-box-associated diseases, such as DiGeorge Syndrome. 
Within cardiac progenitors, we describe both deacetylase-dependent and 
deacetylase-independent mechanisms by which Hdac3 regulates cardiac gene 
expression and distinct cell-type and stage-specific roles of Hdac3. This work 
opens new questions into the nature and regulation of Hdac3 activity, such as 
when and where is Hdac3 enzymatically active during cardiac development, are 
its interactions with other proteins or DNA regulatory sequences transient, and, if 
so, do these dynamic interactions serve as downstream effectors of 
developmental signaling cascades? Further studies utilizing deacetylase-
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deficient and phosphorylation mutants of Hdac3 in the context of cardiac 
development will expand our understanding of the functions and regulation of 
Hdac3 in cardiogenesis. Such work, together with the findings presented in this 
dissertation, will establish the clinical importance of Hdac3 in congenital heart 
disease pathology and help to inform development of preventative and 
therapeutic approaches to combat this prevalent and devastating disease.  
 
	154 
Appendix A – incidence of bicuspid aortic valve and valve hyperplasia in 
tissue-specific Hdac3 knockout mice 
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Appendix B – Mesodermal deletion of Hdac3 
Overview 
This dissertation describes stage- and cell type-specific requirements for Hdac3 
during cardiac development. Based on these findings, I have conducted 
preliminary analysis to determine the effects of loss of Hdac3 in the mesoderm, 
which is a precursor to both the primary heart field and second heart field, which 
are examined in the main body of this dissertation. Using Mesp1-Cre, I deleted 
Hdac3 in the mesoderm (Figure B1 A) and discovered complete lethality of 
Hdac3Mesp1KO embryos between E9.5 and E12.5 (Table B1).  Hdac3Mesp1KO 
embryos exhibited heart looping defects at E9.5 (Figure B1 B-G), associated with 
shortening of the outflow tract when measured at E10.5 (Figure B1 H-J). The 
abnormally looped Hdac3Mesp1KO hearts show Hdac3 deletion within the outflow 
tract and atrioventricular cushions and both sets of cushions appear significantly 
hypoplastic (Figure B2 A-E). These hearts also exhibit a deficiency in Mesp1-
negative cells in the outflow tract and potential defects in epicardium formation or 
integrity (Figure B2 F-H). Preliminary microarray analysis of E9.5 control and 
Hdac3Mesp1KO hearts, along with staining, indicates defects in extracellular matrix 
and cytoskeletal-related genes in Hdac3Mesp1KO hearts (Figure B3). Comparison 
with other stage-specific knockouts of Hdac3 suggests that these defects are 
specific to the mesoderm or to multiple interacting derivative cell populations 
(Table B2). Further work is required to address the origin and mechanisms of the 
defects observed. 
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Figure	B1.	Abnormal	heart	looping	upon	mesoderm-specific	deletion	of	Hdac3.	
(A)	Bright	field	and	fluorescence	images	of	a	Mesp1-Cre;	TdTomato+/-	E7.5	embryo	show	Mesp1-Cre	expression	in	the	cardiac	crescent.	(B)	LacZ-stained	Hdac3Mesp1KO;	
R26R-LacZ+/-	and	control	E8.5	embryos	demonstrate	abnormal	looping	between	the	outflow	tract	and	ventricle	of	Hdac3Mesp1KO;	R26R-LacZ+/-	hearts.	(C)	Tracing	of	
Hdac3Mesp1KO;	R26R-LacZ+/-	and	control	E8.5	heart	tubes	from	the	frontal	perspective.	
(D)	LacZ-stained	Hdac3Mesp1KO;	R26R-LacZ+/-	and	control	E9.5	embryos	demonstrate	a	spectrum	of	severity	of	outflow	tract	to	right	ventricle	looping	angle	defects.	(E)	Tracing	of	LacZ-stained	Hdac3Mesp1KO;	R26R-LacZ+/-	and	control	E9.5	hearts	depict	the	spectrum	of	increasing	outflow	tract	to	right	ventricle	looping	angle	(dashed	red	lines)	compared	to	control	heart	looping	(purple	dashed	lines).	(F)	Purple	(control)	and	red	(Hdac3Mesp1KO;	R26R-LacZ+/-)	arrows	reflect	the	angle	of	right	ventricle	orientation	relative	to	the	outflow	tract	(black	line)	measured	from	images	of	individual	LacZ-stained	E9.5	embryos.	(G)	Comparison	of	the	angle	between	the	outflow	tract	and	right	ventricle	measured	from	images	LacZ-stained	Hdac3Mesp1KO;	
R26R-LacZ+/-	and	control	E9.5	embryos.	(H)	Hematoxylin-	and	eosin-stained	sections	of	the	outflow	tract	of	Hdac3Mesp1KO	and	control	E10.5	hearts.	Green	and	blue	lines	show	the	upper	and	lower	lengths,	respectively,	of	the	outflow	tract.	(I-J)	Quantification	of	outflow	tract	length,	measured	on	the	(I)	upper	surface	and	(J)	lower	surface	of	the	outflow	tract	in	hematoxylin-	and	eosin-stained	sagittal	sections	of	Hdac3Mesp1KO	and	control	E10.5	hearts.	
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Figure	B2.	Developmental	defects	in	Hdac3Mesp1KO	embryos.	(A)	HDAC3	immunostaining	of	LacZ-stained	Hdac3Mesp1KO;	R26R-LacZ+/-	and	control	embryos	shows	that	HDAC3	protein	expression	is	lost	in	the	Mesp1-Cre	expression	domain,	including	outflow	tract	and	atrioventricular	canal	in	E10.5	hearts.	(B)	Hematoxylin-	and	eosin-stained	sagittal	sections	demonstrate	malformed,	hypoplastic	outflow	tract	cushions	in	E10.5	Hdac3Mesp1KO	hearts.	(C)	Quantification	of	number	of	nuclei	per	outflow	tract	cushion	section,	counted	from	hematoxylin-	and	eosin-stained	sagittal	sections	from	E10.5	embryos.	(D)	Hematoxylin-	and	eosin-stained	sagittal	sections	demonstrate	hypoplastic	atrioventricular	cushions	in	E10.5	Hdac3Mesp1KO	hearts.	(E)	Quantification	of	number	of	nuclei	per	atrioventricular	cushion	section,	counted	from	hematoxylin-	and	eosin-stained	sagittal	sections	from	E10.5	embryos.	
(F)	Hematoxylin-	and	eosin-stained	sagittal	sections	of	LacZ-stained	Hdac3Mesp1KO;	
R26R-LacZ+/-	and	control	E10.5	embryos	demonstrate	a	reduction	in	Mesp1-Cre-negative	cells	in	the	outflow	tract	and	outflow	tract	cushions	in	Hdac3Mesp1KO;	R26R-
LacZ+/-	hearts.	(G)	Hematoxylin-	and	eosin-stained	sections	show	an	uninterrupted	epicardial	layer	around	the	right	ventricle	in	control	E10.5	hearts,	which	is	incomplete	and	fragmented	in	Hdac3Mesp1KO	E10.5	hearts.	(H)	COUP-TFII	immunostaining	shows	epicardial	expression	in	control	E10.5	hearts,	which	is	discontinuous	in	Hdac3Mesp1KO	E10.5	hearts.	
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Figure B3. Gene expression and related extracellular matrix changes in 
Hdac3Mesp1KO hearts. (A) DAVID analysis of microarray data from pooled E9.5 
Hdac3F/F and Hdac3Mesp1KO hearts indicate changes in cytoskeletal, signaling, 
and extracellular matrix genes. (B-C) Movat’s pentachrome staining of E10.5 
hearts show abnormal proteoglycan content (blue) in the outflow tract (B) and 
atrioventricular cushions (C) of Hdac3Mesp1KO hearts. (D-E) Masson’s trichrome 
staining of E10.5 hearts shows abnormal tissue architecture in the myocardium 
of the outflow tract (D) and atrioventricular canal (E) in Hdac3Mesp1KO hearts. 
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